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ABSTRACT 
Viruses are widely modified and used as gene delivery vectors for various applications 
in science and therapeutics. To this end, my thesis focuses on modifying the recombinant 
adeno-associated viral (rAAV) vectors that are identified as a safer choice for cargo delivery 
compared to other known viral vectors. They are widely used in the scientific communities, 
have seen promising outcomes in gene therapy clinical trials, and as of today have three 
products approved to use in humans. However, the natural repertoire of rAAVs have broad 
tropism when delivered systemically, and there is room for further improvement on the 
efficiency and specificity, especially for gene delivery in the central nervous system (CNS). 
The prior work done in Dr. Gradinaru lab addresses the issue by using a directed evolution 
approach called CREATE, Cre recombination-based AAV targeted evolution, to identify 
AAV-PHP.B and AAV-PHP.eB capsids, which broadly transduce the CNS (Deverman et al, 
2016; Chan et al, 2017). CREATE selects for functional lox-flipped viral DNA that crosses 
the blood-brain barrier (BBB) and successfully transduces a specific nerve cell-type 
expressing Cre, thereby applying a strong selection pressure. However, the method is limited 
by its ability to identify a handful of enriched variants, and may also be prone to false 
positives resulting from experimental biases. The effort to fully understand the selection 
landscape, and to select for capsids that are not just efficient towards a cell-type but also 
specific towards it, led to the development of Multiplexed-CREATE (M-CREATE). M-
CREATE allows parallel positive selections across different cell-types of interest, enables 
post-hoc negative selections across off-targets using a next-generation sequencing (NGS) 
based capsid recovery, and retains the principles of Cre-dependent functional recovery from 
CREATE. The method has a synthetic library generation approach to minimize biases within 
selection rounds, a variant replicate feature to identify the signal versus noise within a 
biological system, and an analysis pipeline to group families of enriched variants based on 
amino acid motifs, all of which together increases the confidence in the outcome and the 
throughput from a single experiment. Selections across brain endothelial cells, neurons, and 
astrocytes yielded several AAV-PHP.B-like variants that broadly transduce the CNS, AAV-
PHP.V variants that can efficiently transduce the vascular cells forming the BBB, a AAV-
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PHP.N variant that transduces neurons with greater specificity, and AAV-PHP.C variants 
that cross the BBB without murine strain specificity across tested strains. The AAV-PHP.C 
variants have different amino acid motifs compared to the AAV-PHP.Bs that have been 
previously shown to have limited CNS transduction across some mouse strains due to its 
interaction with the strain specific host cell surface receptor, ly6a, a homolog of which is not 
found in humans. (Hordeaux et al, 2018, Hordeaux et al, 2019; Huang et al, 2019; Batista et 
al, 2019) Therefore AAV-PHP.Cs offer some hope towards translation across other species. 
In summary, the M-CREATE methodology turns out to be a high-confidence, robust 
selection platform to yield several novel viral capsids for use in neuroscience and potential 
gene therapy related applications. 
 
Figure 1.1: Concept of Multiplexed-CREATE 
 
 
x 
M-CREATE is a high-confidence, multiplexed, in vivo selection platform that yields 
vectors (i.e., viral capsids) with desired tropisms. M-CREATE identifies positively 
enriched vectors from on-target tissues or cell types that are also negatively enriched across 
off-targets through next-generation sequencing (NGS)-based vector recovery. The selected 
vector libraries are subjected to clustering based on the shared mutation patterns (or motifs) 
to identify distinct families of vectors, thereby generating multiple candidates to address 
gene delivery challenges. 
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C h a p t e r  1  
BACKGROUND AND MOTIVATION 
Section 1.5 of this chapter has been adapted from: 
Deverman, B.E., Pravdo, P.L., Simpson, B.P., Ravindra Kumar, S., Chan, K.Y., 
Banerjee, A., Wu, W.L., Yang, B., Huber, N., Pasca, S.P., Gradinaru, V. Cre-dependent 
Capsid Selection Yields AAVs for Global Gene Transfer to the Adult Brain. Nature 
Biotechnology 34, 204–209 (2016). https://doi.org/10.1038/nbt.3440 
1.1. VECTORS FOR GENE DELIVERY 
One of the fundamental needs in biology are tools to study cells or associated 
pathologies, and eventually design therapies to treat the impaired cells. At a cellular level, 
all of the above involve an exogenous supply of genes encoding proteins of interest. 
Molecular tools than can package a desired gene and deliver it to a cell are called vectors 
or vehicles. Vectors can turn out to be the most powerful tool for a biologist if we can 
design them to precisely target a cell-type of interest efficiently, and can become a vital 
resource across various disciplines, such as in basic and biomedical sciences and in 
clinics.  
The gene delivery vectors can be broadly classified based on the source as non-
viral and viral vectors.  
Non-viral vectors 
The non-viral delivery systems comprise chemical and biochemical vectors such as 
lipid-based vectors, peptide-based vectors, natural and synthetic polymers, calcium 
phosphates, and metal nanoparticles1–11. These non-viral vectors are attractive for their 
biosafety aspect given their synthetic nature, and thereby their inability to elicit strong 
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immune response in the host. However, these non-viral vectors are limited in their 
applications due to lower transfection efficiency, and have been designed only for fewer 
target cell population given the time, cost, and labor involved in engineering such vectors12–
15.  
Viral vectors 
Viruses that are known to infect mammalian cells are naturally existing vectors, and 
they are subjected to engineering by making them replication deficient, stripping them of 
their toxic genome, and replacing it with our gene of interest to serve as a safe gene delivery 
vector (alias recombinant viral vector). Some viruses have been recognized and engineered 
for this purpose including; retroviruses, lentivirus, adenovirus (AD), adeno-associated virus 
(AAV), herpes simplex virus (HSV), rabies, and baculovirus. However, depending on the 
viral vectors, they have their own pros and cons including tropisms, transduction 
efficiency and specificity, stability of transgene expression, cytotoxicity, and immune 
response, all of which influence their potential applications in science and therapies16–19. 
Some notable vectors are highlighted below. 
Retroviruses 
Retroviruses are RNA viruses, and were the first to be recognized and engineered as a 
viral vector in the 1980s20, and they eventually entered the first gene therapy clinical trial in 
the 1990s for adenosine deaminase deficiency (ADA)21. However, the use of retroviral 
vectors observed a major setback due to its innate ability to randomly integrate into host 
genome, which may at times lead to insertional oncogenesis22–25. Hence, the issues associated 
with the use of these vectors limit their applications26–30. 
Lentivirus 
Lentivirus is a RNA retrovirus, and the recombinant viral vectors31–34 stands out for its 
ability to transduce both dividing and non-dividing cells35–37. Given its broad tropism, these 
recombinant viral vectors have gained a lot of attention in both basic science applications38–
 
 
3 
42 and in gene therapy43–45. However, even with the continuous engineering efforts to reduce 
the random integration events into host genome, the risk is not eliminated46. 
Adenovirus (AD) 
Adenoviruses are non-enveloped, icosahedral, double-stranded DNA viruses that 
are widely used as gene delivery vectors47–49, and also as recombinant viral vaccines50–52. 
ADs are attractive for their ability to exist as episomal DNA (extra-chromosomal DNA 
that does not integrate with host DNA), to package large genomes53 and modified 
tropisms through engineering54,55. However, one of the major drawbacks for gene therapy 
application is their ability to induce strong host innate immune responses56,57, such as the 
one seen in the 18-year-old Jesse Gelsinger case, where a fatal inflammatory response in 
days after administering AD packaged with ornithine-transcarbamylase led to his 
death58,59.  
1.2. ADENO-ASSOCIATED VIRAL VECTORS FOR GENE DELIVERY 
Adeno-associated virus (AAV) 
AAVs are 25 nm, non-enveloped, icosahedral (formed from 60 monomers), DNA 
parvoviruses with a single-stranded 4.7 kb genome60–65. AAVs are replication incompetent, 
and depend on a second virus for infection such as AD or HSV66. The genome carries two 
genes: rep and cap, comprising the Rep proteins (Rep78, Rep68, Rep52, Rep40) that 
coordinate AAV replication67, a capsid assembly-activating protein (AAP)68 and a 
membrane associated accessory protein (MAAP)69 from alternate open reading frames, and 
capsid proteins (VP1, VP2, VP3) that form the capsid coat70. These genes are flanked by 
inverted terminal repeats (ITRs) which are packaging signals for the genome and are 
involved in 2nd strand DNA synthesis in the host cell, and also has a terminal resolution site 
to enable site specific integration into human chromosome 19 (AAVS1)71–74. 
Advantages of using rAAVs as vectors for gene delivery  
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What makes rAAVs appealing for in vivo gene delivery applications is their latent (or 
harmless) infection without the helper virus66,75,76, and most of the viral genome can be 
stripped off to insert the cargo of interest as the only viral sequences required within the 
rAAV genome are the ITRs (145 bases on either end of the genome)77–79. The vectors are 
non-pathogenic, and have been shown to exhibit low immunogenic response. Their long-
term persistence as episomal DNA in transduced cells lowers the risk of random 
chromosomal integration events that are otherwise observed with retroviruses. All of the 
above features make them a safer choice of gene delivery vector over other viruses. Above 
all their ability to transduce both dividing and non-dividing cells makes them widely usable 
for various applications61,78,80–85.  
Current AAV vector applications 
Vectors can find their applications across various disciplines in science.  
Basic Science  
There has been more acceptance in using the rAAV viral vectors in laboratories all 
over the world to address a myriad of science questions that requires delivery of genes to a 
specific target of interest. The scientific needs involve delivering a specific or multiple genes 
under-investigation which includes an endogenous gene, an actuator, a sensor, or a reporter86. 
This could be easily achieved with rAAV viral vectors87.  rAAVs have been used in 
applications like cell circuits tracing88, probing cellular activity using techniques like 
optogenetics or chemogenetics89, building disease models90, etc. The current alternative 
experimental setup using transgenic animals carrying a modified gene has limitations such 
as the cost and time involved in generation and maintenance of transgenic lines. The growing 
needs to cover the diverse cell populations or pathological conditions under investigation 
limits its applications91–93. Compared to transgenics, the gene delivery vectors are easier and 
faster to implement; they could be used to deliver broadly across various targets under 
investigation, higher tissue or cell-type specificity based on the mode of vector delivery, the 
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nature of the cargo, or by the use of engineered vectors; and they allow time-controllable 
gene delivery in a host, which is crucial for studying pathologies87,93.  
Biomedical Science 
The use of AAV viral vectors for drug discovery in vivo can speed up progress in these 
areas of research, thereby increasing the potential to identify new therapeutic targets, and 
therefore newer therapies94–98. 
Gene therapy 
Gene therapy is a methodology that uses identified therapeutic genes to be delivered 
to the diseased cells to repair the loss of function. rAAVs, in addition to their predominant 
use in science, are promising vectors in gene therapies too for treating monogenetic 
disorders99–101. The first long term persistence of gene expression in mammalian brain by 
rAAV based gene delivery led to a great start in 1990s102, which then quickly followed with 
the first human gene therapy trial for cystic fibrosis (CF)103.  In 2008, rAAV was shown to 
have promising outcome to treat leber congenital amarosus (LCA)104–106.   
Three rAAV based gene therapies have been approved till date to use in clinics. In 
2012, the first gene replacement therapy using rAAV based drug named Glybera, was 
approved by the European Regulatory Commission (ERC) to treat lipoprotein lipase 
deficiency (LPLD)107. In 2017, Food and Drug Administration (FDA) approved the first 
rAAV based gene therapy in US, named Luxturna (voretigene neparvovec-rzyl) to correct 
RPE65 mutation-associated inherited retinal dystrophy108–110. In 2019, FDA approved 
Zolgensma (onasemnogene abeparvovec) to treat spinal muscular atrophy (SMA)111,112. In 
addition to these approved therapies, currently ~14% of the gene therapies that have entered 
the clinical trials uses rAAVs, which is at 2nd position following ~27% using vaccinia virus. 
Other trials comprise ~11% using ADs or retroviruses, ~6% using LVs, ~4% using naked or 
plasmid DNA, and ~1% using HSV. 
Current limitations of AAVs 
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While the properties of AAVs certainly account for their use in research labs and 
clinics, their use needs a significant improvement on the transduction efficiency and target 
specificity113. There are currently 12 known serotypes of AAVs with sequence similarity 
between 50 - 99% that are known to exhibit different but overlapping tropisms80. These 
tropisms are often attributed to their uptake by specific cell surface receptors. For instance, 
AAV2 binds to heparin sulfate receptor114 and AAV9 binds to galactose receptor115. In 
addition to these major receptors, several have identified co-receptors which contribute to 
their cellular uptake116,117. While these receptors contribute to some differences in the tropism 
among serotypes, these receptors are broadly expressed across different tissues. In other 
words, the AAVs are naturally evolved to have broad tropisms, and this needs to be addressed 
if we want to use them as safe vehicles for gene delivery to a specific target. In addition to 
the serotype specific receptors and co-receptors, the AAVs are also known to have a 
universal receptor AAVR, and this could be crucial for host cell infectivity118–123.   
Given the presence of multiple receptors and incomplete understanding of the biology, 
alternate approaches have been taken to tackle the issue on off-target transduction such as by 
performing localized injection to deliver the cargo124, or cargo engineering to restrict 
expression to cell populations of interest, or by coupling injection of AAVs carrying 
transgene that is controlled by a recombinase enzyme such as Cre into Cre-transgenic 
animals to get specificity in transgene expression93. Having said that, these approaches aren’t 
always feasible and are often very invasive. Alternative strategies to achieve highly targeted 
gene delivery and protein expression are desired in areas that are anatomically hard to access 
for AAV injection, in cell-types with unknown specific regulatory elements, and in cell-types 
with lack of availability of cell-type specific transgenic lines.  
1.3 ENGINEERING AAV CARGOS FOR EFFICIENT AND TARGETED PROTEIN 
EXPRESSION 
AAVs with improved transduction efficiencies and improved cell-type specificity, i.e., 
with minimal off-target transduction via systemic injection would open up many potential 
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applications in science to begin with and may eventually find their purpose in gene therapies 
too.  
These are currently addressed by various modifications done to the cargo or the rAAV 
genome125–127. To improve transduction efficiency, strong ubiquitous promoters or enhancers 
have been engineered to fit into the rAAV genome size limit95,128,129. ITRs have also been 
mutated to engineer to a self-complementary AAV (scAAV) version which can deliver the 
genome as a double stranded DNA (dsDNA) instead of a ssDNA but at half the genome size 
(2.35 kb)130. This scAAV version alleviates the rate limiting step of the second strand 
synthesis in the host cell, thereby shown to improve the transduction efficiency.  
To restrict expression of delivered cargo to the cell-types of interest, regulatory 
elements are engineered to fit the needs. Cell-type specific promoters or enhancers can 
regulate expression in a defined cell population129,131,132. Inducible promoters (such as 
tetracycline inducible promoter) can control the dose or time of expression133. Other 
regulatory elements such as microRNA targeting signal are identified across cell-types of 
interest and can selectively suppress expression in a cell type where the recognized miRNA 
can act on it134–137.  
While the cargo engineering is a welcome addition to improve the efficiency and 
specificity of the vector delivered gene expression, these strategies do not completely 
alleviate the problem when a non-invasive systemic delivery is preferred where the vectors 
still deliver genes across different organs, thereby turning on the immune response in the 
host cell138. Also, these regulatory elements can have varying degrees of specificity or 
efficiency across cell-types. Hence it is only seen as an added advantage to the existing 
vectors, and not a definitive solution to the problem of broad tropism. 
1.4 ENGINEERING AAV CAPSIDS TO MODIFY THE VECTOR TROPISM  
Engineering AAV capsids to overcome the current limitations has been of great 
interest to the field. For instance, neuron-specific AAVs will be useful for neural circuit 
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mapping studies139, and the organ specific ones, say heart, lung and kidney, will find broad 
applications to study pathologies and to develop disease models140–142. Broadly, the 
availability of these specific variants can facilitate non-invasive delivery of vectors, which 
will simplify the whole procedure involved in gene delivery both in science and in clinics. 
Several groups have attempted to address this problem using a rational or semi-rational 
approach143–148 or directed evolution approach113,149–153. Progress with the rational design has 
been slow due to our limited understanding of the capsid structure-function relationship. In 
light of this, directed evolution seems to have more promise for vector engineering because 
it requires little to no knowledge of a receptor target or mechanism of entry93,154.  
1.5 IN VIVO SELECTION OF AAV CAPSIDS USING CREATE 
Recombinant AAVs are the preferred vehicles for many in vivo gene transfer 
applications across cell populations; however, applications involving gene transfer to the 
central nervous system (CNS) are limited due to the lower transduction efficiency and 
specificity from natural or engineered vectors via systemic delivery across species, and often 
requires invasive routes of delivery or very high doses of vector93,143,155,156. This is because 
for intravenous delivery, the highly selective blood-brain barrier (BBB) poses a serious 
challenge, and the cellular heterogeneity of the CNS presents further challenges for gene 
transfer applications.  
Cre recombination-based AAV targeted evolution method (CREATE) 
In 2016, Deverman, B., et al157 developed an in vivo selection method to provide 
selective pressure for capsids that cross the BBB and functionally transduce CNS cell types. 
This method, called CREATE (Cre-recombination based AAV targeted evolution) is a Cre 
recombination–dependent approach to selectively recover capsids that transduce predefined 
Cre-expressing target cell populations. CREATE uses an rAAV capsid genome (rAAV-Cap-
in-cis-lox) that couples a full-length AAV cap gene, controlled by regulatory elements from 
the AAV rep gene with a Cre-invertible switch (Figure 1.2). By building capsid libraries 
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within the rAAV-Cap-in-cis-lox backbone and delivering the virus libraries to animals with 
Cre expression in a defined cell population, the system enables the selective amplification 
and recovery of sequences that have transduced the target population (Figure 1.2)157. 
 
Figure 1.2: Cre-dependent recovery of AAV capsid sequences from transduced target cells. 
 
(a) An overview of the CREATE selection process. PCR is used to introduce diversity (full 
visual spectrum vertical band) into a capsid gene fragment (yellow). The fragment is cloned 
into the rAAV genome harboring the remaining capsid gene (gray) and is used to generate a 
library of virus variants. The library is injected into Cre transgenic animals, and PCR is used 
to selectively recover capsid sequences from Cre+ cells. (b) The rAAV-Cap-in-cis-lox rAAV 
genome. Cre inverts the polyadenylation (pA) sequence flanked by the lox71 and lox66 sites. 
PCR primers (half arrows) are used to selectively amplify Cre-recombined sequences. (c) 
PCR products from Cre recombination–dependent (top) and –independent (bottom) 
amplification of capsid library sequences recovered from two Cre+ or Cre− mice are shown. 
Schematics (bottom) show the PCR amplification strategies. (d) Schematic shows the AAV 
genes within the Rep-AAP AAV helper plasmid and the proteins encoded by the cap gene. 
Stop codons inserted in the cap gene eliminate VP1, VP2 and VP3 capsid protein expression. 
(e) DNase-resistant AAV vector genomes (vg) produced with the split AAV2/9 Rep-AAP 
and rAAV-Cap-in-cis-lox genome (top) as compared to the vg produced with standard 
AAV2/9 Rep-Cap helper and rAAV-UBC-mCherry genome (middle) or with the AAV2/9 
Rep-AAP and rAAV-UBC-mCherry genome (bottom). n = 3 independent trials per group; 
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mean ± s.d.; **P < 0.01, ***P < 0.001; one-way ANOVA and Tukey's multiple-
comparison test. (f) Cloning the 7-mer capsid library into the rAAV-ΔCap-in-cis vector. (g) 
The AAV9 surface model shows the location of the 7-mer inserted between amino acids (aa) 
588 and 589 (magenta). Sites encoded with the PCR-generated library fragment (aa 450–
592) are shown in yellow157.  
 
Using CREATE, the natural serotype AAV9 that is known to cross the BBB less 
efficiently was chosen to evolve by targeted insertion of a randomized 7-mer (7-amino acid 
long peptide) within a surface-exposed site of the capsid (between AA588-589) and then 
intravenously injected this large library (a theoretical library size of ~1.28 billion variants) 
in a Cre-transgenic mouse where Cre expression was restricted to the CNS cell-type of 
interest. GFAP-Cre, an astrocyte specific Cre transgenic line was chosen given the high 
prevalence of this cell population in the CNS. Two weeks post in vivo selection, the mice 
were sacrificed to collect the brain and spinal cord. The viral DNA was extracted from the 
tissue, and selectively amplified the viral DNA from the Cre-positive cells using primers that 
can selectively yield a PCR product of lox-flipped viral DNA. This was then pooled together 
to make a second viral library for the second round of selection157.  
Post two rounds of selection, the recovered variants were cloned back in Escherichia 
coli, and the highly enriched variants were identified by sanger sequencing. The outcome 
resulted in a handful of enriched variants, each of which had a unique 7-mer motif. A rAAV 
capsid variant called AAV-PHP.B expressed the transgene broadly in CNS and the 
transduction efficiency was at least 40-fold higher compared to the parent (Figures 1.3)157.  
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Figure 1.3: AAV-PHP.B mediates efficient gene delivery throughout the CNS after 
intravenous injection in adult mice. 
 
(a) ssAAV9:CAG-GFP or ssPHP.B:CAG-GFP, at 1 × 1012 or 1 × 1011 vg/mouse (right), was 
intravenously injected into adult mice. Images show GFP expression 3 weeks after injection. 
Representative images of GFP IHC in the brains of mice given AAV9 (left) or B (middle 
and right). Scale bar, 1 mm. 
 
The follow-up work from the Gradinaru lab, by Chan, K., et al133 reported additional 
AAV variants using CREATE. One new variant AAV-PHP.S provides efficient transduction 
of sensory neurons and cardiac muscle, and the second reported variant, AAV-PHP.eB, that 
was further evolved from AAV-PHP.B parent, exhibits broad CNS transduction with higher 
neuron transduction efficiency compared to AAV-PHP.B. 
In summary, these studies support the use of CREATE to evolve AAVs that show 
greater efficiency for the desired nerve cell types. 
1.6 RESEARCH MOTIVATION 
Thesis aims 
1.  To expand the potential use of the engineered PHP vectors through development of a 
detailed easy-to-follow protocol, and establish strategies to achieve transgene expression in 
specific cell population through cargo engineering, and study the usage of vectors across 
mouse strains or species. 
AAV-PHP.eB or AAV-PHP.B’s ability to broadly transduce different cell-types of 
CNS has been well received by the scientific community for neuroscience applications158–
163. However, as every study involves specific cargos to deliver into the desired cell 
populations, its usage can be broadened by establishing a detailed and optimized protocol to 
help scientists produce these vectors in a laboratory setting for their own needs. Further, these 
engineered vectors can further benefit from strategies to refine the delivered transgene 
expression in a select population under investigation across different host systems.  
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2. To build a high-confidence in vivo selection platform in order to overcome current 
limitations of existing selection technology such as CREATE, and thereby speed up the 
development of the AAV toolkit to target distinct cell populations of the central nervous 
system via systemic delivery.  
Developing highly efficient target specific and safe vehicles are ambitious goals to 
achieve and any significant success in this direction will benefit the scientific and medical 
communities. Such selective tropism requires an in vivo selection platform where we can 
perform parallel positive selections across targets of interest, and couple the process with 
post-hoc negative selections across off-targets. I would like to approach this by building upon 
the CREATE method that would allow us to find high performing variants in different mouse 
nerve cell types by positive and negative selection, henceforth referred to Multiplexed-
CREATE.  
The selected capsids could be supplemented with strategies to further refine the 
expression to the target cell population such as the one described earlier involving cargo 
engineering. 
Current limitations with CREATE method 
The published CREATE system allows us to do positive selection133,157. In other 
words, we can enrich for improved variants with several rounds of selection. While this is 
optimal to select for high transduction efficiency, this may not be the best strategy if we want 
to look for other traits such as selective tropism, functional viruses with no tropism, broad 
tropisms, etc. Also, the CREATE method does not provide us with an understanding of how 
the enriched variants performed in every step of the selection. This is very useful information 
for the experimenter to analyze the root cause for enrichment. Were these variants recovered 
because they highly transduced the cells of interest, or simply because of some other bias 
introduced by variabilities in virus production, DNA library assembly, or PCR amplification? 
Since we lacked this first-hand knowledge on the performance of variants in the CREATE 
method, we often do not have much confidence about which variants to test individually. 
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Current limitations with the translation of AAV-PHP.B vectors across mouse strains 
and species 
The recent works from different laboratories pointed out the limitations with the use 
of AAV-PHP.B variants across mouse strains. A mouse strain, BALB/cJ, was first identified 
to lack the enhanced CNS transduction seen with AAV-PHP.B or eB vectors164. Follow-up 
studies later noticed that the transduction was not consistent across different strains of mice, 
and broadly classified mouse strains that had PHP.B permissibility to those that did not165,166. 
This suggested that the BBB across strains of mice is not conserved. The differences across 
these strains led to the identification of the endothelial cell membrane protein receptor, ly6a, 
to be responsible for the AAV-PHP.B or eB uptake by the endothelial cells that forms the 
BBB165,167,168. This not only limits the use of these vectors across mouse strains but also their 
ability to translate across species as such the homolog for ly6a is not found in humans. Hence 
to potentially translate the use of vectors across different strains of mouse and across species, 
we need to select for new variants that may surpass the current limitations on translation. 
 
 
 
 
 
14 
C h a p t e r  2  
CHARACTERIZATION AND PRODUCTION OF SYSTEMIC AAV 
VECTORS FOR WIDESPREAD AND TARGETED GENE 
DELIVERY IN RODENTS 
Challis, R. C.*, Ravindra Kumar, S.*, Chan, K. Y., Challis, C., Beadle K., Jang, M. J., 
Kim H. M., Rajendran, P. S., Tompkins, J. D., Shivkumar, K., Deverman, B. E., Gradinaru, 
V. Systemic AAV vectors for widespread and targeted gene delivery in rodents. Nature 
Protocol 14, 379–414 (2019). https://doi.org/10.1038/s41596-018-0097-3 
*equal contribution. 
 
2.1 SUMMARY 
We recently developed adeno-associated virus (AAV) capsids to facilitate efficient 
and noninvasive gene transfer to the central and peripheral nervous systems. However, a 
detailed protocol for generating and systemically delivering novel AAV variants was not 
previously available. In this protocol, we describe how to produce and intravenously 
administer AAVs to adult mice to specifically label and/or genetically manipulate cells in 
the nervous system and organs, including the heart. The procedure comprises three separate 
stages: AAV production, intravenous delivery, and evaluation of transgene expression. The 
protocol spans 8 d, excluding the time required to assess gene expression, and can be 
readily adopted by researchers with basic molecular biology, cell culture, and animal work 
experience. We provide guidelines for experimental design and choice of the capsid, cargo, 
and viral dose appropriate for the experimental aims. The procedures outlined here are 
adaptable to diverse biomedical applications, from anatomical and functional mapping to 
gene expression, silencing, and editing. 
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2.2 INTRODUCTION 
Recombinant AAVs (rAAVs) are commonly used vehicles for in vivo gene transfer 
and promising vectors for therapeutic applications169. However, AAVs that enable efficient 
and noninvasive gene delivery to defined cell populations are needed. Current gene 
delivery methods (e.g., intra-parenchymal surgical injections) are invasive, and alternatives 
such as intravenous administration require high viral doses and provide relatively 
inefficient transduction of target cells. We previously developed Cre recombination-based 
AAV targeted evolution (CREATE) to engineer and screen for AAV capsids that are 
capable of more efficient gene transfer to specific cell types via the vasculature133,134,157. 
Compared to naturally occurring capsids (e.g., AAV9), the novel AAV-PHP capsids 
identified by CREATE exhibit markedly improved tropism for cells in the adult mouse 
central nervous system (CNS), peripheral nervous system (PNS), and visceral organs. In 
this protocol, we describe how to package genetic cargo into AAV-PHP capsids and 
intravenously administer AAVs for efficient, noninvasive, and targeted gene delivery at 
sites throughout the body (Figure 2.1).  
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Figure 2.1: Overview of the protocol. 
 
The Procedure comprises three main stages: AAV production (Steps 1–42), intravenous 
delivery (Steps 43–49), and evaluation of transgene expression (Step 50). The pAAV 
plasmid contains the rAAV genome (e.g., containing a fluorescent reporter, shown in 
green) (Figure 2.6 and Table 2.T1), which is packaged into an AAV-PHP capsid via triple 
transient transfection. Systemic administration of AAV-PHP viruses is achieved by retro-
orbital injection into wild-type or transgenic mice; transgene expression is evaluated after 
adequate time has passed for viral transduction and protein expression. AAV-PHP viruses 
target cells in the CNS (e.g., in the brain and spinal cord) or PNS and visceral organs (e.g., 
in the heart and gut). Filled green circles represent transduced cells. For illustrative 
purposes, we use fluorescent labeling as an example of how to assess transgene expression; 
however, assessment can take other forms (see ‘Experimental design’ section for details). 
See Figure 2.7a for a time line of the Procedure. 
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Among our new capsid variants133,134,157, AAV-PHP.B and the further evolved 
AAV-PHP.eB efficiently transduce neurons and glia throughout the CNS (Figure 2.2); 
another variant, AAV-PHP.S, displays improved tropism for neurons within the PNS 
(Figure 2.3) and organs, including the gut133 and heart (Figure 2.4). Importantly, these 
capsids target cell populations that are normally difficult to access because of their location 
(e.g., sympathetic, nodose, dorsal root, and cardiac ganglia) (Figures 2.3a–c and 2.4d) or 
broad distribution (e.g., throughout the brain or enteric nervous system) (Figures 2.2 and 
2.3d) and can be utilized in several mouse and rat strains (Figure 2.5). Together with the 
capsid, the genetic cargo (or rAAV genome) can be customized to control transgene 
expression (Figure 2.6 and Table 2.T1). The rAAV genome contains the components 
required for gene expression, including promoters, transgenes, protein trafficking signals, 
and recombinase-dependent expression schemes. Hence, different capsid–cargo 
combinations create a versatile AAV toolbox for genetic manipulation of diverse cell 
populations in wild-type and transgenic animals. Here, we provide researchers, especially 
those new to working with AAVs or systemic delivery, with resources that will help them 
utilize AAV-PHP viruses in their own research. 
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Figure 2.2: AAV-PHP.eB and gene regulatory elements enable cell type–specific gene 
expression in the brain. 
 
(a–c), We used AAV-PHP.eB to package single-stranded (ss) rAAV genomes that express 
fluorescent reporters (XFPs), each with two nuclear localization signals (NLS), from cell 
type–specific promoters. Genomes containing the hSyn1, MBP, or GFAP (GfABC1D) 
promoters were used to target neurons, oligodendrocytes, or astrocytes, respectively. 
Viruses were co-delivered by retro-orbital injection to 7-week-old C57BL/6N mice (n = 2) 
at 3 × 1011 vector genomes (vg)/virus (9 × 1011 vg total). Native fluorescence in coronal 
brain sections was evaluated 4 weeks later using confocal microscopy. All sections were 
mounted in Prolong Diamond Antifade before imaging. (a), Cell type–specific, nuclear-
localized XFPs label distinct cell types throughout the brain. Tile scan of a coronal brain 
slice, presented as a maximum-intensity projection; inset shows a zoomed-in view of the 
hippocampus. XFPs were mNeonGreen (mNG; green), tdTomato (tdT; red), and 
mTurquoise2 (mTurq2; blue). Scale bars, 1 mm and 500 µm (inset). (b,c), Antibody 
staining can be used to determine the specificity and efficiency of cell type–specific 
promoters. (b), Brain sections were stained with NeuN (purple), Olig2 (light blue), and 
S100 (purple) to mark neurons, oligodendrocyte lineage cells, and a population of glia that 
consists mainly of astrocytes, respectively. NLS-mNG (green), NLS-tdT (red), and NLS-
mTurq2 (dark blue) indicate nuclear-localized XFPs. Images are from a single z plane. 
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Scale bar, 100 µm. (c), AAV-PHP.eB differentially transduces various regions and cell 
types throughout the brain. ‘Specificity’ or ‘Efficiency’ are defined as the ratio of double-
labeled cells to the total number of XFP- or antibody-labeled cells, respectively. For image 
processing, median filtering and background subtraction using morphological opening 
were first applied to each image to reduce noise and correct imbalanced illumination. Each 
nucleus expressing XFPs and labeled with antibodies was then segmented by applying a 
Laplacian of Gaussian filter to the pre-processed images. We considered cells that were 
both expressing XFPs and labeled with antibodies if the nearest center-to-center distance 
between blobs (nuclei or cell bodies) in two channels was <7 µm (half of the cell body 
size). Five images per brain region were analyzed in each mouse; we excluded images with 
tissue edges because bright edges prevent accurate cell detection. Mean ± s.e.m. is shown. 
(d,e), miRNA target sequences (TS) miR-204-5p or miR-708-5p135 can be used to achieve 
expression that is more restricted to neurons or astrocytes, respectively. (d), The indicated 
pairs of vectors were separately packaged into AAV-PHP.eB and co-administered via 
retro-orbital injection to 6- to 8-week-old C57BL/6J mice (n = 2) at 1 × 1011 vg/virus (2 × 
1011 vg total); mNG and control XFP fluorescence were evaluated 3 weeks later using 
confocal microscopy. The CAG-mNG genome (green) contained no miRNA TS (left) or 
three tandem copies of miR-204 (middle) or miR-708 (right) TS; the CAG-XFP genome 
(magenta) contained no miRNA TS and was injected as an internal control. miR-204 
reduced expression in cells with the morphology of astrocytes, and miR-708 reduced 
expression in cells with neuronal morphology. Scale bar, 100 µm. (e), ssAAV-
PHP.eB:CAG-GCaMP6f-3x-miR122-TS (left) or ssAAV-PHP.eB:CAG-GCaMP6f-3x-
miR204-5p-3x-miR122-TS (right) was injected into 6- to 8-week-old C57BL/6J mice (n = 
2) at 1 × 1011 vg/mouse; gene expression was evaluated 3 weeks later using confocal 
microscopy. The miR-204 TS reduced GCaMP6f expression (green) in S100+ glia 
(magenta) in the cortex. Both vectors contained three tandem copies of miR-122 to reduce 
expression in hepatocytes136. Insets and asterisks highlight representative images of S100+ 
glia. Scale bars, 50 µm and 10 µm (insets). Refer to Table 2.T1 for details of rAAV 
genomes. Experiments on vertebrates conformed to all relevant governmental and 
institutional regulations and were approved by the Institutional Animal Care and Use 
Committee (IACUC) and the Office of Laboratory Animal Resources at the California 
Institute of Technology. In our primary publication133, results were obtained using the 
C57BL/6J mouse line. pA, polyadenylation signal; W, WPRE. 
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Figure 2.3: AAV-PHP.S transduces neurons throughout the PNS. 
 
We used AAV-PHP.S to package single-stranded (ss) rAAV genomes that express 
fluorescent reporters from either neuron-specific (e.g., hSyn1 and TH (tyrosine 
hydroxylase)) or ubiquitous promoters (e.g., CAG). Viruses were delivered by retro-orbital 
injection to 6- to 8-week-old C57BL/6J or Cre transgenic mice, and transgene expression 
was evaluated 2–3 weeks later. Whole-mount tissues were optically cleared using either 
ScaleSQ170 (a (right), c, and d) or RIMS171,172 (b) and imaged using wide-field or confocal 
microscopy; confocal images are presented as maximum-intensity projections. (a), ssAAV-
PHP.S:hSyn1-mNeonGreen and ssAAV-PHP.S:CAG-DIO-mRuby2 were co-injected into a 
TH-IRES-Cre mouse at 1 × 1012 vg/virus (2 × 1012 vg total). Native mNeonGreen (green) and 
mRuby2 (red) fluorescence were assessed 2 weeks later using wide-field (left) or confocal 
fluorescence microscopy (right). Images are from the second to sixth thoracic (T2–T6) (left) 
and eighth cervical to second thoracic (C8–T2) (right) paravertebral ganglia, which provide 
sympathetic innervation to thoracic organs, including the heart. Arrows denote 
mNeonGreen+ nerve fibers. Scale bars, 1 mm (left) and 500 µm (right). (b), ssAAV-
PHP.S:CAG-DIO-eYFP was injected into a TRPV1-IRES-Cre mouse at 1 × 1012 vg; gene 
expression in a nodose ganglion was evaluated 3 weeks later. Scale bar, 200 µm. (c), A 
mixture of three separate viruses (ssAAV-PHP.S:CAG-DIO-XFPs) was injected into a 
TRPV1-IRES-Cre mouse at 1 × 1012 vg/virus (3 × 1012 vg total); gene expression in a dorsal 
root ganglion was evaluated 2 weeks later. XFPs were mTurquoise2 (blue), mNeonGreen 
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(green), and mRuby2 (red). Scale bar, 200 µm. (d), ssAAV-PHP.S:mTH-GFP and 
ssAAV-PHP.S:hSyn1-tdTomato-f (farnesylated) were co-injected into a C57BL/6J mouse at 
5 × 1011 vg/virus (1 × 1012 vg total); gene expression in the duodenum was assessed 22 d later. 
The image stack includes both the myenteric and submucosal plexuses. Inset shows a 
zoomed-in view of ganglia containing TH+ cell bodies (green); tdTomato-f (red) labels both 
thick nerve bundles and individual fibers. Scale bars, 200 µm (left) and 50 µm (right). Refer 
to Table 2.T1 for details of rAAV genomes. Experiments on vertebrates conformed to all 
relevant governmental and institutional regulations and were approved by the Institutional 
Animal Care and Use Committee (IACUC) and the Office of Laboratory Animal Resources 
at the California Institute of Technology. In our primary publication133, results were obtained 
using the ChAT-IRES-Cre driver mouse line. 
 
 
 
 
Figure 2.4: AAV-PHP.S for mapping the anatomy and physiology of the heart. 
 
AAV-PHP.S viruses were delivered by retro-orbital injection to 6- to 8-week-old C57BL/6J 
or Cre transgenic mice. (a), AAV-PHP.S transduces the heart more efficiently than the 
current standard, AAV9. ssAAV9:CAG-NLS-GFP or ssAAV-PHP.S:CAG-NLS-GFP were 
injected into C57BL/6J mice at 1 × 1012 vg/mouse. Native GFP fluorescence was assessed in 
whole-mount hearts 4 weeks later using wide-field fluorescence microscopy 
(unpaired t test, t7 = 8.449, ****P <0.0001). For AAV9 and AAV-PHP.S, n = 5 and 4 mice, 
respectively. a.u., arbitrary units. Mean ± s.e.m. is shown. Scale bar, 3 mm. (b), A mixture 
of three viruses (ssAAV-PHP.S:CAG-XFPs) was injected into a C57BL/6J mouse at 3.3 × 
1011 vg/virus (1 × 1012 vg total); gene expression in cardiac muscle was evaluated 11 d later. 
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Individual cardiomyocytes can be easily distinguished from one another. Scale bar, 200 
µm. (c), A mixture of three viruses (ssAAV-PHP.S:CAG-DIO-XFPs) was injected into a 
TRPV1-IRES-Cre mouse at 1 × 1012 vg/virus (3 × 1012 vg total); gene expression in cardiac 
nerves was evaluated 2 weeks later. Scale bar, 50 µm. (d), ssAAV-PHP.S:Ef1ɑ-DIO-ChR2-
eYFP was injected into ChAT-IRES-Cre mice (n = 2) at 1 × 1012 vg; gene expression in a 
cardiac ganglion was evaluated 3 weeks later (left). Ex vivo intracellular recordings were 
performed after 5 weeks of expression. Differential interference contrast (DIC) image 
(middle) shows the optical fiber for light delivery and electrode for concurrent intracellular 
recordings; inset shows a higher-magnification image of a selected cell (asterisk). 
Cholinergic neurons generated action potentials in response to 473-nm light pulses (5 Hz, 20 
ms) (right). Scale bars, 50 µm (left), 300 µm (middle), and 10 µm (inset). Whole-mount 
tissues in (b), (c), and (d) (left) were optically cleared using ScaleSQ170 and imaged using 
confocal microscopy; confocal images are presented as maximum-intensity projections. 
XFPs in (b) and (c) were mTurquoise2 (blue), mNeonGreen (green), and mRuby2 (red). 
Refer to Table 2.T1 for details of rAAV genomes. The pAAV-Ef1ɑ-DIO-ChR2-eYFP 
plasmid was a gift from K. Deisseroth, Stanford University (Addgene, plasmid no. 20298). 
Experiments on vertebrates conformed to all relevant governmental and institutional 
regulations and were approved by the Institutional Animal Care and Use Committee 
(IACUC) and the Office of Laboratory Animal Resources at the California Institute of 
Technology. In our primary publication133, results were obtained using the ChAT-IRES-Cre 
driver mouse line. 
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Figure 2.5: AAV-PHP.B and AAV-PHP.eB can be used in several mouse and rat strains. 
 
(a), AAV-PHP.B transduces the brain more efficiently than AAV9 in C57BL/6J, FVB/NCrl, 
and 129S1/SvImJ mice, but not in BALB/cJ mice. ssAAV9:CAG-mNeonGreen or ssAAV-
PHP.B:CAG-mNeonGreen were systemically delivered to 6- to 8-week-old C57BL/6J (n = 
1–2 mice per group), FVB/NCrl (n = 2 mice per group), 129S1/SvImJ (n = 2 mice per group), 
and BALB/cJ mice (n = 2 mice per group) at 1 × 1012 vg/mouse. 3 weeks later, sagittal brain 
sections were mounted in Vectashield and imaged using confocal microscopy. Imaging and 
display parameters are matched across all panels. Scale bar, 2 mm. (b–e), Examples of AAV-
PHP.B- and AAV-PHP.eB-mediated brain transduction for fluorescent labeling (b,c) and 
calcium imaging (d,e) in different mouse and rat strains. Gene expression was evaluated 
using confocal microscopy. (b), ssAAV-PHP.eB:CAG-tdTomato (Addgene) was delivered 
by retro-orbital injection to a 10-week-old 129T2/SvEmsJ mouse at 3 × 1011 vg; tdTomato 
fluorescence (red) was examined 2 weeks later. Scale bars, 1 mm (top) and 100 µm 
(insets). (c), ssAAV-PHP.eB:CAG-mRuby2 was administered by tail-vein injection to a 6-
week-old female Fischer rat at 3 × 1012 vg; 3 weeks later, brain slices were mounted in 
Prolong Diamond Antifade for imaging. Scale bars, 2 mm (top) and 100 µm (insets). (d), 
ssAAV-PHP.eB:CMV-hSyn1-GCaMP6f-3x-miR122-TS was delivered by tail-vein 
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injection to a 4-week-old female Long-Evans rat at 1 × 1013 vg; 3 weeks later, brain slices 
were stained with a GFP antibody (green) for imaging. Scale bars, 1 mm (top left) and 100 
µm (insets). The vector contained three tandem copies of miRNA target sequence (TS) miR-
122 (CAAACACCATTGTCACACTCCA) to reduce expression in hepatocytes136. Images 
in (d) courtesy of M. Fabiszak/W. Freiwald lab, Rockefeller University. (e), ssAAV-
PHP.B:CaMKIIa-CaMPARI (calcium-modulated photoactivatable ratiometric integrator173) 
was administered by retro-orbital injection to a 8-week-old FVB/NCrl mouse at 3 × 1011 vg 
and cortical expression was assessed 2 weeks later. Images are a 50-µm maximum-intensity 
projection of the cortex (left) and 500-µm-thick ScaleSQ170-cleared 3D volume (right). Scale 
bars, 100 µm. Experiments on vertebrates conformed to all relevant governmental and 
institutional regulations and were approved by the Institutional Animal Care and Use 
Committee (IACUC) and the Office of Laboratory Animal Resources at the California 
Institute of Technology. In our primary publication157, results were obtained using the 
C57BL/6J mouse line. CaMKIIa, calcium/calmodulin-dependent protein kinase type IIa; 
CMV, cytomegalovirus early enhancer element. 
 
 
 
 
 
Figure 2.6: A modular AAV toolbox for cell type–specific gene expression. 
 
The rAAV genome, contained in a pAAV plasmid (not shown), consists of an expression 
cassette flanked by two 145-bp inverted terminal repeats (ITRs); the entire genome, 
including the ITRs, cannot exceed 4.7–5 kb. The promoters, transgenes, localization 
signals, and recombination schemes are interchangeable. Gene regulatory elements, such 
as promoters and microRNA (miRNA) target sequences (TS) (Figure 2.2d,e), determine 
the strength and specificity of transgene expression125. Transgenes may be constitutively 
expressed or flanked by recombination sites for flippase (Flp)- or Cre recombinase (Cre)-
dependent expression. In the latter approach, the transgene remains in the double-floxed 
inverted orientation (DIO); Cre-mediated inversion of the transgene enables cell type–
specific expression in transgenic animals (Figures 2.3a–c and Figures 2.4c,d). 
Localization sequences further restrict gene expression to distinct cellular compartments 
such as the nucleus (via one or more nuclear localization signals (NLS)) (Figure 2.2a,b), 
cytosol (via a nuclear exclusion signal (NES)174), or cell membrane (via farnesylation175, 
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the CD4-2176 transmembrane (TM) targeting domain, or PDZ177 protein–protein 
interaction domains) (Figure 2.3d). Note that the 3ʹ UTR contains the woodchuck hepatitis 
posttranscriptional regulatory element (WPRE) (609 bp) and a polyadenylation signal (e.g., 
the human growth hormone (hGH) polyA) (479 bp) (not shown), both of which enhance 
transgene125. We recommend that foreign genes be codon-optimized to match the host 
species to increase expression from the rAAV genome. Use sequence-editing and 
annotation software to determine the unique attributes of each rAAV genome. In Table 
2.T1, we list genomes used here and in our previous work133,157; see also Addgene’s 
plasmid repository for pAAVs that may be suitable for different applications. CRISPR, 
clustered regularly interspaced short palindromic repeats; DREADDs, designer receptors 
exclusively activated by designer drugs; shRNA, short hairpin RNA. 
 
 
 Vector name pAAV- Expression class Addgene 
no. 
Tunable expression 
TREa-mTurquoise2 
tTA-dependent 
99113 
TRE-eYFP 104056 
TRE-mRuby2 99114 
TRE-DIOb-mTurquoise2 
Cre- and tTA-
dependent 
99115 
TRE-DIO-eYFP 117383 
TRE-DIO-tdTomato 99116 
TRE-DIO-mRuby2 99117 
CAGc-tTAd 
Inducer 
99118 
hSyn1e-tTA 99119 
ihSyn1f-tTA 99120 
ihSyn1-DIO-tTA 99121 
Tissue-wide 
expression 
CAG-mTurquoise2 
Constitutive 
99122 
CAG-eYFP 104055 
CAG-mRuby2 99123 
CAG-NLSg-GFP 104061 
CAG-DIO-mTurquoise2 
Cre-dependent 
104059 
CAG-DIO-eYFP 104052 
 
 
26 
 Vector name pAAV- Expression class Addgene 
no. 
CAG-DIO-mRuby2 104058 
Cell type–specific 
expression 
hSyn1-mTurquoise2 
Cell type–specific 
99125 
hSyn1-eYFP 117382 
hSyn1-mRuby2 99126 
GFAPh-2xNLS-mTurquoise2 104053 
hSyn1-2xNLS-mTurquoise2 118025 
MBPi-2xNLS-tdTomato 104054 
mTHj-GFP 99128 
hSyn1-tdTomato-fk 104060 
GFAP-mKate2.5-f 99129 
mDlxl-NLS-mRuby2 99130 
CAG-eYFP-3x-miR204-5p-
TSm 
117380 
CAG-eYFP-3x-miR708-5p-TSn 117381 
CAG-GCaMP6f-3x-miR204-
5p-3x-miR122-TSo 
117384 
 
Table 2.T1: pAAV plasmids  
A comprehensive list of pAAV plasmids used in this and related work133,157. aTREpi, 
second-generation tetracycline-regulated promoter. bDIO, double-floxed inverted 
orientation. cCAG, synthetic promoter containing the cytomegalovirus early enhancer 
element, the promoter, first exon, and first intron of chicken beta-actin gene, and the splice 
acceptor from the rabbit beta-globin gene. dtTA, tetracycline-controlled 
transactivator. ehSyn1, human synapsin I promoter. fihSyn1, inducible intron human 
synapsin I promoter. gNLS, nuclear localization signal. hGFAP (GfABC1D), glial fibrillary 
acidic protein promoter. iMBP, myelin basic protein promoter. jmTH, mouse tyrosine 
hydroxylase promoter. kf, farnesylation signal from c-Ha-Ras. lmDlx, mouse distal-less 
homeobox promoter. mmiR-204-5p-TS: AGGCATAGGATGACAAAGGGAA. nmiR-
708-5p-TS: CCCAGCTAGATTGTAAGCTCCTT. omiR-122-TS: 
CAAACACCATTGTCACACTCCA. 
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Overview of the protocol  
We provide an instruction manual for users of AAV-PHP variants. The procedure 
includes three main stages (Figure 2.1): AAV production (Steps 1–42), intravenous 
delivery (Steps 43–49), and evaluation of transgene expression (Step 50).  
The AAV production protocol is adapted from established methods. First, HEK293T 
cells are transfected with three plasmids178–180 (Steps 1–3, Figure 2.1 and Figure 2.7): (i) 
pAAV, which contains the rAAV genome of interest (Figure 2.6 and Table 2.T1); (ii) 
pUCmini-iCAP-PHP, which encodes the viral replication and capsid proteins (Table 2.T2); 
and (iii) pHelper, which encodes adenoviral proteins necessary for replication. Using this 
triple-transfection approach, a single-stranded rAAV genome is packaged into an AAV-
PHP capsid in HEK293T cells. AAV-PHP viruses are then harvested181 (Steps 4–14), 
purified182,183 (Steps 15–31), and titered by quantitative PCR (qPCR)184 (Steps 32–42) 
(Figure 2.7). Purified viruses are intravenously delivered to mice via retro-orbital 
injection185 (Steps 43–49), and gene expression is later assessed using molecular, 
histological, or functional methods relevant to the experimental aims (Step 50).  
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Figure 2.7: Time line and AAV harvest procedure. 
 
(a), Time line of the procedure. The entire protocol spans 8 d, excluding pause points on days 
5 (Steps 11 and 14), 6 (Step 31), and 7 (Step 35) and the time required to evaluate transgene 
expression (Step 50). Days 1–7 (Steps 1–42) constitute the AAV production stage (Figure 
2.1). (b), Schematic of the AAV harvest procedure, with images corresponding to indicated 
steps. The iodixanol-based purification protocol does not eliminate empty capsids (i.e., 
capsids that fail to package an rAAV genome), as determined by negative-staining 
transmission electron microscopy; empty particles are characterized by an electron-dense 
core. Scale bar, 50 nm. Gray arrows and text denote steps at which the supernatant and pellet 
can be bleached and discarded (Steps 13 and 18). 
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AAV-
PHP 
capsid 
Plasmid 
name 
In vivo characteristics Production 
efficiency 
Addgene 
no. 
AAV-
PHP.B 
pUCmini-
iCAP-PHP.B 
Broad CNS transduction Good 103002 
AAV-
PHP.B2 
pUCmini-
iCAP-
PHP.B2 
Broad CNS transduction Good 103003 
AAV-
PHP.B3 
pUCmini-
iCAP-
PHP.B3 
Broad CNS transduction Good 103004 
AAV-
PHP.eB 
pUCmini-
iCAP-
PHP.eB 
Broad CNS transduction Good 103005 
AAV-
PHP.S 
pUCmini-
iCAP-PHP.S 
Broad transduction in PNS 
and visceral organs 
Good 103006 
AAV-
PHP.Aa 
piCAP-
PHP.A 
Broad astrocyte transduction 
in CNS 
Poor CLOVER 
 
Table 2.T2: AAV-PHP capsid plasmids 
 
AAV-PHP capsid plasmids have a built-in tTA-TRE-based inducible amplification loop to 
increase virus production. If the rAAV genome has a tetracycline-regulated element (e.g., 
TRE), the tTA on the capsid plasmid will drive a high level of expression from the TRE-
containing rAAV genome, which may reduce virus production. To increase viral yields, 
increase the number of dishes per viral prep. aGiven the poor production efficiency of AAV-
PHP.A, and its tendency to aggregate after purification, we suggest using AAV-PHP.eB to 
target astrocytes. Use an astrocyte promoter, such as GFAP, to drive transgene expression 
(Figure 2.2a-c). To request AAV-PHP.A (listed as CLOVER in the table), 
visit http://www.clover.caltech.edu/. iCAP, inducible cap expression; pUCmini, pUC origin 
of replication. 
 
This protocol is optimized to produce AAVs at high titer (≥1 × 1013 vector genomes 
(vg)/ml and ≥1 × 1012 vg/dish) and with high transduction efficiency in vivo133,157. 
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Applications of the method  
We anticipate that AAV-PHP capsids (Table 2.T2) can be used to package rAAV 
genomes (contained in pAAV plasmids that are available through Addgene and elsewhere) 
(Figure 2.6 and Table 2.T1) to enable a wide range of biomedical applications. Below, we 
highlight current and potential applications of this method.  
Anatomical mapping  
Fluorescent reporters are commonly used for cell type–specific mapping and 
phenotyping133,186,187 (Figures 2.2–2.5). AAV-mediated multicolor labeling (e.g., 
Brainbow188) is especially advantageous for anatomical mapping approaches that require 
individual cells in the same population to be distinguished from one another. We and others 
have demonstrated the feasibility of this approach in the brain133,188 retina188, heart (Figure 
2.4b,c), and gut133, as well as the peripheral ganglia (Figure 2.3c). Spectrally distinct 
labeling is well-suited for studying the organization of cells (e.g., cardiomyocytes (Figure 
2.4b)) in healthy and diseased tissues and long-range tract tracing of individual fibers 
through extensive neural networks (e.g., the enteric133 or cardiac nervous systems (Figure 
2.4c)).  
Functional mapping  
AAV-PHP capsids are also relevant for probing cell function. AAV-PHP.B was 
previously used to target distinct neural circuits throughout the brain for 
chemogenetic158,189 and optical imaging applications190,191. We predict that AAV-PHP 
viruses will be beneficial for manipulating neural networks that are typically difficult to 
access, such as peripheral circuits controlling the heart (Figure 2.4d), lungs192, or gut193. 
AAV-PHP variants could also be utilized to interrogate the function of non-neuronal cell 
types, including cardiomyocytes194, pancreatic beta cells195,196, and hepatocytes197. 
Harnessing AAV-PHP viruses to modulate cell physiology may reveal novel roles for 
different cells in regulating organ function and/or animal behavior198. 
 
 
31 
Gene expression, silencing, and editing  
AAV-PHP viruses can be used to test potential therapeutic strategies that would 
benefit from organ wide or systemic transgene expression199. Recently, AAV-PHP.B was 
used to treat158 and model159 neurodegenerative diseases with widespread pathology. Other 
potential applications include gene editing (e.g., via CRISPR161,200–202) or silencing (e.g., 
via shRNA203); importantly, these approaches could be utilized to broadly and 
noninvasively manipulate cells in both healthy and diseased states for either basic research 
or therapeutically motivated studies.  
AAV capsid engineering  
AAV-PHP capsids can be further evolved for more efficient transduction of specific 
organs and cell types throughout the body. This protocol can be used for AAV engineering 
applications (e.g., our in vivo capsid selection method CREATE133,157). Using a modified 
transfection protocol (Steps 1–3 and online methods in ref.157), DNA libraries (generated 
by diversification of the AAV cap gene) are packaged to produce AAV capsid libraries, 
which are then harvested (Steps 4–14 and online methods in ref.157), purified (Steps 15–
31), and titered (Steps 32–42). Libraries are systemically administered to Cre transgenic 
animals (Steps 43–49) or wild-type animals in which Cre is introduced (e.g., by AAV 
delivery), and Cre-dependent cap recovery from tissues of interest facilitates further rounds 
of selection to isolate enriched variants. This protocol can also be used to characterize novel 
serotypes identified with CREATE or other engineering methods204. 
Limitations of the method  
A major limitation of AAV capsids, including AAV-PHP variants, is their relatively 
small packaging capacity (<5 kb). Some elements of the rAAV genome, such as the 
woodchuck hepatitis posttranscriptional regulatory element (WPRE), can be truncated127 or 
removed126,205 to accommodate larger genetic components. The development of smaller 
promoters128,129 and dual expression systems206, in which genetic elements are split between 
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two or more viruses (requiring efficient co-transduction), has also enabled the delivery of 
larger genomes. Continued development of these approaches will help bypass restrictions on 
rAAV genome size. Intravenous administration of AAVs also presents unique challenges. 
For example, systemic transduction may be undesirable for applications in which highly 
restricted gene expression is vital to the experimental outcome. Possible off-target 
transduction, due to the broad tropism of AAV-PHP variants and/or lack of compatible cell 
type–specific promoters, can be reduced by miRNA-mediated gene silencing. Sequences 
complementary to miRNAs expressed in off-target cell populations can be introduced into 
the 3ʹ UTR of the rAAV genome (Figure 2.6); this has been shown to reduce off-target 
transgene expression and better restrict expression to cell types of interest137,207 (Figure 
2.2d,e). Another challenge of systemic delivery is that it requires a high viral load, which can 
elicit an immune response against the capsid and/or transgene and reduce transduction 
efficiency in vivo208. Immunogenicity of AAVs may be exacerbated by empty capsid 
contamination in viral preparations209,210. The viral purification protocol (Steps 15–31) 
reduces, but does not eliminate, empty capsids (Figure 2.7b). If this poses a concern for 
specific applications, viruses can be purified using an alternative approach181,182,211. The 
generation of viruses for systemic administration may impose a financial burden on 
laboratories due to the doses of virus required. Nevertheless, viral-mediated gene delivery is 
inexpensive compared to creating and maintaining transgenic animals. Moreover, 
intravenous injection is faster, less invasive, and less technically demanding than other routes 
of AAV administration, such as stereotaxic injection, thereby eliminating the need for 
specialized equipment and survival surgery training.  
Experimental design  
Before proceeding with the protocol, a number of factors should be considered, namely 
the expertise and resources available in the lab; the animal model, capsid, and rAAV genome 
to be used; the dose for intravenous administration; and the method(s) available for assessing 
transgene expression. Each of these topics is discussed below to guide users in designing 
their experiments.  
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Required expertise and resources  
This protocol requires that the scientists have basic molecular biology, cell culture, and 
animal work experience. Users should be approved to handle laboratory animals, human cell 
lines, and AAVs. A background in molecular cloning is advantageous, although not 
necessary if relying on available plasmids. In addition to having the above expertise, the labs 
must be equipped for the molecular and cell culture work relevant to the procedure; we 
suggest that users read through the entire ‘Materials’ and ‘Procedure’ sections beforehand 
to ensure that the required reagents and equipment are available and appropriate safety 
practices and institutional approvals are in place. 
Animal model  
This protocol describes the production of AAVs for intravenous delivery to 6- to 8-
week-old male and female mice. AAV-PHP viruses have been validated in C57BL/6J 
mice133,157,158,160 (Figures 2.2–2.5) and numerous Cre driver lines133,158,189,190, including, but 
not limited to, TH-IRES-Cre (Figure 2.3), TRPV1-IRESCre (Figures 2.3 and 2.4), and 
ChAT-IRES-Cre mice133 (Figure 2.4). Intriguingly, AAV-PHP.B demonstrates low 
transduction throughout the brain when systemically administered to BALB/cJ mice164 
(Figure 2.5a). However, the neurotropic properties of AAV-PHP.B are not limited to the 
C57BL/6J strain in which they were selected. AAV-PHP.B transduces the brain more 
efficiently than AAV9 in both FVB/NCrl and 129S1/SvImJ mice (Figure 2.5a). We also 
show examples of AAV-PHP.eB transducing neurons in C57BL/6NCrl (Figure 2.2a–c) 
and 129T2/SvEmsJ mice (Figure 2.5b), as well as Fischer (Figure 2.5c) and Long Evans 
rats (Figure 2.5d). Compared to AAV9 and AAV-PHP.B, AAV-PHP.eB results in more 
efficient neuronal transduction in Sprague–Dawley rats after either intravenous 
administration or intra-parenchymal stereotaxic injections159,162. We predict that AAV-
PHP capsids can be used in multiple species and strains for diverse applications, such as 
those requiring fluorescent labeling (Figure 2.5a–c) and calcium imaging (Figure 2.5d,e). 
We have not compared the transduction efficiencies of AAV9 and AAV-PHP capsids 
across all rodent strains and species or determined the optimal dose for transducing specific 
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organs and cell types in different animal models. Users should test these parameters to 
determine the utility of AAV-PHP variants in their research. See ‘Reagents’ for mouse and 
rat catalog numbers.  
Selecting an AAV-PHP capsid  
We recommend choosing an AAV-PHP capsid (Table 2.T2) based on its tropism and 
production efficiency. Capsid properties are listed in Supplementary Table 2.ST1; we 
include species, organs, and cell populations examined to date and note typical viral yields. 
We anticipate that most researchers will use AAV-PHP.eB (Addgene, plasmid no. 103005) 
or AAV-PHP.S (Addgene, plasmid no. 103006) in their experiments. AAV-PHP.eB and 
AAV-PHP.S produce viral yields similar to those of other high-producing naturally 
occurring serotypes (e.g., AAV9) and enable efficient, noninvasive gene transfer to the 
CNS or PNS and visceral organs, respectively133 (Figures 2.2–2.5). The earlier capsid 
variants, which provide widespread CNS transduction, either produce suboptimal yields 
(AAV-PHP.A)157 or have since been further evolved for enhanced transduction efficiency 
in vivo (AAV-PHP.B (Addgene, plasmid no. 103002))133. We therefore recommend using 
AAV-PHP.eB for CNS applications, especially when targeting neurons. Note, however, 
that the chosen capsid will ultimately depend on the experimental circumstances; multiple 
factors, including species212, strain164 (Figure 2.5), age213, gender214, and health215, can 
influence AAV tropism. Testing the AAV-PHP variants in a variety of experimental 
paradigms will continue to reveal the unique attributes of each capsid and identify those 
most suitable for different applications.  
Selecting an rAAV genome  
Users must select an rAAV genome, contained in a pAAV plasmid, to package into 
the capsid (Figures 2.1 and 2.6; Table 2.T1). In Table 2.T1, we list the pAAVs used here 
(Figures 2.2–2.4) and in our previous work133,157; we direct users to Addgene’s plasmid 
repository for additional pAAVs developed for various applications. Depending on the 
experimental aims, users can elect to design their own genomes125 and clone from existing 
 
 
35 
pAAVs. When customizing plasmids, it is imperative that the rAAV genome, the 
sequence between and including the two inverted terminal repeats (ITRs), does not exceed 
4.7–5 kb (Figure 2.6); larger genomes will not be fully packaged into AAV capsids, 
resulting in truncated genomes and low titers. The ITRs are 145-bp sequences that flank 
the expression cassette and are required for replication and encapsidation of the viral 
genome. ITRs are typically derived from the AAV2 genome and must match the serotype 
of the rep gene contained in the capsid plasmid; pUCmini-iCAP-PHP plasmids contain the 
AAV2 rep gene and are therefore capable of packaging genomes with AAV2 ITRs (i.e., 
almost any pAAV available from Addgene). Other genetic components (e.g., promoters, 
transgenes, localization signals, and recombination schemes) are interchangeable and can 
be customized for specific applications (Figure 2.6).  
Dosage for intravenous administration  
The optimal dose for intravenous administration to target cell populations must be 
determined empirically. We encourage users to refer to Figures 2.2–2.5 and related work 
for suggested AAV-PHP viral doses. AAV-PHP variants have been successfully 
administered to adult mice133,157,158,160 (Figures 2.2–2.5), neonatal mice158, and neonatal 
and adult rats159,162 (Figure 2.5c,d) for fluorescent labeling; they have also been used for 
calcium imaging190,191 and optogenetic (Figure 2.4d), chemogenetic158,189, and therapeutic 
applications158,159. We typically administer between 1 × 1011 and 5 × 1011 vg of AAV-
PHP.eB or between 3 × 1011 and 1 × 1012 vg of AAV-PHP.S to adult mice (6–8 weeks old). 
However, dosage will vary depending on the target cell population, desired fraction of 
transduced cells, and expression level per cell. AAVs independently and stochastically 
transduce cells, typically resulting in multiple genome copies per cell133. Therefore, higher 
doses generally result in strong expression (i.e., high copy number) in a large fraction of 
cells, whereas lower doses result in weaker expression (i.e., low copy number) in a smaller 
fraction of cells. To achieve high expression in a sparse subset of cells, users can employ 
a two-component system in which transgene expression is dependent on co-transduction 
of an inducer (e.g., a vector expressing Cre216, Flp133, or the tetracycline-controlled 
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transactivator (tTA)133); inducers are injected at a lower dose (typically 1 × 109 to 1 × 
1011 vg) to limit the fraction of cells with transgene expression. Note that transgenes and 
gene regulatory elements (e.g., enhancers, promoters, and miRNA target sequences 
(Figure 2.2d,e)) can influence gene expression levels. Therefore, users should assess 
transgene expression from a series of doses and at several time points after intravenous 
delivery to determine the optimal experimental conditions.  
Evaluation of transgene expression  
Following in vivo delivery, AAV transduction and transgene expression increase 
over the course of several weeks. Although expression is evident within days after 
transduction, it does not reach a steady-state level until at least 3–4 weeks after 
transduction. Therefore, we suggest waiting for a minimum of 2 weeks before evaluating 
fluorescent labeling133,157–159 (Figures 2.2–2.5) and at least 3–4 weeks before beginning 
optogenetic (Figure 2.4d), chemogenetic158,189, and calcium imaging190,191 experiments. 
Note that, like other AAVs, AAV-PHP variants are capable of providing long-term 
transgene expression. AAV-PHP.B-mediated cortical expression of a genetically encoded 
calcium indicator, GCaMP6s, was reported to last at least 10 weeks post-injection without 
toxic side effects191 (i.e., nuclear filling217), and we have observed GFP expression 
throughout the brain >1 year after viral administration (see Supplementary Figure 4 in 
ref.157 ). However, the time points suggested here are only meant to serve as guidelines; 
gene expression is contingent on multiple factors, including the animal model, capsid, 
genome, and dose. The appropriate method(s) for evaluating transgene expression will vary 
among users and may include functional (e.g., optical imaging217), histological218 (e.g., 
using endogenous fluorescence, antibodies, or molecular probes), or molecular (e.g., 
Western blot219 or qPCR133) approaches220. To assess transduction efficiency across 
different organs, users can perform a qPCR-based vector biodistribution assay, in which 
vector genomes are quantified and normalized to the mouse genome (e.g., a housekeeping 
gene)157. Other approaches typically involve examining fluorescent protein expression in 
thin or thick (≥100 µm) tissue samples. The CLARITY-based methods such as passive 
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CLARITY technique (PACT) and perfusion-assisted agent release in situ (PARS)171 
render thick tissues optically transparent while preserving their three-dimensional 
molecular and cellular architecture, and facilitate deep imaging of large volumes (e.g., 
using confocal or light-sheet microscopy)221–223. Cleared tissues are compatible with 
endogenous fluorophores, including commonly used markers such as GFP157,171,218, 
eYFP171, and tdTomato218. However, some fluorescent signals, such as those from 
mTurquoise133, mNeonGreen, and mRuby2, can deteriorate in chemical clearing reagents. 
To visualize these reporters, we suggest using optical clearing reagents such as refractive 
index-matching solution (RIMS)218 or ScaleSQ170 (Figures 2.3a,c,d, 2.4b–d, and 2.5e) or 
commercially available mounting media (Step 50) (Figure 2.5a,c). Some fluorescent 
proteins are sensitive to photobleaching. For example, mRuby2 may bleach over long 
imaging sessions or at high magnification; tdTomato exhibits similar spectral properties 
and may be a more suitable alternative, given its photostability224. Also, note that auto-
fluorescent lipofuscin accumulates in aging post-mitotic tissues (e.g., the brain and heart)225 
and may interfere with examination of transduced cells; in this case, either reduce auto-
fluorescence using histological methods218,226 or, if possible, inject younger adults (≤8 
weeks old) and determine the minimum time required for transgene expression. 
2.3 MATERIALS 
Biological materials  
Caution: To address the issue of cell line misidentification and cross-contamination, it is 
recommended that cell lines be regularly checked to ensure they are authentic and are not 
infected with mycoplasma.  
● Plasmids, supplied as bacterial stabs (Addgene; see Table 2.T1 and Table 2.T2 for 
plasmids used in this and related work)  
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Critical: Three plasmids (pAAV, pUCmini-iCAP-PHP, and pHelper) are required for 
transfection (Figure 2.1). The pHelper plasmid is available in Agilent’s AAV helper-free 
kit (Agilent, cat. no. 240071).  
● Human embryonic kidney (HEK) cells (293 or 293T; ATCC, cat. no. CRL 1573 or CRL 
3216, respectively)  
Caution: HEK cells pose a moderate risk to laboratory workers and the surrounding 
environment and must be handled according to governmental and institutional regulations. 
Experiments involving HEK cells were performed using biosafety level 2 practices as 
required by the California Institute of Technology and the US Centers for Disease Control 
and Prevention.  
Critical: HEK293 and HEK293T cells constitutively express two adenoviral genes, E1a 
and E1b, which are required for AAV production in these cells180; we do not recommend 
using an alternative producer cell line with this protocol.  
● Plasmid DNA containing the target sequence to be amplified during AAV titration; used 
for preparing the DNA standard stock  
Critical: The plasmid used to make the DNA standard must contain the same target 
sequence as the pAAV plasmid used to generate virus. The target sequence must be within 
the rAAV genome; we typically amplify a portion of the WPRE or hGH polyA (see Figure 
2.6 caption for abbreviations and ‘Reagents’ for primer sequences).  
● Animals to be injected. Wild-type mouse strains used in this work include C57BL/6J 
(Jackson Laboratory, stock no. 000664), C57BL/6NCrl (Charles River Laboratories, strain 
code 027), FVB/NCrl (Charles River Laboratories, strain code 207), 129S1/SvImJ 
(Jackson Laboratory, stock no. 002448), and 129T2/SvEmsJ (Jackson Laboratory, stock 
no. 002065). Cre driver lines include ChAT-IRES-Cre (Jackson Laboratory, stock no. 
028861, heterozygous), TH-IRES-Cre (European Mutant Mouse Archive, stock no. 
EM00254, heterozygous), and TRPV1-IRES-Cre mice (Jackson Laboratory, stock no. 
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017769, homozygous). Fischer rats (Charles River Laboratories, strain code 002) and 
Long-Evans rats (Charles River Laboratories, strain code 006) were used in Figure 2.5. 
All rats were 4–6 weeks old at the time of AAV administration; mice were 6–10 weeks 
old. Refer to the ‘Experimental design’ section, Figure 2.5, and Supplementary Table 
2.ST1 for species and strain considerations.  
Caution: Experiments on vertebrates must conform to all relevant governmental and 
institutional regulations. Animal husbandry and experimental procedures involving mice 
and rats were approved by the Institutional Animal Care and Use Committee (IACUC) and 
the Office of Laboratory Animal Resources at the California Institute of Technology.  
● For molecular cloning: Recombination-deficient Escherichia coli strains such as NEB 
stable (New England Biolabs, cat. no. C3040H), Stbl3 (Invitrogen, cat. no. C737303), or 
SURE 2 competent cells (Agilent, cat. no. 200152) 
Reagents 
Plasmid DNA preparation  
● Agarose (Amresco, cat. no. N605-250G)  
● Antibiotics (e.g., carbenicillin disodium salt; Alfa Aesar, cat. no. J61949-06; all plasmids 
used in this work carry antibiotic resistance genes to ampicillin/carbenicillin)  
● DNA ladder (100 bp–10 kb; New England Biolabs, cat. no. N0550S)  
● Lysogeny broth (LB; Amresco, cat. no. J106-1KG)  
Critical: For large-scale plasmid preparations, such as maxi and giga preps, we typically 
use Plasmid+ media (Thomson Instrument, cat. no. 446300), an enriched medium 
formulated to support higher cell densities and plasmid yields, as compared to those of LB.  
● LB with agar (Sigma-Aldrich, cat. no. L3147-1KG)  
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● NucleoBond Xtra Maxi endotoxin-free (EF) plasmid purification kit (Macherey-
Nagel, cat. no. 740424.50)  
Critical: Triple transient transfection requires large amounts of pUCmini-iCAP-PHP (22.8 
µg/dish) and pHelper plasmid DNA (11.4 µg/dish) (Supplementary Table 2.ST2, ‘Detailed 
calculations’ sheet); isolating these plasmids may be more convenient with a giga-scale 
purification kit (NucleoBond PC 10000 EF; Macherey-Nagel, cat. no. 740548). All 
plasmids should be purified under endotoxin-free conditions. Endotoxin contamination in 
plasmid preparations can reduce transfection efficiency, and contaminating endotoxins in 
viral preparations could elicit immune reactions in mammals in vivo.  
● Restriction enzymes, including SmaI (New England Biolabs, cat. no. R0141S); used for 
verifying plasmid and ITR integrity  
● Sequencing primers (Integrated DNA Technologies); used for verifying plasmid 
sequence integrity  
● SYBR Safe DNA gel stain (Invitrogen, cat. no. S33102)  
● Tris-acetate-EDTA (TAE) buffer (50×; Invitrogen, cat. no. B49)  
Cell culture  
● DMEM (high glucose, GlutaMAX supplement, pyruvate; Gibco, cat. no. 10569-044)  
● 70% (vol/vol) Ethanol (prepare from absolute ethanol; J.T. Baker, cat. no. 8025)  
Caution: Ethanol is flammable.  
● FBS (GE Healthcare, cat. no. SH30070.03)  
Critical: Divide into aliquots and store at −20 °C for up to 1 year. Avoid freeze–thaw 
cycles.  
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● MEM non-essential amino acids (NEAA) solution (100×; Gibco, cat. no. 11140-050)  
● Penicillin–streptomycin (pen–strep; 5,000 U/ml; Gibco, cat. no. 15070-063)  
Critical: Divide into aliquots and store at −20 °C for up to 1 year. Avoid freeze–thaw 
cycles.  
● TrypLE Express enzyme (1×; phenol red; Gibco, cat. no. 12605-036)  
Transfection  
● Polyethylenimine (PEI), linear, molecular weight (MW) 25,000 (Polysciences, cat. no. 
23966-1)  
Critical: Compared to other commonly used transfection reagents (e.g., Lipofectamine or 
calcium phosphate), PEI is less expensive, given the scale of transfection, and produces 
high viral yields (≥1 × 1012 vg/dish), which are needed for systemic administration.  
● Water for injection (WFI) for cell culture (Gibco, cat. no. A1287304)  
● Dulbecco’s PBS (DPBS; 1×; no calcium, no magnesium; Gibco, cat. no. 14190-250)  
● 1 N Hydrochloric acid (HCl) solution (suitable for cell culture; Sigma-Aldrich, cat. no. 
H9892)  
Caution: HCl is corrosive. Use personal protective equipment.  
AAV production  
● 10% (vol/vol) Bleach (prepare fresh from concentrated liquid bleach (e.g., Clorox)) 
Critical: AAV contaminated equipment, surfaces, and labware must be disinfected for 10 
min with fresh 10% (vol/vol) bleach; ethanol is not an effective disinfectant against non-
enveloped viruses. AAV waste disposal should be conducted according to federal, state, 
and local regulations.  
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● Dry ice; optional  
● KCl (Macron Fine Chemicals, cat. no. 6858-06)  
● MgCl2·6H2O (Macron Fine Chemicals, cat. no. 5958-04)  
● Sodium chloride (NaCl; Millipore, cat. no. SX0420-3)  
● OptiPrep (60% (wt/vol) iodixanol) density gradient medium (Cosmo Bio USA, cat. no. 
AXS-1114542-5)  
● Phenol red solution (Millipore, cat. no. 1072420100)  
● Pluronic F-68 nonionic surfactant (10% (vol/vol) solution; Gibco, cat. no. 24040-032); 
optional  
● Polyethylene glycol (PEG; MW 8,000; Sigma-Aldrich, cat. no. 89510-1KG-F)  
● Salt-active nuclease (SAN; 25 U/µl; ArcticZymes, cat. no. 70910-202)  
● Tris, ultrapure (MP Biomedicals, cat. no. 819620)  
● UltraPure DNase/RNase-free distilled water (Invitrogen, cat. no. 10977-023)  
● WFI for cell culture (Gibco, cat. no. A1287304)  
● DPBS (1×; no calcium, no magnesium; Gibco, cat. no. 14190-250)  
AAV titration  
● CaCl2 (anhydrous; J.T. Baker, cat. no. 1311-01)  
● DNase I recombinant (RNase-free; 10 U/µl; Roche Diagnostics, cat. no. 4716728001)  
● MgCl2·6H2O (Macron Fine Chemicals, cat. no. 5958-04)  
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● NaCl (Millipore, cat. no. SX0420-3)  
● N-lauroylsarcosine sodium salt (Sigma-Aldrich, cat. no. L9150-50G) 
● Primers corresponding to the target sequence to be amplified during qPCR (Integrated 
DNA Technologies) WPRE-forward: GGCTGTTGGGCACTGACAAT WPRE-reverse: 
CCGAAGGGACGTAGCAGAAG hGH polyA-forward: GTGCCCACCAGCCTTGTC 
hGH polyA-reverse: TGTCTTCCCAACTTGCCCCTT  
Critical: The proximity of the primer binding sites to the ITRs can affect titering results; 
do not use primers corresponding to the ITRs. Note that titers measured with different 
primers or across laboratories may not be directly comparable.  
● Proteinase K (recombinant, PCR grade; 50 U/ml (2.5 U/mg); Roche Diagnostics, cat. no. 
03115828001)  
● Qubit dsDNA HS Assay Kit (Invitrogen, cat. no. Q32854)  
● ScaI-HF restriction enzyme (New England Biolabs, cat. no. R3122S) or other enzyme 
that cuts outside of the rAAV genome and within the pAAV backbone  
● SYBR Green master mix (Roche Diagnostics, cat. no. 04913850001)  
● Tris, ultrapure (MP Biomedicals, cat. no. 819620)  
● UltraPure DNase/RNase-free distilled water (Invitrogen, cat. no. 10977-023)  
● UltraPure EDTA (0.5 M, pH 8.0; Invitrogen, cat. no. 15575-020)  
● UltraPure Tris-HCl (1 M, pH 7.5; Invitrogen, cat. no. 15567-027)  
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Intravenous (retro-orbital) injection  
● 10% (vol/vol) Bleach, prepared fresh, or equivalent disinfectant (e.g., Accel TB surface 
cleaner; Health Care Logistics, cat. no. 18692)  
● Isoflurane, USP (Piramal Critical Care, cat. no. 66794-017-25)  
Caution: Isoflurane is a halogenated anesthetic gas associated with adverse health 
outcomes in humans and must be handled according to governmental and institutional 
regulations. To reduce the risk of occupational exposure during rodent anesthesia, waste 
gas was collected in a biosafety cabinet using a charcoal scavenging system as approved 
by the California Institute of Technology.  
● Proparacaine hydrochloride ophthalmic solution, USP (0.5% (wt/vol); Akorn 
Pharmaceuticals, cat. no. 17478-263-12)  
● DPBS (1×; no calcium, no magnesium; Gibco, cat. no. 14190-250)  
Equipment  
Plasmid DNA preparation equipment  
● Centrifuge (Beckman Coulter, model no. Allegra X-15R)  
● Gel electrophoresis system (Bio-Rad horizontal electrophoresis system)  
● Gel-imaging system (Bio-Rad, Gel Doc EZ system)  
● Incubating shaker (Eppendorf, model no. I24)  
● Incubator (Thermo Fisher Scientific, Heratherm model) or 37 °C warm room  
● Sequence-editing and annotation software (e.g., Lasergene by DNASTAR 
(https://www.dnastar.com/ software/lasergene/), SnapGene by GSL Biotech 
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(http://www.snapgene.com/), or Vector NTI by Thermo Fisher Scientific 
(https://www.thermofisher.com/us/en/home/life-science/cloning/vector-
ntisoftware.html))  
● Spectrophotometer (Thermo Fisher Scientific, NanoDrop model)  
Plasmid DNA preparation supplies  
● Petri dishes (100 mm × 15 mm; Corning, cat. no. 351029)  
● Test tubes (14 ml; Corning, cat. no. 352059)  
● Ultra Yield flasks and AirOtop seals (250 ml; Thomson Instrument Company, cat. nos. 
931144 and 899423, respectively); use with Plasmid+ media. Alternatively, use LB and 
standard Erlenmeyer flasks.  
AAV production equipment  
● Biological safety cabinet  
Caution: HEK293T cells and AAVs are biohazardous materials and must be handled 
according to governmental and institutional regulations. All experiments involving the 
aforementioned materials were performed in a Class II biosafety cabinet with annual 
certification as required by the California Institute of Technology and the US Centers for 
Disease Control and Prevention.  
● Centrifuge that can reach speeds up to 4,000g, refrigerate to 4 °C, and accommodate 250-
ml conical centrifuge tubes (Beckman Coulter, model no. Allegra X-15R)  
● Fluorescence microscope for cell culture (Zeiss, model no. Axio Vert A1)  
● Incubator for cell culture (humidified at 37 °C with 5% CO2; Thermo Fisher Scientific, 
model no. Heracell 240i)  
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● Laboratory balance (with a readability of 5–10 mg)  
● Support stand with rod and clamp (VWR International, cat. nos. 12985-070, 60079-534, 
and 89202-624, respectively) (Figure 2.8f) 
 
Figure 2.8: AAV purification procedure. 
 
(a,b), In Step 16, pipette the iodixanol density gradients (Supplementary Video 2.V1, 0:00–
1:45, or Supplementary Video 2.V2, 0:00–1:13). (a), Layer the 25% (wt/vol) iodixanol 
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underneath the 15% layer. (b), Add layers of increasing density under the previous layer; 
the gradients should have a sharp delineation between layers. (c), In Step 18, load the 
supernatant (Sup.) from Step 17 (Figure 2.7b) above the 15% layer (Supplementary Video 
2.V1, 1:46–2:22; the same step is also shown in Supplementary Video 2.V2, 1:14–1:55). 
(d,e), In Step 19, fill each tube up to the neck with SAN digestion buffer and insert a black 
cap (d); place a spacer on top before weighing the tubes (e). (f), After ultracentrifugation 
(Step 22), secure the tube into the clamp setup above a container of fresh 10% (vol/vol) 
bleach (Step 24). Allow 10 ml of DPBS to begin dripping through the syringe filter unit 
into an Amicon filter device (Step 25). (g), In Step 26, collect the virus (Supplementary 
Video 2.V3, 0:00–1:30). Insert the needle ~4 mm below the 40/60% interface (i.e., where 
the tube just starts to curve). Do not collect virus (asterisk) until the black cap is removed; 
do not collect from the white protein layer at the 25/40% interface. (h), In Step 27, filter 
the virus/iodixanol (Supplementary Video 2.V3, 1:31–2:32). Inject the virus below the 
DPBS in the filter-attached syringe barrel before pushing the virus/DPBS through the 
syringe filter unit and into the Amicon filter device. 
 
● Ultracentrifuge (preparative ultracentrifuge for in vitro diagnostic use; Beckman Coulter, 
model no. Optima XE-90, with a Type 70Ti fixed-angle rotor)  
Caution: During ultracentrifugation, rotors are subjected to enormous forces (350,000g in 
this protocol). Rotor failure can have catastrophic consequences, including irreparable 
damage to the centrifuge and laboratory and fatal injuries to personnel. Inspect the rotors 
for signs of damage or weakness before each use, and always follow the manufacturer’s 
instructions while operating an ultracentrifuge.  
● Water bath (Fisher Scientific, Isotemp model)  
AAV production supplies  
● Amicon Ultra-15 centrifugal filter devices (100-kDa molecular weight cutoff; Millipore, 
cat. no. UFC910024)  
● Barrier pipette tips (low binding, 1,000 µl; Genesee Scientific, cat. no. 23-430)  
● Cell scrapers (25-cm handle × 3-cm blade; Corning, cat. no. 353089)  
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● Centrifuge tube racks for 250-ml tubes, 6-well (Universal Medical, cat. no. HS23224) 
or empty beakers  
● Conical centrifuge tubes (50 ml, 250 ml, and 500 ml (optional); Corning, cat. nos. 
352098, 430776, and 431123, respectively)  
● Costar Spin-X centrifuge tube filters (Corning, cat. no. 07-200-385); optional  
● Empty, sterile media bottles  
● OptiSeal tubes (Beckman Coulter, cat. no. 361625); includes black caps  
● OptiSeal tube kit (Beckman Coulter, cat. no. 361662); includes a tube rack, spacers, and 
spacer- and tube-removal tools  
● Pipet-Aid XL portable pipetting device (Drummond Scientific, cat. no. 4-000-105) 
Critical: Use a pipetting device with precise control to pour the density gradients (Step 16) 
and load the virus (Step 18).  
● pH indicator strips (Millipore, cat. nos. 109532 and 109584)  
● Screw-cap vials (1.6 ml; National Scientific Supply, cat. no. BC16NA-PS)  
● Serological pipettes (2 ml, 5 ml, 10 ml, 25 ml, and 50 ml; Corning, cat. no. 356507, and 
Genesee Scientific, cat. nos. 12-102, 12-104, 12-106, and 12-107, respectively)  
Critical: Corning brand 2-ml serological pipettes consistently fit into OptiSeal tubes while 
pouring the density gradients (Step 16A) and loading the virus (Step 18); other brands 
should be tested before use.  
● Stericup sterile vacuum filtration system (0.22 µm; 1 liter; Millipore, cat. no. 
S2GPU11RE)  
● Sterile bottles (500 ml; VWR International, cat. no. 89166-106)  
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● Syringes (5 ml and 10 ml; BD, cat. nos. 309646 and 309604, respectively)  
● Syringe filter units (0.22 µm; Millipore, cat. no. SLGP033RS)  
● Tissue culture dishes (150 mm × 25 mm; Corning, cat. no. 430599)  
● Tubing, e.g., polytetrafluoroethylene (PTFE) standard tubing (2 mm i.d. × 3 mm o.d.; 
Fluorostore) and Tygon tubing (2 mm i.d. × 4 mm o.d.; United States Plastics, cat. no. 
57658); optional  
Critical: Ensure that the PTFE tubing fits on the tip of a 5-ml serological pipette and into 
an Optiseal tube before pouring the density gradients (Step 16B). Use the Tygon tubing to 
secure the PTFE tubing at the pipette tip.  
● 16-gauge × 1 1/2 inch needles (BD, cat. no. 305198) 
AAV titration equipment  
● Centrifuge (Eppendorf, model no. 5418)  
● Dry bath and heating blocks (Fisher Scientific, Isotemp models)  
● PCR plate spinner (VWR International, cat. no. 89184) or centrifuge equipped with plate 
adapters  
● Quantitative PCR machine (Analytik Jena, model no. qTOWER 2.2)  
● Qubit 3.0 fluorometer (Invitrogen, cat. no. Q33216)  
AAV titration supplies  
● Barrier pipette tips (low binding; 10 µl, 20 µl, 200 µl, and 1,000 µl; Genesee Scientific, 
cat. nos. 23-401, 23-404, 23-412, and 23-430, respectively)  
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● DNA Clean & Concentrator kit (Zymo Research, cat. no. D4033 (DCC-25)), for 
purification of up to 25 µg of the DNA standard  
● Microcentrifuge tubes (1.5-ml DNA/RNA LoBind; Eppendorf, cat. no. 86-923)  
● Qubit assay tubes (Invitrogen, cat. no. Q32856)  
● Sealing film for 96-well PCR plates (Genesee Scientific, cat. no. 12-529)  
● Stericup sterile vacuum filtration system (0.22 µm, 250 ml; Millipore, cat. no. 
SCGPU02RE)  
● Sterile bottles (250 ml; VWR International, cat. no. 89166-104)  
● 96-well PCR plates (Genesee Scientific, cat. no. 24-310W)  
Intravenous (retro-orbital) injection equipment  
● Animal anesthesia system (VetEquip, cat. no. 901806, 901807, or 901810)  
Critical: Most animal facilities provide anesthesia systems equipped with an induction 
chamber, isoflurane vaporizer, nose cone, and waste gas scavenging system.  
Intravenous (retro-orbital) injection supplies  
● Activated charcoal adsorption filters (VetEquip, cat. no. 931401)  
● Insulin syringes with permanently attached needles (31 gauge × 5/16 inches; BD, cat. no. 
328438)  
● Oxygen gas supply (Airgas)  
● Screw-cap vials (1.6 ml; National Scientific Supply, cat. no. BC16NA-PS)  
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Reagent setup  
Critical: All reagents used for viral production and administration should be prepared using 
endotoxin-free materials. Glassware is not endotoxin-free, and autoclaving does not 
eliminate endotoxins. To minimize contamination, we dissolve chemicals in sterile bottles 
by shaking and/or heating to mix, use demarcations on bottles to bring solutions to the final 
volume, and use pH strips rather than a pH meter. When filter-sterilizing solutions, do so 
in a biosafety cabinet.  
Plasmid DNA  
Grow bacterial stocks in LB or Plasmid+ media containing the appropriate selective 
antibiotic; refer to the Addgene catalog for suggested growth conditions. Use a large-scale 
endotoxin-free plasmid purification kit to isolate plasmids; elute plasmid DNA with the 
supplied Tris-EDTA (TE) buffer. Measure the DNA purity and concentration using a 
spectrophotometer and freeze at −20 °C or −80 °C for up to several years.  
Critical: Always verify the integrity of purified plasmids by Sanger sequencing (using a 
DNA sequencing facility) and restriction digestion (https://www.neb.com/tools-a nd-
resources) before proceeding with downstream applications. pAAV plasmids contain ITRs 
(Figure 2.6) that are prone to recombination in E. coli. pAAVs should be propagated in 
recombination-deficient strains such as NEB Stable, Stbl3, or SURE 2 competent cells to 
prevent unwanted recombination. After purification, pAAVs should be digested with SmaI 
to confirm the presence of ITRs, which are required for replication and encapsidation of 
the viral genome; use sequence-editing and annotation software to determine the expected 
band sizes. Note that it is difficult to sequence through the secondary structure of ITRs227; 
avoid ITRs when designing sequencing primers.  
Critical: Create bacterial glycerol stocks and store at –80 °C for up to several years.  
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Cell culture media  
Add 25 ml of FBS, 5 ml of NEAA, and 5 ml of pen–strep to a 500-ml bottle of 
DMEM. Invert to mix and store at 4 °C for up to several months; warm to 37 °C before 
use. The resulting cell culture media should have a final concentration of 5% (vol/vol) FBS, 
1× NEAA, and 50 U/ml pen–strep.  
Critical: To quickly expand cells for large viral preps, consider using a final concentration 
of 10% (vol/vol) FBS in the cell culture media; see guidelines on cell culture below.  
Cell culture  
Thaw HEK293T cells according to the manufacturer’s recommendations. Passage 
cells using either TrypLE Express enzyme or a standard trypsinization protocol for 
adherent cultures228. Seed cells in 150-mm tissue culture dishes with a final volume of 20 
ml of media per dish. Maintain in a cell culture incubator at 37 °C with 5% CO2.  
Critical: We suggest passaging cells at a ratio of 1:3 (i.e., divide one dish of cells into three 
new dishes of cells) every other day when expanding cells for viral production; split cells 
at a 1:2 ratio (or 6 × 104 cells/cm2) 24 h before transfection. Use higher split ratios if using 
10% (vol/vol) FBS. Always use sterile technique.  
Critical: Follow the manufacterer’s recommendations to create frozen stocks of HEK cells.  
PEI stock solution  
Pipette 50 ml of WFI water into a 50-ml conical centrifuge tube for later use. Add 
323 mg of PEI to the remaining 950 ml bottle of WFI water and adjust the pH to 2–3 by 
adding 1 N HCl suitable for cell culture, keeping track of the volume of HCl added. Heat 
in a 37 °C water bath for several hours (or overnight) and occasionally shake to mix. Once 
dissolved, add reserved WFI water to a total volume of 1 liter. Filter-sterilize, make aliquots 
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in 50-ml conical centrifuge tubes, and store at −20 °C for up to 1 year. We routinely 
freeze–thaw our PEI aliquots.  
Critical: Both our PEI stock solution recipe and PEI calculations (Supplementary Table 
2.ST2, ‘Detailed calculations’ sheet) are based on ref.178. We adjust the pH to 2–3 so that 
PEI dissolves in water. The designated pH range does not appear to adversely affect cell 
viability, transfection efficiency, or viral titers. The transfection solution, created by mixing 
the PEI + DPBS master mix and DNA + DPBS solution (Step 2 and Supplementary Table 
2.ST2), has a final pH of 6.5–7.0. To transfect one dish, 2 ml of transfection solution is 
added to 20 ml of media (Step 2), which further dilutes the PEI.  
PEI + DPBS master mix  
Thaw PEI in a 37 °C water bath. Bring the PEI to room temperature (RT; 23 °C) and 
vortex to mix. Add PEI and DPBS to a 50-ml conical centrifuge tube and vortex again to 
mix. Use Supplementary Table 2.ST2 (‘Transfection calculator’ sheet) to calculate the 
volumes of PEI (cell I9) and DPBS (cell J9) needed.  
Critical: Prepare fresh master mix before use.  
DNA + DPBS  
Bring plasmid DNA to RT and briefly vortex to mix. For each viral prep, add DNA 
and DPBS to a 50-ml conical centrifuge tube; the solution is vortexed in Step 2. Use 
Supplementary Table 2.ST2 (‘Transfection calculator’ sheet) to calculate the quantities of 
DNA (e.g., cells E9, E11, and E13) and DPBS (e.g., cell F9) needed.  
Critical: Prepare fresh DNA + DPBS solution before use. Re-measure plasmid DNA 
concentrations immediately before use; multiple freeze–thaw cycles may cause DNA 
degradation.  
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SAN digestion buffer  
Add 29.22 g of NaCl, 4.85 g of Tris base, and 2.03 g of MgCl2·6H2O to a 1-liter 
bottle of WFI water and shake to mix. Filter-sterilize and store at RT for up to several 
months. The resulting SAN digestion buffer should have a final pH of ~10.0 and a final 
concentration of 500 mM NaCl, 40 mM Tris base, and 10 mM MgCl2.  
SAN + SAN digestion buffer  
Add 100 U of SAN (4 µl of 25 U/µl SAN) per milliliter of SAN digestion buffer; 
pipette to mix.  
Critical: Prepare fresh solution before use.  
40% (wt/vol) PEG stock solution  
Decant ~500 ml of WFI water into a 500-ml sterile bottle for later use. Add 146.1 g 
of NaCl to the remaining 500 ml (in the 1-liter bottle of WFI water) and shake/heat until 
dissolved. Once completely dissolved, add 400 g of PEG and heat at 37 °C overnight for 
up to 2 nights. Add reserved WFI water to a total volume of 1 liter. Filter-sterilize and store 
at RT for up to several months. The resulting stock solution should have a final 
concentration of 2.5 M NaCl and 40% (wt/vol) PEG.  
Critical: Prepare in advance. To expedite the procedure, heat the solution at 65 °C until the 
PEG is dissolved. The solution will appear turbid, but no flecks of PEG should remain; the 
mixture will become clear upon cooling.  
Critical: Pre-wet the entire filter surface with a minimal volume of water before adding the 
solution. This solution is extremely viscous and will take 1–2 h to filter.  
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DPBS + high salt  
Add 29.22 g of NaCl, 93.2 mg of KCl, and 101.7 mg of MgCl2·6H2O to a 500-ml 
bottle of DPBS and shake to mix. Filter-sterilize and store at RT for up to several months. 
The resulting buffer should have a final concentration of 1 M NaCl, 2.5 mM KCl, and 1 
mM MgCl2 (in addition to the salts in the DPBS).  
DPBS + low salt  
Add 2.92 g of NaCl, 93.2 mg of KCl, and 101.7 mg of MgCl2·6H2O to a 500-ml 
bottle of DPBS and shake to mix. Filter-sterilize and store at RT for up to several months. 
The resulting buffer should have a final concentration of 100 mM NaCl, 2.5 mM KCl, and 
1 mM MgCl2 (in addition to the salts in the DPBS). 
Iodixanol density gradient solutions (15%, 25%, 40%, and 60% (wt/vol) iodixanol)  
For each layer, add iodixanol (OptiPrep), DPBS + high salt or DPBS + low salt, and 
phenol red (if applicable) to a 50-ml conical centrifuge tube. Invert or briefly vortex to mix. 
Use Supplementary Table 2.ST3 to determine the volumes of each reagent needed. The 
25% and 60% layers contain phenol red, which turns the solutions red and yellow, 
respectively, and facilitates clear demarcation of the gradient boundaries (Figure 2.8).  
Critical: Prepare fresh solutions on the day of AAV purification. Alternatively, prepare up 
to 1 d in advance; store at RT and protect from light. Do not pour the density gradients 
until Step 16.  
Critical: In Step 16B, prepare more iodixanol solutions than are needed. For six or fewer 
gradients, prepare enough of each solution to pour an extra gradient. For eight gradients, 
prepare enough of each solution to pour two extra gradients. The extra solution is needed 
to fill the 5-ml pipette and prevent an air bubble from disturbing the gradient when 
releasing the last of the required volume.  
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DNase digestion buffer  
Use a 50-ml serological pipette to measure 247.5 ml of UltraPure water into a 250-
ml sterile bottle. Add 55.5 mg of CaCl2, 2.5 ml of 1 M Tris-HCl, and 508 mg of 
MgCl2·6H2O and shake to mix. Filter-sterilize and store at RT for up to several months. 
The resulting buffer should have a final concentration of 2 mM CaCl2, 10 mM Tris-HCl, 
and 10 mM MgCl2.  
DNase I + DNase digestion buffer  
Add 50 U of DNase I per milliliter of digestion buffer (a 1:200 dilution of 10 U/µl 
DNase); pipette to mix.  
Critical: Prepare fresh solution before use.  
Proteinase K solution  
Use a 50-ml serological pipette to measure 250 ml of UltraPure water into a 250-ml 
sterile bottle. Add 14.61 g of NaCl and shake to mix. Add 2.5 g of N-lauroylsarcosine 
sodium salt to the mixture and gently swirl to mix; N-lauroylsarcosine sodium salt is a 
surfactant and will generate bubbles during vigorous mixing. Filter-sterilize and store at 
RT for up to several months. The resulting solution should have a final concentration of 1 
M NaCl and 1% (wt/vol) N-lauroylsarcosine sodium salt.  
Proteinase K + proteinase K solution  
Add 100 µg of proteinase K per milliliter of solution (a 1:200 dilution of 50 U/ml 
(2.5 U/mg) proteinase K); pipette to mix.  
Critical: Prepare fresh solution before use.  
 
 
 
57 
DNA standard stock  
Set up a single 50-µl restriction digest reaction; use 60–80 U (3–4 µl) of ScaI (or 
another suitable enzyme) to linearize 20 µg of the plasmid DNA containing the target 
sequence. Run a small amount of the reaction on an agarose gel to ensure complete 
digestion. Purify the reaction using two DNA clean-up columns. Measure the DNA 
concentration (ng/µl) using a spectrophotometer. Dilute to ~5–10 × 109 single-stranded (ss) 
DNA molecules/µl and use the Qubit assay to verify the concentration (ng/µl). Divide into 
20-µl aliquots in DNA/RNA LoBind microcentrifuge tubes and freeze at −20 °C for up to 
1 year.  
Critical: Before preparing the standard, use sequence-editing and annotation software to 
confirm that the plasmid contains a single ScaI site in the ampicillin resistance gene. 
Critical: Refer to ref.184 and use Supplementary Table 2.ST4 (cells B7–10) to calculate the 
number of ssDNA molecules in a given plasmid (cell B13). We typically use linearized 
pAAV-CAG-eYFP diluted to 10 ng/µl, which corresponds to 6.6×109 ssDNA molecules/µl 
(Supplementary Table 2.ST4, ‘Example’ sheet).  
DNA standard dilutions  
Prepare three sets of eight (1:10) serial dilutions of the DNA standard stock. For each 
set, begin by pipetting 5 µl of the standard into 45 µl of UltraPure water (standard no. 8). 
Mix by vortexing for 3 s and proceed with the seven remaining dilutions (standard no. 7 to 
standard no. 1). The final concentrations of the standard dilutions should range from 5–10 
× 108 (standard no. 8) to 5–10 × 101 (standard no. 1) ssDNA molecules/µl.  
Critical: Prepare fresh solutions in DNA/RNA LoBind microcentrifuge tubes immediately 
prior to use; at low concentrations, the linearized DNA is prone to degradation and/or 
sticking to the walls of the tube184. One 20-µl aliquot of the DNA standard stock will 
provide enough DNA for preparing the dilutions and verifying the concentration via the 
Qubit assay before qPCR. 
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qPCR master mix  
Prepare a qPCR master mix for the total number of reactions (i.e., wells) needed. One 
reaction requires 12.5 µl of SYBR Green master mix, 9.5 µl of UltraPure water, and 0.5 µl 
of each primer (from a 2.5-µM stock concentration), for a total of 23 µl/well. Pipette or 
vortex for 1–2 s to mix.  
Critical: Prepare fresh solution before use.  
Equipment setup  
Clamp setup for AAV purification  
Attach the rod to the support stand. Secure the clamp 25–30 cm above the stand 
(Figure 2.8f).  
Anesthesia system  
Place the induction chamber, nose cone, and waste gas scavenging system (e.g., 
activated charcoal adsorption filters) inside a biosafety cabinet. We recommend using an 
anesthesia system in which the isoflurane vaporizer and oxygen supply remain outside of 
the cabinet workspace. Connect the associated tubing such that the input is from the 
vaporizer/oxygen supply and the output is to the charcoal scavenging device229. 
2.4 PROCEDURE 
Caution: AAVs are biohazardous materials and must be handled according to 
governmental and institutional regulations. Experiments involving AAVs were performed 
using biosafety level 2 practices as required by the California Institute of Technology and 
the US Centers for Disease Control and Prevention.  
Critical: The entire procedure spans 8 d, excluding pause points and the time required to 
evaluate transgene expression (Figure 2.7a). There are no pause points between days 1 and 
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5, until Step 11; once cells have been transfected, AAVs are harvested on days 3 and 5. 
Plan accordingly during this time window.  
Triple transient transfection of HEK293T cells  
● Timing 1–2 h  
Critical: For capsids that package well (i.e., AAV9, AAV-PHP.B, AAV-PHP.eB, and 
AAV-PHP.S), the PEI transfection protocol typically yields ≥1 × 1012 vg per 150-mm dish, 
as measured post purification133,157. Before starting the protocol, determine the number of 
dishes needed per viral prep and use Supplementary Table 2.ST2 (‘Transfection 
calculator’ sheet) to calculate the quantities of PEI, DPBS, and plasmid DNA required for 
transfection. Skip to Step 43 if custom AAVs were obtained elsewhere.  
1. 24 h before transfection, seed HEK293T cells in 150-mm dishes to attain 80–90% 
confluency the next day228. Incubate the cells in a cell culture incubator at 37 °C with 5% 
CO2.  
2.  At the time of transfection, make the PEI + DPBS master mix and the DNA + DPBS 
solution for each viral prep (Reagent setup and Supplementary Table 2.ST2, ‘Transfection 
calculator’ sheet). Using a 5- or 10-ml serological pipette, add the required volume of the 
PEI + DPBS master mix (e.g., ‘Transfection calculator’ cell G9) dropwise to the DNA + 
DPBS solution (e.g., ‘Transfection calculator’ cells E9 + E11 + E13 + F9) while gently 
vortexing to mix. Cap the tube and thoroughly vortex for 10 s to mix. Allow the mixture to 
sit at RT for 2–10 min. Add 2 ml of the transfection solution dropwise to each dish and 
swirl to mix before returning the dishes to the cell culture incubator.  
Critical step: We use a pAAV:pUCmini-iCAP-PHP:pHelper plasmid ratio of 1:4:2 based 
on micrograms of DNA. We use 40 µg of total DNA per 150-mm dish (5.7 µg of pAAV, 
22.8 µg of pUCmini-iCAP-PHP, and 11.4 µg of pHelper) (Supplementary Table 2.ST2, 
‘Detailed calculations’ sheet). The plasmid ratio was optimized during the initial 
development of the AAV production protocol; 1:4:2 gave the best viral yields.  
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Critical step: The transfection solution will appear slightly cloudy because of the 
formation of DNA–PEI complexes178,179. Allowing the mixture to sit for >10 min may 
reduce transfection efficiency.  
Critical step: Users can opt to run a positive transfection/virus production control (e.g., 
pAAV-CAG-eYFP); this is especially important if using an untested rAAV genome. 
Refer to Table 2.T3 for troubleshooting tips. 
3.  Change the media 12–24 h post transfection by aspirating the old media in 10% (vol/vol) 
bleach and replacing it with 20 ml of fresh, warmed media (Reagent setup).  
Critical step: Do not allow the cells to remain without media for more than a few minutes. 
To protect the cells from unwanted stress, aspirate the media from five plates at a time and 
promptly replace it with new media. PEI is moderately cytotoxic179 and cell death of up to 
20% is common230. Do not allow the media to remain unchanged for more than 24 h post 
transfection. Failure to change the media in a timely manner will result in poor cell health 
and low titers.  
Critical step: Beginning 72 h post transfection, examine the cells under a fluorescence 
microscope to assess fluorescent protein expression, if applicable. Note that expression of 
the rAAV genome does not necessarily correlate with final viral yield and will depend on 
the reporter and/or promoter under investigation.  
Refer to Table 2.T3 for troubleshooting tips. 
AAV harvest  
● Timing 5 d  
Caution: rAAVs, although replication-incompetent, are potent gene-delivery vehicles and 
must be handled according to governmental and institutional regulations. The safety of 
packaged transgenes (e.g., oncogenic genes) should be carefully considered. Perform all 
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procedures in a certified biosafety cabinet and clean AAV-contaminated equipment, 
surfaces, and labware with fresh 10% (vol/vol) bleach.  
Critical: Carefully label all tubes and replace gloves, pipettes, and cell scrapers between 
viral preps to avoid cross-contamination. Refer to Figure 2.7b for a schematic of the AAV 
harvest procedure.  
4.  Harvest the cell culture media 72 h (3 d) post transfection. Tilt each dish at a 30° angle 
and use a 25-ml serological pipette to collect the media. Store in an empty, sterile media 
bottle or sterile 500-ml bottle at 4 °C until Step 6. Replace the media with 20 ml of fresh, 
warmed media (Reagent setup).  
Caution: Tilt dishes away from the front grill of the biosafety cabinet to prevent media 
from spilling out of the biosafety cabinet.  
Critical Step: To avoid cross-contamination, harvest the media from one viral prep at a 
time.  
Critical Step: For AAV-PHP production in HEK293T cells, the media at 72 h post 
transfection contains ~2 × 1011 vg per dish, or 10–20% of the expected viral yield. Failure 
to collect and change media at this time point will decrease yields.  
Critical Step: If time is limited, media and cells can be harvested together at 72 h or 96 h 
rather than 120 h (Step 5), but total yields will be reduced.  
5.  Harvest the media and cells 120 h (5 d) post-transfection. Use a cell scraper to gently 
scrape the cells in the media. After scraping the first dish, prop it at a 30° angle, using an 
empty 1.5-ml microcentrifuge tube rack for support. Scrape down the residual cells and 
media such that they are pooled together. Return the dish lid and scrape the next plate; prop 
dishes up against one another along the length of the biosafety cabinet until scraping is 
complete. Use a 25-ml serological pipette to collect the media and cells from each dish; 
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transfer to a 250-ml conical centrifuge tube. Pool the media and cells from up to 10 
dishes in a single tube.  
Caution: Scrape the cells with a forward motion (i.e., away from the front grill of the 
biosafety cabinet) to prevent media and cells from splashing out of the biosafety cabinet. 
If a spill does occur at this or any other step, immediately cover with paper towels and 
carefully saturate the towels with fresh 10% (vol/vol) bleach.  
Critical Step: To avoid cross-contamination, harvest the media and cells from one viral 
prep at a time.  
Critical Step: For larger viral preps (6–10 dishes), a 250- or 500-ml conical centrifuge tube 
can be used to harvest the media and cells (Steps 5–9). However, we recommend using two 
250-ml tubes in Step 10B because the PEG pellet (Step 12) is difficult to remove from the 
walls and edges of 500-ml tubes (Step 14).  
6.  Combine the media collected at 72 h post transfection (Step 4) with the media and cells 
collected at 120 h post transfection (Step 5). For smaller viral preps (1–5 dishes), use option 
A. For larger preps (6–10 dishes), use option B.  
(A) Harvest from 1–5 dishes  
(i) Pour the media collected in Step 4 into the corresponding 250-ml tube of media and 
cells collected in Step 5.  
Critical Step: Save the bottles from Step 4 for Step 8.  
(B) Harvest from 6–10 dishes  
(i) Pour the media collected in Step 4 into a new 250-ml tube.  
Critical Step: Save the bottles from Step 4 for Step 8.  
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7.  Centrifuge the media and cells at 2,000g for 15 min at RT. Ensure that the tube caps 
are tightly secured. Centrifugation will result in the formation of a cell pellet (Figure 2.7b).  
8.  Pour off the supernatant (i.e., the clarified media) into the corresponding bottle from 
Step 4. Allow excess media to drip back down onto the beveled edge of the 250-ml tube; 
remove using a P1000 pipette and add to the supernatant. Store the supernatant at 4 °C until 
Step 10.  
Critical Step: Failure to remove excess media from the pellet will cause several milliliters 
of media to dilute the SAN digestion buffer in Step 9.  
9.  Cell pellet resuspension. Prepare 5 ml of SAN + SAN digestion buffer (Reagent setup) 
per viral prep. For smaller viral preps (1–5 dishes), use option A. For larger preps (6–10 
dishes), use option B.  
(A) Harvest from 1–5 dishes  
(i) Use a 5-ml serological pipette to gently resuspend the cell pellet in 5 ml of SAN + SAN 
digestion buffer; pipette into a 50-ml tube to finish resuspending the pellet (Figure 2.7b).  
(ii) Incubate in a 37 °C water bath for 1 h and store at 4 °C until Step 14 (up to 1 d).  
Critical Step: Be sure to collect the entire pellet, which will stick to the walls and beveled 
edges of 250-ml tubes. Save the 250-ml tubes for Step 10.  
Critical Step: The high salt content of SAN digestion buffer lyses the cells, which release 
the viral particles and nucleic acids into the solution. Initially, the cell lysate may be viscous 
and difficult to pipette; SAN will degrade nucleic acids and reduce the viscosity after 
incubation at 37 °C. The pH of the lysate will decrease to 8–9 or lower during cell lysis, 
but the lysate should appear pink rather than yellow/orange because of residual phenol red 
(Figure 2.7b). Note that the expression of fluorescent proteins from strong promoters (e.g., 
CAG) can alter the color of the lysate.  
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Critical Step: (Optional) Collect a 30-µl sample from the cell lysate for troubleshooting; 
store at 4 °C for up to 1 week. If the viral yield is lower than expected, the sample can be 
titered (Steps 32–42) to determine at which stage the virus may have been lost.  
Refer to Table 2.T3 for troubleshooting tips. 
 (B) Harvest from 6–10 dishes  
(i) Use a 10-ml serological pipette to partially resuspend the smaller cell pellet in 5 ml of 
SAN + SAN digestion buffer. Pipette into the second 250-ml tube containing the larger 
pellet and resuspend together; pipette into a 50-ml tube to finish resuspending the pellet 
(Figure 2.7b).  
(ii) Incubate in a 37 °C water bath for 1 h and store at 4 °C until Step 14 (up to 1 d). 
Critical Step: Be sure to collect the entire pellet, which will stick to the walls and beveled 
edges of 250-ml tubes. Save the 250-ml tubes for Step 10.  
Critical Step: The high salt content of SAN digestion buffer lyses the cells, which release 
viral particles and nucleic acids into solution. Initially, the cell lysate may be viscous and 
difficult to pipette; SAN will degrade nucleic acids and reduce the viscosity after 
incubation at 37 °C. The pH of the lysate will decrease to 8–9 or lower during cell lysis, 
but the lysate should appear pink rather than yellow/orange because of residual phenol red 
(Figure 2.7b). Note that expression of fluorescent proteins from strong promoters (e.g., 
CAG) can alter the color of the lysate.  
Critical Step: (Optional) Collect a 30-µl sample from the cell lysate for troubleshooting; 
store at 4 °C for up to 1 week. If the viral yield is lower than expected, the sample can be 
titered (Steps 32–42) to determine at which stage the virus may have been lost.  
Refer to Table 2.T3 for troubleshooting tips. 
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10.  Retrieve the supernatant collected in Step 8. For smaller viral preps (1–5 dishes), 
use option A. For larger preps (6–10 dishes), use option B.  
(A) Harvest from 1–5 dishes  
(i) Pour the supernatant from Step 8 into the corresponding 250-ml tube from Step 9. 
Critical Step: (Optional) Collect a 30-µl sample from the media for troubleshooting; store 
at 4 °C for up to 1 week. If the viral yield is lower than expected, the sample can be titered 
(Steps 32–42) to determine at which stage the virus may have been lost.  
(B) Harvest from 6–10 dishes  
(i) Equally divide the supernatant from Step 8 between the two corresponding 250-ml tubes 
from Step 9.  
Critical Step: (Optional) Collect a 30-µl sample from the media for troubleshooting; store 
at 4 °C for up to 1 week. If the viral yield is lower than expected, the sample can be titered 
(Steps 32–42) to determine at which stage the virus may have been lost.  
11.  Use a 25-ml or 50-ml serological pipette to add a 1/5 final volume of 40% (wt/vol) 
PEG stock solution to the supernatant (i.e., the supernatant should contain a final 
concentration of 8% (wt/vol) PEG solution). Tighten the cap and thoroughly invert ten 
times to mix. Incubate on ice for 2 h. 
Critical Step: For AAV production in HEK293T cells, the cell culture media contains a 
large fraction of the expected yield231. Failure to PEG-precipitate AAV particles in the 
media will result in lower viral yields181.  
Pause Point: The PEG–media mixture can be incubated at 4 °C overnight.  
12.  Centrifuge the PEG–media mixture at 4,000g for 30 min at 4 °C. Centrifugation will 
result in the formation of a PEG pellet (Figure 2.7b).  
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13.  Pour off the supernatant (i.e., the PEG-clarified media) into a used media collection 
bottle for bleaching. Allow excess media to drip back down onto the beveled edge of the 
250-ml tube; aspirate or pipette to remove.  
14.  PEG pellet resuspension. Prepare 1 ml of SAN + SAN digestion buffer (Reagent setup) 
per viral prep. For smaller viral preps (1–5 dishes), use option A. For larger preps (6–10 
dishes), use option B.  
(A) Harvest from 1–5 dishes  
(i) Use a P1000 pipette to carefully resuspend the PEG pellet in 1 ml of SAN + SAN 
digestion buffer; pipette into the corresponding lysate from Step 9 (Figure 2.7b).  
(ii) Incubate in a 37 °C water bath for an additional 30 min.  
Critical Step: Resuspending the PEG pellet is difficult and will take ~5 min per pellet. Be 
sure to collect the entire pellet, some of which will stick to the walls and beveled edges of 
250-ml tubes. During resuspension, avoid air bubbles, which can be difficult to collect with 
a pipette and may disrupt capsid structure. Do not use a serological pipette to resuspend 
the pellet, which can become lodged within the barrel of the pipette. 
Critical Step: (Optional) Collect a 30-µl sample from the PEG pellet resuspension, before 
adding it to the corresponding lysate, for troubleshooting; store at 4 °C for up to 1 week. If 
the viral yield is lower than expected, the sample can be titered (Steps 32–42) to determine 
at which stage the virus may have been lost.  
Pause Point: Store the lysate at 4 °C overnight. Alternatively, use a dry ice–ethanol bath 
to freeze the lysate; store at −20 °C for up to 1 week.  
(B) Harvest from 6–10 dishes  
(i) Use a P1000 pipette to partially resuspend one of the PEG pellets in 1 ml of SAN + 
SAN digestion buffer. Pipette into the second 250-ml tube containing the second pellet and 
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carefully resuspend together; pipette into the corresponding lysate from Step 9 (Figure 
2.7b). 
(ii) Incubate in a 37 °C water bath for an additional 30 min.  
Critical Step: Resuspending the PEG pellet is difficult and will take ~5 min per pellet. Be 
sure to collect the entire pellet, some of which will stick to the walls and beveled edges of 
250-ml tubes. During resuspension, avoid air bubbles, which can be difficult to collect with 
a pipette and may disrupt capsid structure. Do not use a serological pipette to resuspend 
the pellet, which can become lodged within the barrel of the pipette.  
Critical Step: (Optional) Collect a 30-µl sample from the PEG pellet resuspension, before 
adding it to the corresponding lysate, for troubleshooting; store at 4 °C for up to 1 week. If 
the viral yield is lower than expected, the sample can be titered (Steps 32–42) to determine 
at which stage the virus may have been lost.  
Pause Point: Store the lysate at 4 °C overnight. Alternatively, use a dry ice–ethanol bath 
to freeze the lysate; store at −20 °C for up to 1 week.  
AAV purification  
● Timing 1 d  
Critical:  One iodixanol density gradient is sufficient to purify virus from up to ten 150-
mm dishes. If more than ten dishes per prep are used, divide the lysate into more than one 
gradient. The AAV purification steps are most easily learned by visualization; refer to 
Figure 2.8 and Supplementary Videos 2.ST1–3 for details.  
15.  Determine the number of gradients needed and prepare the iodixanol density gradient 
solutions (Reagent setup and Supplementary Table 2.ST3). Set the OptiSeal tubes in the 
rack provided in the OptiSeal tube kit; alternatively, use the long edge of a 50-ml tube 
Styrofoam rack.  
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Caution: Check the OptiSeal tubes for defects; tubes with dents may collapse during 
ultracentrifugation.  
16. Pour the density gradients (Figure 2.8a,b and Supplementary Video 2.V1, 0:00–1:45, 
or Supplementary Video 2.V2, 0:00–1:13). Each gradient is composed of the following 
layers: 6 ml of 15% (wt/vol) iodixanol, 6 ml of 25% (wt/vol) iodixanol, 5 ml of 40% 
(wt/vol) iodixanol, and 5 ml of 60% (wt/vol) iodixanol (Supplementary Table 2.ST3). Pour 
the layers with a 2- or 5-ml serological pipette. We typically use a 2-ml pipette; using a 5-
ml pipette is faster but requires the use of PTFE and Tygon tubing and extra reagents. To 
load the layers with a 2-ml pipette, choose option A. To load the layers with a 5-ml pipette, 
choose option B.  
(A) Loading with a 2-ml pipette  
(i) Begin by pipetting 6 ml (measure to the 3 ml mark twice) of 15% (wt/vol) iodixanol to 
each tube. Next, add 6 ml of 25% (wt/vol) iodixanol under the 15% layer by lightly 
touching the pipette tip to the bottom of the tube and slowly releasing the solution (Figure 
2.8a and Supplementary Video 2.V1, 0:13–1:29). Continue adding layers of increasing 
density under the previous layer. The gradients should have a sharp delineation between 
layers (Figure 2.8b).  
Critical Step: When loading the 25%, 40%, and 60% layers with a 2-ml pipette, stop 
releasing the solution and slowly remove the pipette once the iodixanol is ~5 mm from the 
tip of the pipette (Supplementary Video 2.V1, 0:42–0:58 and 1:20–1:25). This will prevent 
an air bubble from disturbing the gradient. The remaining iodixanol will be released when 
the pipette is removed from the tube.  
Critical Step: Corning brand 2-ml serological pipettes consistently fit into OptiSeal tubes; 
other brands should be tested before use.  
Refer to Table 2.T3 for troubleshooting tips. 
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 (B) Loading with a 5-ml pipette  
(i) Attach a piece of tubing (see Equipment) to a 5-ml pipette. Begin by pipetting 6 ml of 
15% (wt/vol) iodixanol into each tube. Next, add 6 ml of 25% (wt/vol) iodixanol under the 
15% layer by lightly touching the tubing to the bottom of the tube and slowly releasing the 
solution (Supplementary Video 2.V2, 0:17–1:13). Continue adding layers of increasing 
density under the previous layer. The gradients should have a sharp delineation between 
layers (Figure 2.8b).  
Critical Step: Fill the 5-ml pipette with more layer solution than is needed (e.g., an extra 1 
ml per layer); this will prevent an air bubble from disturbing the gradient when releasing 
the last of the required volume (Supplementary Video 2.V2, 1:09–1:11). Remember to 
prepare extra solution (Reagent setup).  
Refer to Table 2.T3 for troubleshooting tips. 
17.  Centrifuge the lysate from Step 14 at 2,000g for 10 min at RT. Centrifugation will 
result in the formation of a pellet (Figure 2.7b).  
18.  Use a 2-ml serological pipette to load the supernatant (i.e., the clarified lysate) (~6–7 
ml total) from Step 17 above the 15% (wt/vol) iodixanol layer (Figure 2.8c and 
Supplementary Video 2.V1, 1:46–2:22 or Supplementary Video 2.V2, 1:14–1:55). Touch 
the pipette tip to the surface of the 15% layer and slowly release the lysate such that a layer 
forms on top. 
Critical Step: Use a pipetting device with precise control. Do not allow the lysate to drip 
from the pipette tip onto the 15% layer; this will cause the lysate to mix with the gradient. 
Note that Corning brand 2-ml serological pipettes consistently fit into OptiSeal tubes; other 
brands should be tested before use.  
Critical Step: The pellet may be soft, making it difficult to retrieve all of the supernatant. 
After loading 6–7 ml of lysate above the 15% layer, spin the lysate for an additional 15 
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min at 3,000g at RT; use a P200 or P1000 pipette to slowly load the remaining 
supernatant onto the lysate layer. Discard the pellet in 10% (vol/vol) bleach or a biohazard 
waste bin.  
Critical Step: (Optional) Collect a 30-µl sample from the lysate for troubleshooting; store 
at 4 °C for up to 1 week. If the viral yield is lower than expected, the sample can be titered 
(Steps 32–42) to determine at which stage the virus may have been lost.  
19. Using a 2-ml serological pipette, fill each tube up to the neck with SAN digestion 
buffer. Firmly insert a black cap (Figure 2.8d) and place a spacer on top (Figure 2.8e). 
Caps and spacers are provided with the OptiSeal tubes and in the OptiSeal tube kit, 
respectively.  
Caution: Overfilling the tube can cause a spill when inserting the black cap. Handling the 
tubes without caps, or with loosely fitted caps, can also cause spills.  
Caution: Avoid air bubbles, which can cause the OptiSeal tubes to collapse during 
ultracentrifugation.  
Critical Step: The black cap should fit right above or touch the lysate.  
20.  Weigh the tubes with the caps and spacers on. Balance the tubes to within 5–10 mg of 
each other using SAN digestion buffer. Be sure to adjust the tube weight in the biosafety 
cabinet; use the tube removal tool provided with the OptiSeal tube kit to remove the black 
cap and add the appropriate volume of SAN digestion buffer with a P20 or P200 pipette.  
Caution: Failure to balance the tubes before ultracentrifugation could result in damaged 
equipment.  
21.  Place the ultracentrifuge rotor in the biosafety cabinet. Load the tubes and fasten the 
lid.  
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Caution: Ensure that the rotor is in proper working order. This includes checking that 
the o-rings are intact, as cracked o-rings can cause virus to spill during ultracentrifugation. 
Also, check that the rotor and tubes are completely dry; moisture between tubes and the 
tube cavity can cause tubes to collapse. To prevent damage to the rotor, set it on a paper 
towel so that the over-speed disk at the bottom is not scratched.  
22.  Carefully transfer the rotor to the ultracentrifuge. Spin the Type 70 Ti rotor at 350,000g 
(58,400 r.p.m.) for 2 h and 25 min at 18 °C with slow acceleration (no. 3; the instrument 
will take 3 min to accelerate to 500 r.p.m., followed by maximum acceleration) and 
deceleration (no. 9; the instrument will decelerate at maximum speed until it reaches 500 
r.p.m., then take 6 min to stop) profiles. Alternatively, a Type 60 Ti rotor can be used at 
358,000 g (59,000 r.p.m.).  
Caution: Always follow the manufacturer’s instructions while operating an ultracentrifuge.  
23.  During ultracentrifugation, gather the supplies and equipment for Steps 24–27. 
Assemble the clamp setup (Equipment setup) and collect one of each of the following per 
gradient: Amicon Ultra-15 centrifugal filter device, 5-ml syringe, 10-ml syringe, 0.22-µm 
syringe filter unit, and a 16-gauge needle.  
24.  After ultracentrifugation, bring the rotor inside the biosafety cabinet and remove the 
lid. Use the spacer removal tool provided with the OptiSeal tube kit to remove the spacer 
from the first tube. Next, use the tube removal tool to grip the tube neck. Slowly remove 
the tube from the rotor and secure it into the clamp setup above a 500-ml or 1-liter beaker 
containing fresh 10% (vol/vol) bleach (Figure 2.8f). Clean the side of the tube with a paper 
towel or a Kimwipe sprayed with 70% (vol/vol) ethanol.  
Caution: The black cap may become dislodged from the tube during removal, increasing 
the likelihood of a spill. Try replacing the cap before removing the tube from the rotor. 
Otherwise, replace the cap once the tube is secured in the clamp setup.  
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Caution: If a tube collapses during ultracentrifugation, take extra care when removing 
the tube from the rotor. Use fresh 10% (vol/vol) bleach to wipe the tube before proceeding 
with AAV purification. Viruses purified from collapsed tubes may have lower yields.  
Refer to Table 2.T3 for troubleshooting tips. 
25.  Prepare the supplies for Steps 26 and 27. First, remove and save the plunger from a 
10-ml syringe. Attach a 0.22-µm syringe filter unit to the syringe barrel and place it on top 
of an Amicon filter device. Next, add 10 ml of DPBS to the barrel and allow the solution 
to begin dripping through the syringe filter unit and into the filter device (Figure 2.8f). 
Last, attach a 16-gauge needle to a 5-ml syringe.  
Critical Step: Amicon filter devices contain traces of glycerine. If this interferes with 
downstream applications, rinse the device with DPBS before use. (Optional) Rinse the 
filtration membrane of the Amicon filter device by adding 15 ml of DPBS to the top 
chamber and centrifuging at 3,000 g for 1 min at RT; discard the flow-through. The 
manufacturer recommends using the device immediately after rinsing.  
26.  From the tube clamped in Step 24, collect the virus from the 40/60% interface and 
40% layer182,183 (Figure 2.8g and Supplementary Video 2.V3, 0:00–1:30). Hold the top of 
the OptiSeal tube with your non-dominant hand; use your dominant hand to hold the 
needle/syringe. Use a forward-twisting motion to insert the needle ~4 mm below the 
40/60% interface (i.e., where the tube just starts to curve). Use the tube removal tool in 
your non-dominant hand to remove the black cap from the tube to provide a hole for air 
entry. With the needle bevel up, use the needle/syringe to collect 4.0–4.5 ml of virus/ 
iodixanol from the 40/60% interface and 40% layer. Do not collect from the white protein 
layer at the 25/40% interface; as this interface is approached, rotate the needle bevel down 
and continue collecting from the 40% layer. Firmly replace the black cap before removing 
the needle from the tube.  
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Caution: Keep your hands out of the path of the needle to prevent accidental exposure 
to AAVs. Failure to firmly replace the black cap before removing the needle will cause the 
AAV-contaminated solution to flow out of the needle hole in the tube and potentially onto 
and out of the biosafety cabinet. Perform this step over a large beaker of fresh 10% (vol/vol) 
bleach (Figure 2.8f).  
Critical Step: The virus should concentrate at the 40/60% interface and within the 40% 
layer10. There will not be a visible virus band, but the phenol red in the 25% and 60% 
layers helps to better define the 40% cushion. 
Critical Step: Before attempting to collect virus from the density gradient, practice on an 
OptiSeal tube filled with water.  
Critical Step: (Optional) Collect a 30-µl sample from the virus/iodixanol for 
troubleshooting; store at 4 °C for up to 1 week. If the viral yield is lower than expected, the 
sample can be titered (Steps 32–42) to determine at which stage the virus may have been 
lost.  
Refer to Table 2.T3 for troubleshooting tips. 
27.  Add the 4.0–4.5 ml of virus/iodixanol to the syringe barrel containing 10 ml of DPBS 
(prepared in Step 25) (Figure 2.8h and Supplementary Video 2.V3, 1:31–2:06). Layer the 
virus below the DPBS by placing the needle near the bottom of the barrel and pressing on 
the plunger. Insert the 10-ml syringe plunger into the barrel and push the virus/DPBS 
mixture through the syringe filter unit and into the Amicon filter device (Supplementary 
Video 2.V3, 2:07–2:32). Mix well using a P1000 pipette.  
Critical Step: This filtration step reduces the likelihood of clogging the filtration membrane 
in the Amicon filter device. The virus/iodixanol mixture will be difficult to push through 
the syringe filter unit; DPBS will be easy to push through as it washes the filter.  
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Critical Step: AAVs adhere to hydrophobic surfaces, including plastics; use low-binding 
pipette tips (Reagents). Pluronic F-68 is a nonionic surfactant that may reduce virus loss 
associated with sticking to plastics. (Optional) Include 0.001% (vol/vol) Pluronic F-68 in 
the DPBS for Steps 27–30. 28 Centrifuge the virus/DPBS mixture at 3,000g for 5–8 min 
at RT, or until the volume of the solution remaining in the top chamber of the Amicon filter 
device is 500–1,500 µl (>10× concentrated).  
Critical Step: This step may take longer because iodixanol initially slows the passage of 
the solution through the filtration membrane.  
29.  Discard the flow-through for bleaching. Add 13 ml of DPBS to the virus in the top 
chamber and use a P1000 pipette to mix.  
Critical Step: Remove the filter device, which contains the virus, before discarding the 
flow through.  
30.  Centrifuge the virus/DPBS mixture as in Step 28. Wash the virus two more times for 
a total of four buffer exchanges. During the last spin, retain 300–500 µl of solution in the 
top chamber.  
Critical Step: The third and fourth washes may require only a 2–3-min spin until the desired 
volume remains in the top chamber.  
Critical Step: The volume retained in the top chamber will affect the final virus 
concentration (vg/ml) (i.e., the lower the volume, the higher the concentration). A final 
volume of 300–500 µl should work for most applications, assuming a production efficiency 
of at least 1 × 1012 vg/dish and a dose and injection volume of no more than 1 × 1012 vg 
and 100 µl, respectively (see ‘Experimental design’ section and Step 43 for dose and 
injection volume recommendations, respectively). For direct injections, a final volume of 
200 µl may be optimal. Note that retaining too low a volume may cause the virus to 
aggregate during storage at 4 °C (see Step 42 for details).  
 
 
75 
31.  Use a P200 pipette to transfer the virus from the top chamber of the Amicon filter 
device directly to a 1.6-ml screw-cap vial; store at 4 °C.  
Critical Step: Amicon filter devices are not sterile. If this is a concern for specific 
applications, the virus can be filter-sterilized before storage. (Optional) Filter-sterilize the 
virus. Use a P200 pipette to transfer the virus from the top chamber of the Amicon filter 
device directly to a Costar Spin-X filter unit within a centrifuge tube. Centrifuge the virus 
at 3,000 g for 1 min at RT. Discard the filter unit and transfer the purified virus from the 
centrifuge tube to a 1.6-ml screw-cap vial; store at 4 °C.  
Critical Step: The screw-cap vials are not low protein binding; however, they help prevent 
the formation of aerosols when opening and closing the tubes. We store AAVs in screw-
cap vials at 4 °C and typically use them within 3 months, during which time we have not 
noticed a decrease in titers or transduction efficiency in vivo. We have not rigorously tested 
the effects of long-term storage at −20 °C or −80 °C for systemically delivered viruses.  
Refer to Table 2.T3 for troubleshooting tips. 
Pause Point: Store the purified virus at 4 °C for up to 3 months.  
AAV titration  
● Timing 1 d  
Critical: The AAV titration procedure below is adapted from ref.184. Each virus sample is 
prepared in triplicate in separate 1.5-ml DNA/RNA LoBind microcentrifuge tubes and later 
loaded into a 96-well plate for qPCR. All solutions must be accurately pipetted and 
thoroughly mixed; qPCR is highly sensitive to small changes in DNA concentration.  
32.  Prepare a plan for the PCR plate setup. Allocate the first 24 wells (A1–B12) for the 
DNA standards such that standard no. 1 occupies wells A1–A3, standard no. 2 occupies 
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wells A4–A6, and so on. Use the remaining wells for the virus samples such that the first 
virus sample occupies wells C1–C3, the second sample occupies wells C4–C6, and so on.  
Critical Step: Include DPBS as a negative control and a virus sample with a known 
concentration as a positive control; prepare the controls with the virus samples in Steps 33–
40.  
33.  Use DNase I to digest DNA that was not packaged into the viral capsid. Prepare DNase 
I + DNase digestion buffer (Reagent setup) and add 100 µl to each 1.5-ml tube. Vortex 
each virus for 1–2 s to mix; alternatively, use a P200 pipette to mix. Add 2 µl of the virus 
to each of three tubes. Vortex for 1–2 s to mix and spin down (2,000g, RT, 10 s); incubate 
in a 37 °C water bath for 1 h.  
Critical Step: Do not vortex/pipette the virus vigorously or vortex longer than 1–2 s; 
exposure to force may disrupt capsid structure.  
Critical Step: When dipping the pipette tip into the virus stock, insert the tip just below the 
surface of the liquid rather than dipping it deep inside. Excess virus carried on the outside 
of the tip will carry over into the DNase digestion buffer and cause variations in the titer.  
Critical Step: Prepare each virus sample in triplicate.  
34.  Inactivate the DNase. Add 5 µl of EDTA to each tube; vortex for 1–2 s to mix, spin 
down (2,000 g, RT, 10 s), and incubate in a 70 °C dry bath for 10 min.  
Critical Step: DNase must be inactivated or else it will degrade the viral genome when it 
is released from the viral capsid in Step 35.  
35.  Use proteinase K to digest the viral capsid and release the viral genome. Prepare 
proteinase K + proteinase K solution (Reagent setup) and add 120 µl to each tube. Vortex 
for 1–2 s to mix and spin down (2,000 g, RT, 10 s); incubate in a 50 °C dry bath for 2 h.  
Pause Point: Samples can be incubated at 50 °C overnight.  
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36.  During the last 20 min of the proteinase K digestion, prepare the DNA standard 
dilutions (Reagent setup) and use the Qubit assay to measure the concentration (ng/µl) of 
the DNA standard stock. 
Critical Step: The concentration of the standard stock solution is used to generate the 
standard curve after qPCR (Supplementary Table 2.ST4, cell B9). To measure the 
concentration of the standard stock solution, use the Qubit fluorometer, which measures 
low DNA concentrations with high sensitivity and accuracy.  
37.  Inactivate the proteinase K. Incubate the tubes in a 95 °C dry bath for 10 min.  
Caution: Tube caps may pop open unexpectedly; use safety glasses while removing the 
tubes from the 95 °C dry bath.  
Critical Step: Proteinase K must be inactivated or else it will digest the DNA polymerase 
during qPCR.  
38.  Allow the tubes to cool for 5 min. Vortex each sample for 1–2 s to mix and add 3 µl 
to a new tube containing 897 µl of UltraPure water (a 1:300 dilution). Vortex the diluted 
samples for 3 s to mix.  
39.  Prepare the qPCR master mix (Reagent setup).  
40.  Load the PCR plate based on the experimental plan from Step 32. First, pipette 23 µl 
of qPCR master mix into each designated well. Next, pipette 2 µl of each standard into 
wells A1–B12. Last, pipette 2 µl of each diluted sample from Step 38 into wells C1 and 
onward. Seal the plate with sealing film and briefly spin down (500 g, RT, 10 s) in a plate 
spinner.  
41. Place the PCR plate into the qPCR machine. Use the following cycling parameters: 
Step 1: 95 °C, 10 min Step 2: 95 °C, 15 s Step 3: 60 °C, 20 s Step 4: 60 °C, 40 s Repeat 
steps 2–4 40×.  
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42.  When the qPCR run is complete, export the cycle threshold (Ct) values to an Excel 
file. Copy and paste the Ct values into Supplementary Table 2.ST4 (‘AAV titration 
calculator’ sheet) to generate a standard curve and calculate the titer (vg/ml) (cell G27) of 
each virus; calculate per-plate production (vg/dish) (cell K27) to assess production 
efficiency. Be sure to enter the appropriate values in cells B7–10 and B18; see ‘Example’ 
sheet.  
Critical Step: If the titer is ≥1 × 1014 vg/ml, the virus may aggregate during storage at 4 
°C. Dilute the virus to between 2 × 1013 and 5 × 1013 vg/ml with DPBS and re-titer the 
diluted stock.  
Refer to Table 2.T3 for troubleshooting tips. 
Intravenous (retro-orbital) injection  
● Timing <5 min per mouse, excluding setup and cleanup time  
Caution: Follow appropriate institutional and governmental guidelines and regulations for 
husbandry and handling of laboratory animals. Compared to tail-vein injections, retro-
orbital injections require less technical expertise and may cause less distress in mice185; 
however, tail-vein injections appear to result in similar AAV distribution158,160.  
Critical: When possible, verify viral transduction and transgene expression in vitro before 
systemic administration. Note that co-injecting AAVs with other substances (e.g., dyes) 
could affect infectivity in vivo and should be tested independently.  
Critical: Re-titer viruses before injection if more than 1 month has passed since titration; 
this will ensure that animals are administered the most accurate dose possible.  
43.  Determine the dose of virus to administer per mouse (see ‘Experimental design’ section 
for recommendations). Divide the dose (vg) by the titer (vg/ml) (Supplementary Table 
2.ST4, cell G27) to calculate the volume of virus needed to inject one mouse. In a screw-
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cap vial, prepare a master mix of virus based on the number of animals to be injected; 
briefly vortex each virus and master mix for 1–2 s before use. Transport the virus on ice 
once it is ready for injection.  
Caution: Do not inject more than 10% of the mouse blood volume, which corresponds to 
150 µl for a 25-g mouse.  
Critical Step: Depending on the user, it is easiest to inject 40–80 µl/mouse. If <40 µl/mouse 
is required, use DPBS or saline to dilute the virus such that a larger volume is injected. If 
more than 80 µl/mouse is required, it may be more convenient to re-concentrate the virus 
or perform two separate injections; follow institutional guidelines for multiple eye 
injections. Virus will be lost in the event of an unsuccessful injection; therefore, prepare 
more master mix than is required.  
Critical Step: To reduce the chance of contaminating the virus stock, avoid using the 
original virus stock; bring only an aliquot of what is needed for the injections.  
Critical Step: Do not store diluted viruses; only dilute what is needed immediately before 
injection.  
Refer to Table 2.T3 for troubleshooting tips. 
44.  Assemble the anesthesia system229 (Equipment setup) inside the biosafety cabinet.  
45.  Remove the mouse from its cage and place it in the induction chamber. Anesthetize 
the mouse with 1–5% isoflurane in oxygen.  
Caution: Isoflurane must be handled according to federal, state, and local regulations.  
46.  While the mouse is being induced, load an insulin syringe with virus. Remove the dead 
space in the syringe barrel by gently ejecting the virus back into the tube such that air 
bubbles are expelled. Load the syringe again and repeat the procedure until no bubbles 
remain in the barrel.  
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Caution: Introducing air into the vascular system can be fatal.  
Critical Step: Introducing air into the virus may cause protein denaturation; perform this 
step gently and only until no bubbles remain in the syringe barrel.  
47.  Remove the anesthetized mouse from the induction chamber. Place the animal in a 
prone position on a small stack of paper towels. Position the mouse such that its head is 
situated on the same side as the operator’s dominant hand. Place the nose cone on the 
mouse to maintain anesthesia.  
48.  Use the index finger and thumb of the non-dominant hand to draw back the skin above 
and below the eye, causing the eye to slightly protrude from the socket185. With the 
dominant hand, insert the needle, bevel down, at a 30–45° angle into the medial canthus 
and through the conjunctival membrane. The needle should be positioned behind the globe 
of the eye in the retro-orbital sinus. Slowly release the virus into the sinus and gently 
remove the needle.  
Caution: Assess anesthetic depth by loss of pedal reflex (via toe pinch) before inserting the 
needle into the retro-orbital sinus. Any movement of the eye or skin when the needle is 
inserted indicates incorrect needle placement. Keep hands out of the path of the needle to 
prevent accidental exposure to AAVs. Do not recap needles; discard into an approved 
biohazardous sharps container immediately after use.  
Critical Step: No liquid should leak out of the eye after viral delivery; likewise, little to no 
bleeding should be observed.  
Refer to Table 2.T3 for troubleshooting tips. 
49.  Following viral injection, apply mild pressure to the eyelid. Apply 1–2 drops of 
proparacaine to the corneal surface to provide local analgesia. After recovery from 
anesthesia, place the mouse in a clean cage.  
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Caution: Monitor the eye daily after injection for 2 d, or according to institutional 
guidelines. 
Evaluation of transgene expression  
● Timing variable; see ‘Experimental design’ section  
Caution: Follow appropriate institutional and governmental guidelines and regulations for 
husbandry and handling of laboratory animals.  
50.  To assess endogenous fluorescence in fixed tissue (Figures 2.2–2.5), anesthetize and 
transcardially perfuse232 the animals after sufficient time has passed for viral transduction 
and protein expression (see ‘Experimental design’ section for recommendations). Cut 
thin233 or thick234 tissue slices and mount them in RIMS171,218 or a commercially available 
mounting media such as Prolong Diamond Antifade (Thermo Fisher Scientific, cat. no. 
P36965) or Vectashield (Vector Laboratories, cat. no. H-1000-10). Alternatively, use 
PACT- or PARS-based clearing171,218 of whole organs or animals, respectively, or another 
clearing method (e.g., ScaleSQ170). Ensure that the chosen clearing protocol is compatible 
with the fluorescent protein(s) under investigation (see ‘Experimental design’ and 
‘Anticipated results’ sections for details). Native fluorescence can be visualized using a 
fluorescence microscope (e.g., Keyence BZ-X700), confocal microscope (e.g., Zeiss LSM 
880), or light-sheet microscope (e.g., custom-made218 or LaVision BioTec 
UltraMicroscope II), depending on the tissue volume and desired imaging resolution. For 
experiments without fluorescent labels, evaluate transgene expression using molecular 
(e.g., qPCR3 or Western blot219), histological218 (e.g., with antibodies or molecular probes), 
or functional (e.g., optical imaging217) methods relevant to the experimental aims. 
Regardless of the approach used to evaluate gene expression, cell type–specific promoters 
should be verified at this stage in the protocol; we typically assess cell morphology and/or 
use antibody staining to confirm specificity133 (Figure 2.2b,c).  
Refer to Table 2.T3 for troubleshooting tips. 
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2.5 TROUBLESHOOTING  
Troubleshooting advice can be found in Table 2.T3. 
Table 2.T3: Troubleshooting table 
Step Problem Possible 
reason 
Solution 
2 
(Transfection) 
Transfection 
solution is not 
cloudy 
DNA–PEI 
complexes 
have not 
formed 
Thoroughly vortex the transfection 
solution for 10 s and incubate at RT 
for 2–10 min before use; always 
use PEI at RT 
Transfection 
miscalculation 
Carefully follow the instructions in 
the Reagent setup and 
Supplementary Table 2 
(‘Transfection calculator’ sheet) to 
prepare the PEI + DPBS master 
mix and DNA + DPBS solutions 
3 
(Transfection) 
Low or no 
fluorescent 
protein expression 
post transfection 
Low DNA 
purity 
Use an endotoxin-free plasmid 
purification kit to isolate plasmids; 
assess DNA purity (i.e., 260/280 
and 260/230 ratios) before 
transfection 
Mutations in 
plasmids 
Verify the integrity of pAAV 
plasmids by sequencing and 
restriction digestion before 
transfection 
Poor cell health 
Maintain cells in an actively 
dividing state at recommended 
ratios (Reagent setup). Ensure cells 
are not over-confluent at the time of 
transfection, and change media no 
more than 24 h post transfection 
Weak 
fluorescent 
reporter and/or 
promoter, or 
promoter 
Include a positive transfection 
control (e.g., pAAV-CAG-eYFP). 
Note that some promoters may take 
2–3 d to show expression 
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Step Problem Possible 
reason 
Solution 
cannot initiate 
gene 
expression in 
HEK293T cells 
Transgene 
expression 
depends on Flp 
or Cre 
recombinase 
Include a positive transfection 
control (see above) 
Transfection 
miscalculation 
Carefully follow the instructions in 
the Reagent setup and 
Supplementary Table 2 
(‘Transfection calculator’ sheet) to 
prepare the PEI + DPBS master 
mix and DNA + DPBS solutions 
9 (AAV 
harvest) 
Cell lysate is not 
pink 
pH of the lysate 
is too low 
Check the pH of the lysate by 
pipetting 30 µl onto a pH strip; 
adjust the pH to 8.5 with NaOH 
suitable for cell culture. In 
subsequent viral preps, ensure that 
the pH of SAN digestion buffer is 
~10.0; during cell lysis, the pH 
should drop to 8.5–9.0, which is 
optimal for SAN digestion 
Fluorescent 
protein 
expression 
from a strong 
promoter (e.g., 
CAG) 
Expression of blue/green or red 
fluorescent proteins from strong 
promoters can cause the lysate to 
turn yellow or red, respectively; 
proceed with AAV production 
16 (AAV 
purification) 
Density gradients 
have no clear 
delineation 
between iodixanol 
layers 
Layers are 
mixed 
Repour the gradients 
(Supplementary Video 1, 0:00–
1:45, or Supplementary Video 2, 
0:00–1:13); gradients should be 
poured fresh and not allowed to sit 
for too long 
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Step Problem Possible 
reason 
Solution 
24 (AAV 
purification) 
Tube collapsed 
during 
ultracentrifugation 
An air bubble 
was trapped 
underneath the 
black cap 
Carefully remove the tube from the 
rotor and wipe it with fresh 10% 
(vol/vol) bleach before proceeding 
with AAV purification. In future 
viral preps, remove air bubbles 
with a P200 pipette before 
ultracentrifugation 
The rotor 
and/or OptiSeal 
tubes were not 
in proper 
working order 
Carefully remove the tube from the 
rotor and wipe it with fresh 10% 
(vol/vol) bleach before proceeding 
with AAV purification. In future 
viral preps, check that the rotor and 
tubes are completely dry; moisture 
between tubes and the tube cavity 
can cause tubes to collapse. Also 
check tubes for dents before 
pouring the density gradients 
26 (AAV 
purification) 
Cannot puncture 
the OptiSeal tube 
with the needle 
Not enough 
force is used 
Use a forward-twisting motion to 
insert the needle into the tube 
(Supplementary Video 3, 0:06–
0:21); practice on an OptiSeal tube 
filled with water 
Two holes were 
punctured through 
the OptiSeal tube 
Too much force 
was used 
See above. Do not remove the 
needle; carefully insert a new 
needle and proceed to collect virus 
Cannot collect 
virus with the 
needle 
Black cap was 
not removed 
Use the tube removal tool to 
remove the black cap from the tube 
after inserting the needle but before 
collecting virus (Fig. 8g and 
Supplementary Video 3, 0:22–
0:30); practice on an OptiSeal tube 
filled with water 
Plastic from the 
tube is lodged 
inside the 
needle 
Firmly replace the black cap and 
remove the needle from the tube; 
insert a new needle into the same 
hole, remove the black cap, and try 
collecting virus again 
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Step Problem Possible 
reason 
Solution 
Density gradient 
flows out of the 
needle hole in the 
tube after removal 
of the needle 
Black cap was 
not firmly 
replaced 
Act quickly; use the beaker of 
bleach to catch the liquid and 
firmly replace the black cap to stop 
the flow. In subsequent viral preps, 
ensure that the black cap is replaced 
before removing the needle from 
the tube (Supplementary Video 3, 
1:19–1:30); practice on an OptiSeal 
tube filled with water 
31 (AAV 
purification) 
Purified virus is 
cloudy 
The 
virus/DPBS 
mixture was not 
mixed and 
contains 
iodixanol 
Repeat the buffer exchanges in 
Steps 28–30. In future viral preps, 
thoroughly mix the virus/DPBS 
mixture using a P1000 pipette in 
Steps 27, 29, and 30 
Unknown material 
is suspended in 
purified virus 
Salt, DNA, or 
viral 
precipitation 
Before titering or injecting the 
virus, spin down the precipitate at 
3,000g for 5 min at RT and transfer 
the supernatant (i.e., the virus) to a 
new screw-cap vial. We have not 
noticed a decrease in titer after 
removing precipitate from our 
preps; however, it is a good practice 
to re-titer a virus if precipitate has 
formed 
Bacterial 
contamination 
Bleach the virus. In future viral 
preps, filter-sterilize viruses after 
purification, and only open tubes 
containing viruses in a biosafety 
cabinet. During intravenous 
injections, never use the original 
virus stock; bring only an aliquot of 
what is needed for injection 
Carry-over 
from the 
filtration 
membrane of 
Filter-sterilize the virus 
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Step Problem Possible 
reason 
Solution 
the Amicon 
filter device 
42 (AAV 
titration) 
No SYBR signal 
detected for DNA 
standards or virus 
samples 
Missing 
reagents (e.g., 
primers) in 
qPCR reaction 
Check that all qPCR reagents were 
added to the master mix and that 
the DNA standards and virus 
samples were added to their 
respective wells 
Degraded 
reagents 
Use fresh, properly stored qPCR 
reagents 
No SYBR signal 
detected for virus 
samples 
DNase was not 
inactivated, 
resulting in 
degradation of 
the viral 
genome during 
proteinase K 
treatment 
Repeat the titration procedure; be 
sure to inactivate DNase with 
EDTA at 70 °C (Step 34) 
Proteinase K 
was not 
inactivated, 
resulting in 
degradation of 
DNA 
polymerase 
during qPCR 
Repeat the titration procedure; be 
sure to inactivate Proteinase K at 95 
°C (Step 37) 
Triplicates do not 
have similar Ct 
values 
Inaccurate 
pipetting and/or 
inadequate 
mixing of 
reagents 
Repeat the qPCR; pipette 
accurately and thoroughly mix all 
reagents before use 
Standard curve is 
not linear 
Inaccurate 
pipetting and/or 
inadequate 
mixing of 
reagents while 
preparing the 
Repeat the qPCR; pipette 
accurately and thoroughly mix all 
reagents while preparing the DNA 
standard dilutions. Note that at low 
concentrations (high Ct values), 
standard nos. 1 and 2 will deviate 
from linearity (Supplementary 
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Step Problem Possible 
reason 
Solution 
DNA standard 
dilutions 
Table 4, ‘Example’ sheet). This is 
normal; the qPCR does not need to 
be repeated 
DNA standards 
degraded 
and/or stuck to 
the walls of 1.5-
ml tubes 
Repeat the qPCR; prepare the DNA 
standard dilutions fresh, 
immediately before use, and use 
only DNA/RNA LoBind 
microcentrifuge tubes. Note that at 
low concentrations (high Ct 
values), standard nos. 1 and 2 will 
deviate from linearity 
(Supplementary Table 4, 
‘Example’ sheet). This is normal; 
the qPCR does not need to be 
repeated 
Viral yield is 
lower than 
expected 
(Supplementary 
Table 4, cell K27) 
Transfection, 
AAV harvest, 
AAV 
purification, 
and/or AAV 
titration were 
not successful 
Include a positive 
transfection/virus production 
control (e.g., pAAV-CAG-eYFP) 
and a positive titration control. To 
determine at which stage the virus 
may have been lost, collect a 30-µl 
sample from the cell lysate (Step 9), 
the media before PEG precipitation 
(Step 10), the PEG pellet 
resuspension (Step 14), and the 
lysate before (Step 18) and after 
iodixanol purification (Step 26). 
Store samples at 4 °C for up to 1 
week for titering (Steps 32–42) 
  
AAV capsid 
and/or genome 
results in poor 
production 
efficiency 
Scale up viral preps to ensure 
enough virus is produced for 
downstream applications 
ITRs 
underwent 
recombination 
After plasmid purification, but 
before transfection, digest pAAVs 
with SmaI to confirm the presence 
of ITRs, which are required for 
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Step Problem Possible 
reason 
Solution 
during bacterial 
growth 
replication and encapsidation of the 
viral genome; always propagate 
pAAVs in recombination-deficient 
bacterial strains 
43 
(intravenous 
injection) 
A large volume 
(e.g., more than 
100 µl, depending 
on user 
preference) of 
virus needs to be 
injected 
Virus 
concentration is 
too low 
Reconcentrate the virus using an 
Amicon filter device. Add 13 ml of 
DPBS and the virus to the top 
chamber of the Amicon filter 
device and use a P1000 pipette to 
mix. Centrifuge at 3,000g at RT 
until the desired volume of solution 
remains in the top chamber 
48 
(Intravenous 
injection) 
Virus spills out of 
the eye during 
injection 
Incorrect 
needle 
placement 
Absorb the spilled virus using a 
paper towel; disinfect AAV-
contaminated surfaces and 
materials with fresh 10% (vol/vol) 
bleach or an equivalent 
disinfectant. Load the same insulin 
syringe with more virus, position 
the needle behind the globe of the 
eye in the retro-orbital sinus, and 
try the injection again. Practice 
injections using DPBS or saline 
until comfortable with the 
procedure 
Bleeding before, 
during, or after 
injection 
Incorrect 
needle 
placement 
Position the needle behind the 
globe of the eye in the retro-orbital 
sinus; never puncture the eye itself. 
Inject the virus slowly; following 
injection, carefully remove the 
needle at the same angle at which it 
was inserted. Practice injections 
using DPBS or saline until 
comfortable with the procedure 
Needle is left in 
the injection 
site for too long 
Once the needle is correctly placed 
in the eye, immediately inject the 
virus 
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Step Problem Possible 
reason 
Solution 
50 
(Evaluation of 
transgene 
expression) 
Weak or no 
transgene 
expression in the 
tissue of interest 
Sufficient time 
has not passed 
for protein 
expression 
Wait longer for optimal protein 
expression 
Dose is too low, 
or dose is too 
high, causing 
cell toxicity 
Inject multiple animals with a 
series of doses and sacrifice them at 
different time points (e.g., weekly) 
to determine the optimal dose 
Titer is 
inaccurate 
Re-titer viruses before injection if 
more than 1 month has passed since 
titration; this will ensure that the 
animals are administered the most 
accurate dose possible 
Virus degraded 
See above. Store AAV-PHP 
viruses at 4 °C for up to 3 months, 
during which time we have not 
noticed a decrease in titers or 
transduction efficiency in vivo. Do 
not store diluted viruses; dilute only 
what is needed immediately before 
retro-orbital injection 
Weak or no 
expression 
from the AAV 
genome 
Verify the integrity of pAAV 
plasmids by sequencing and 
restriction digestion before 
transfection. If possible, verify 
viral transduction and transgene 
expression in vitro before systemic 
administration 
Poor viral 
injection 
Inject multiple animals to increase 
the chance of success 
Fluorescent 
protein and/or 
signal 
deteriorates in 
chemical-
clearing 
reagents 
Ensure that the chosen clearing 
protocol is compatible with the 
fluorescent protein(s) under 
investigation (see ‘Experimental 
design’ and ‘Anticipated results’ 
sections for details) 
 
 
90 
Step Problem Possible 
reason 
Solution 
Fluorescent signal 
photobleaches 
during imaging 
Fluorescent 
protein is 
sensitive to 
photobleaching 
(e.g., during 
long imaging 
sessions or at 
high 
magnification) 
Use a different fluorescent protein 
with similar spectral properties but 
higher photostability (e.g., 
tdTomato rather than mRuby2, or 
eGFP rather than Emerald) 
Lipofuscin 
accumulation 
Aging tissue 
Reduce autofluorescence using 
histological methods (e.g., Sudan 
black) or, if possible, inject 
younger adults (≤8 weeks old) and 
determine the minimum time 
required for transgene expression 
 
2.6 TIMING 
Refer to Figure 2.7a for a time line of the Procedure.  
Steps 1–3, triple transient transfection of HEK293T cells: 1–2 h  
Steps 4–14, AAV harvest: 5 d  
Steps 15–31, AAV purification: 1 d  
Steps 32–42, AAV titration: 1 d  
Steps 43–49, intravenous (retro-orbital) injection: <5 min per mouse, excluding setup and 
cleanup time Step 50, evaluation of transgene expression: variable. 
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2.7 ANTICIPATED RESULTS 
AAV production  
For capsids that package well (i.e., AAV-PHP.B, AAV-PHP.eB, and AAV-PHP.S), 
the AAV production protocol typically yields ≥1 × 1012 vg per 150-mm dish133,157. 
Production efficiency can be determined for each virus in Step 42 (Supplementary Table 
2.ST4, cell K27). Note that yields may vary from prep to prep and genome to genome. 
Users can gauge production efficiency for each experiment by running a positive control 
(e.g., pAAV-CAG-eYFP).  
Evaluation of transgene expression  
For most applications, users can expect to assess transduced cells beginning 2 or 
more weeks after intravenous injection (see ‘Experimental design’ section for details). The 
chosen method for evaluating transgene expression will vary from user to user and may 
involve molecular, histological, and/or functional approaches220 (Step 50). We typically 
use fluorescent reporters to assess gene expression in thick (≥100 µm), cleared tissue 
samples; below, we discuss expected results for the applications presented here (Figures 
2.2–2.5) and in our previous work133,157.  
Commonly used reporters such as GFP, eYFP, and tdTomato show strong 
fluorescent labeling in PACT- and PARS-cleared tissues, enabling whole-organ and thick-
tissue imaging of transgene expression157,171,218. Most markers, including mTurquoise2, 
mNeonGreen, and mRuby2, can also be detected after mounting labeled tissues in optical 
clearing reagents such as RIMS218 or ScaleSQ170 (Figures 2.3a,c,d, 2.4b-d and 2.5e) or 
commercially available mounting media (Figure 2.5a,c). Depending on the rAAV genome, 
fluorescent proteins can be localized to distinct cellular compartments, including the 
nucleus (via NLS) (Figure 2.2a,b), cytosol (Figures 2.2d,e, 2.3, 2.4b and 2.5), and cell 
membrane (via farnesylation175 or fusion to a membrane protein such as ChR2) (Figures 
2.3d and 2.4d).  
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In summary, we present a comprehensive protocol for the production and 
administration of AAV-PHP viruses. We have validated the ability of AAV-PHP variants 
to provide efficient and noninvasive gene delivery to specific cell populations throughout 
the body. Together, this AAV toolbox equips users with the resources needed for a variety 
of applications across the biomedical sciences. 
2.8 SUPPLEMENTARY INFORMATION 
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Supplementary Table 2.ST1: Use of AAV-PHP capsids for efficient transduction across 
organs and cell populations.  
Species/strains, organs, and cell populations examined to-date following intravenous 
administration of AAV-PHP viruses. To target distinct cell types, use rAAV genomes with 
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cell type–specific gene regulatory elements and/or Cre- or Flp-dependent recombination 
schemes (Figures 2.2-2.4, Figure 2.6 and Table 2.T1). iPSCs, induced pluripotent stem 
cells. The refs. 1190, 2157, 3191, 4158, 5160, 6189, 7159, 8133, 9162. 
Supplementary Table 2.ST2: Transfection calculator.  
This is an interactive calculator and provided as an Excel file (see Step 2 and ‘Reagent 
setup’). Note that our PEI calculations (‘Detailed calculations’ sheet) are based on ref.178. 
 
Supplementary Table 2.ST3: Pouring the iodixanol density gradients.  
Determine the number of gradients needed and prepare the iodixanol density gradient 
solutions (Reagent setup). The 15% layer contains high salt to destabilize ionic interactions 
between viral particles and cell proteins in the clarified lysate183. In Step 16B, prepare more 
solutions than are needed (Reagent setup). 
Supplementary Table 2.ST4: Titration calculator.  
This is an interactive calculator and provided as an Excel file (see Step 42 and ‘Reagent 
setup’). 
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Supplementary Video 2.V1: Pouring gradients part 1 
Steps 16A and 18: Pouring the density gradients and loading the virus. In Step 16A, use a 2-
ml serological pipette to pour the gradients. Next, load the virus (also shown in Step 16B 
(Supplementary Video 2.V2)) 
Supplementary Video 2.V2: Pouring gradients part 2 
Steps 16B and 18: Pouring the density gradients and loading the virus. In Step 16B, use a 
5-ml serological pipette to pour the gradients. Next, load the virus (also shown in Step16A 
(Supplementary Video 2.V1)) 
Supplementary Video 2.V3: Virus collection 
Steps 26–27: Collecting the virus 
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C h a p t e r  3  
MULTIPLEXED CRE-DEPENDENT SELECTION (M-CREATE) YIELDS 
SYSTEMIC AAVS FOR TARGETING DISTINCT BRAIN CELL TYPES 
Ravindra Kumar, S., Miles, T. F., Chen, X., Brown, D., Dobreva, T., Huang, Q., Ding, 
X., Luo, Y., Einarsson, P.H., Greenbaum, A., Jang, J.J., Deverman, B. E., Gradinaru, V. 
Multiplexed Cre-dependent selection yields systemic AAVs for targeting distinct brain cell 
types. Nature Methods (2020). https://doi.org/10.1038/s41592-020-0799-7 
 
3.1 SUMMARY 
Recombinant adeno-associated viruses (rAAVs) are efficient gene delivery vectors 
via intravenous delivery; however, natural serotypes display a finite set of tropisms. To 
expand their utility, we evolved AAV capsids to efficiently transduce specific cell types in 
adult mouse brains. Building upon our Cre-recombination-based AAV targeted evolution 
(CREATE) platform, we developed Multiplexed-CREATE (M-CREATE) to identify 
variants of interest in a given selection landscape through multiple positive and negative 
selection criteria. M-CREATE incorporates next-generation sequencing, synthetic library 
generation, and a dedicated analysis pipeline. We have identified capsid variants that can 
transduce the central nervous system broadly, exhibit bias toward vascular cells and 
astrocytes, target neurons with greater specificity, or cross the blood–brain barrier across 
diverse murine strains. Collectively, the M-CREATE methodology accelerates the 
discovery of capsids for use in neuroscience and gene-therapy applications. 
3.2 INTRODUCTION 
Recombinant adeno-associated viruses (rAAVs) are widely used as gene delivery 
vectors in scientific research and therapeutic applications due to their ability to transduce 
both dividing and non-dividing cells, their long-term persistence as episomal DNA in 
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infected cells, and their low immunogenicity100,155,235–237. However, gene delivery by 
natural AAV serotypes is limited by dose-limiting safety constraints and largely 
overlapping tropisms. AAV capsids engineered by rational design145,146,238,239 or directed 
evolution69,93,143,149,151,152,204,240–243 have yielded vectors with improved efficiencies for 
select cell populations133,147,150,157,187,244,245, yet much work remains to identify a complete 
toolbox of efficient and specific vectors. Previously, we evolved the AAV-PHP.B and 
AAV-PHP.eB variants from AAV9 using a selection method called CREATE157. This 
method applies positive selective pressure for capsids capable of infecting a target cell 
population by pairing a viral genome containing lox sites with in vivo selection in 
transgenic mice expressing Cre in the cell type of interest. This combination allows a Cre–
Lox recombination-dependent PCR amplification of only those capsids which successfully 
deliver their genomes to the nuclei of the target cell type. 
To more efficiently expand the AAV toolbox, we developed Multiplexed-CREATE 
(M-CREATE) (Figure 3.1a and Supplementary Figure. 3.S1a,b), which compares the 
enrichment profiles of thousands of capsid variants across multiple cell types and organs 
within a single experiment. This method improves upon its predecessor by capturing the 
breadth of capsid variants at every stage of the selection process. M-CREATE supports: 
(1) the calculation of an enrichment score for each variant by using next-generation 
sequencing (NGS) to correct for biases in viral production prior to selection, (2) reduced 
propagation of bias in successive rounds of selection through the creation of a post-round 
one synthetic pool library with equal variant representation, and (3) the reduction of false 
positives by including codon replicates of each selected variant in the pool. These 
improvements allow interpretation of variants' relative infection efficiencies across a broad 
range of enrichments in multiple positive selections and enable post-hoc negative screening 
by comparing capsid libraries recovered from multiple target cell types or organs. 
Collectively, these features allow prioritization of capsid variants for validation and 
characterization. 
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To demonstrate the ability of M-CREATE to reveal useful variants missed by its 
predecessor (CREATE), we used the capsid library design that yielded AAV-PHP.B, and 
identified several AAV9 variants with distinct tropisms including variants that have biased 
transduction of brain vascular cells or that can cross the blood–brain barrier (BBB) without 
mouse-strain specificity. 
3.3 RESULTS 
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Figure 3.1: Workflow of M-CREATE and analysis of 7-mer-i selection in round-1. 
 
(a), A multiplexed selection approach to identify capsids with specific and broad tropisms. 
Steps 1–6 describe the workflow in round-1 (R1) selection, steps 7–9 describe round-2 
(R2) selection using the synthetic-pool method, steps 1a, 2a and 6a,b show the 
incorporation of deep sequencing to recover capsids after R1 and R2 selection, and steps 
10–11 describe positive and/or negative selection criteria followed by variant 
characterization. The genes rep2 and cap9 in step 11 refers to rep from AAV2 
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and cap from AAV9, respectively, and the colored bar within cap9 represents 
the targeted mutation. (b), Structural model of the AAV9 capsid (PDB 3UX1) with the 
insertion site for the 7-mer-i library highlighted in red in the 60-meric (left), trimeric 
(middle) and monomeric (right) forms. (c), Empirical cumulative distribution frequency 
(ECDF) of R1 DNA and virus libraries that were recovered by deep sequencing post 
Gibson assembly and virus production, respectively. (d), Distributions of variants 
recovered from three R1 libraries from Tek-Cre, SNAP25-Cre and GFAP-Cre brain tissue 
(n = 2 per Cre line) are shown with capsid libraries, sorted by decreasing order of the 
enrichment score. The enrichment scores of the AAV-PHP.V2 variant are mapped as well. 
 
Analysis of capsid libraries during round-1 selection 
M-CREATE was developed to enable the analysis of capsid variants' behavior within 
and across in vivo selections. By doing so, we aimed to identify capsids with diverse 
tropisms, as well as reveal the capsid sequence diversity within a given tropism. M-
CREATE achieves these aims by incorporating NGS and a synthetic capsid library 
for round- 2 in vivo selection along with a dedicated analysis pipeline to assign capsid 
enrichment values. 
During DNA- and virus-library generation there is potential for biased accumulation 
and over-representation of certain capsid variants, obscuring their true enrichment during 
in vivo selection. These deviations may result from PCR amplification bias in the DNA 
library or sequence bias in the efficiency of virus production across various steps such as 
capsid assembly, genome packaging and purification. We investigated this with a 7-mer-i 
(i for insertion) library, in which a randomized 7-amino acids (AA) library is inserted 
between AA 588 and 589 of AAV9 (Figure 3.1a,b) in the rAAV-ΔCap9-in-cis-Lox2 
plasmid (Methods and Supplementary Figure 3.S1a; theoretical library size, 
3.4 × 1010 unique nucleotide sequences, and an estimated ~1 × 108 nucleotide sequences 
upon transfection). We sequenced the libraries after DNA assembly and after virus 
purification to a depth of 10–20 million (M) reads, which was adequate to capture the bias 
among variants during virus production (Figure 3.1c and Supplementary Figure 3.S1b–
d). The DNA library had a uniform distribution of 9.6 M unique variants within ~10 M 
total reads (read count (RC) mean = 1.0, s.d. = 0.074), indicating minimal bias. In contrast, 
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the virus library had 3.6 M unique variants within ~20 M depth (RC mean = 4.59, 
s.d. = 11.15) indicating enrichment of a subset of variants during viral production. Thus, 
even permissive sites like 588–589 will impose biological constraints on sampled sequence 
space. 
For in vivo selection, we intravenously administered the 7-mer-i viral library in 
transgenic mice expressing Cre in astrocytes (GFAP-Cre), neurons (SNAP25-Cre) or 
endothelial cells (Tek-Cre) at a dose of 2 × 1011 vector genomes (vg) per adult mouse (n = 2 
mice per Cre transgenic line). Two weeks after intravenous (i.v.) injection, we collected 
brain, spinal-cord and liver tissues. We extracted the rAAV genomes from tissues and 
selectively amplified the capsids that transduced Cre-expressing cells (Supplementary 
Figure 3.S1e–i). Upon deep sequencing, we observed ~8 × 104 unique nucleotide variants 
in brain tissue samples (~48% of which were identified in the sequenced portion of the 
virus library) and <50 variants in spinal-cord samples across the transgenic lines, and each 
variant was represented with an enrichment score that reflects the change in relative 
abundance between the brain and the starting virus library (Methods and Figure 3.1d). 
Two features of this dataset stand out. First, the variants recovered from brain tissue 
were disproportionately represented in the sequenced fraction of the viral library, 
demonstrating how production biases can skew selection results. Second, the distribution 
of capsid read counts reveals that more than half of the unique variants recovered after 
selection appear at low read counts. These variants may either have arisen spontaneously 
from errors during experimental manipulation or retain AAV9's basal levels of central 
nervous system (CNS) transduction (Supplementary Figure 3.S1e). 
Unbiased round-2 library design improves the selection outcome 
Concerned that the sequence bias during viral production and recovery would 
propagate across selection rounds despite our post-hoc enrichment scoring, we designed 
an unbiased library based on the round-1 (R1) output (synthetic pool library) via 
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oligonucleotide pools. We compared this library with a library PCR amplified directly 
from the recovered R1 DNA (PCR pool library) (Figure 3.2a and Table 3.T1). 
 
Table 3.T1: Comparison between the two methods for R2 selection. 
 
The table summarizes the pros and cons of selection design parameters by the synthetic pool 
and PCR pool R2 selection methods. 
 
Design Parameters Synthetic pool design PCR pool design 
Carryover of R1 selection bias 
among variants 
No, likelihood of false positives is low 
Yes, potential to minimize by 
normalization 
Carryover of R1 selection induced 
mutants 
No Yes 
Confidence in library performance High, using alternate codon replicates Low 
Customize library or add internal 
controls 
Yes, in an unbiased manner Yes, with greater risk of bias 
Control library size 
Yes, without reducing libraries or 
pooling 
Yes, with libraries reduced for pooling 
Cost for R2 library generation High Low 
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Figure 3.2: Round-2 capsid selections by synthetic pool and PCR pool methods. 
 
(a), Schematic of R2 synthetic pool (left) and PCR pool (right) library design. (b), 
Overlapping bar chart showing the percentage of library overlap between the mentioned 
libraries and their theoretical composition. (c), Histograms of DNA and virus libraries from 
the two methods, where the variants in a library are binned by their read counts (in 
log10 scale) and the height of the histogram is proportional to their frequency. (d), 
Distributions of R2 brain libraries from all Cre transgenic lines (n = 2 mice per Cre Line, 
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mean is plotted) and both methods, in which the libraries are sorted in decreasing order 
of enrichment score (log10 scale). The total number of positively enriched variants from 
these libraries are highlighted by dotted straight lines and AAV9’s relative enrichment is 
mapped on the synthetic pool plot. (e), Comparison of the enrichment scores (log10 scale) 
of two alternate codon replicates for 8,462 variants from the Tek-Cre brain library (n = 2 
mice, mean is plotted). The broken line separates the high-confidence signal (>0.3) from 
noise. For the high-confidence signal (below), a linear least-squares regression is 
determined between the two codons and the regression line (best fit). The coefficient of 
determination r2 is shown. (f), Heat maps representing the magnitude (log2(fold change)) 
of a given amino acid’s relative enrichment or depletion at each position given statistical 
significance is reached (boxed if P ≤ 0.0001, two-sided, two-proportion z-test, P values 
corrected for multiple comparisons using Bonferroni correction). R2 DNA normalized to 
oligopool (top, ~9,000 sequences), R2 virus normalized to R2 DNA (middle, n = ~9,000 
sequences), R2 Tek brain library with enrichment over 0.3 (high-confidence signal) from 
synthetic pool method normalized to R2 virus (bottom, 154 sequences) are shown (n = 2 
for brain library, one per mouse; all other libraries, n = 1). (g), Heat map of Cre-
independent relative enrichment across organs (n = 2 mice per Cre line, mean across 6 
samples from 3 Cre lines is plotted) for variants enriched in the brain tissue of at least one 
Cre-dependent synthetic pool selection (red text, n = 2 mice per cell-type, mean is plotted) 
(left). Zoom-in of the most CNS-enriched variants (middle), and of the variants that are 
characterized in the current study along with spike-in library controls (right) are shown. 
 
The synthetic pool library design comprised: (1) equimolar amounts of ~8,950 capsid 
variants present at high read counts in at least one of the R1 selections from brain and spinal 
cord (Supplementary Figure 3.S1e); (2) alternative codon replicates of those ~8,950 
variants (optimized for mammalian codons) to reduce false positives; and (3) a spike-in 
library of controls (Supplementary Dataset 3.D1), resulting in a total library size of 18,000 
nucleotide variants.  
AAV9 and ~50 additional variants (and their alternative codon duplicates), identified 
in previously described work133,157 (includes well characterized variants like AAV-PHP.B 
or AAV-PHP.eB as well as many variants identified using the previous methodology but 
uncharacterized in vivo) act as internal selection controls and standards for the relative 
performance of the new variants (see Supplementary Dataset 3.D1). The PCR pool library 
was generated by pooling the amplicons from the R1 brain selections after normalization 
based on their relative diversity (see Methods). 
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Both round-2 (R2) virus libraries produced a high titer (~6 × 1011 vg per 10 ng of 
R2 DNA library per 150-mm dish; Supplementary Figure 3.S2a), and ~99% of variants 
of the R2 DNA were found after viral production (Figure 3.2b). However, the distribution 
of the DNA and virus libraries from both designs differed notably. The PCR pool library 
carries forward the R1 selection biases (Figure 3.2c and Supplementary Figure 3.S2b,c) 
where the abundance reflects prior enrichment across tissues in R1 as well as bias from 
viral production and sample mixing. Comparatively, the synthetic pool DNA library is 
more evenly distributed, minimizing bias amplification across selection rounds. 
For in vivo selection, we intravenously administered a dose of 1 × 1012 vg per adult 
transgenic mouse into three of the previously used Cre lines (n = 2 mice per Cre transgenic 
line, GFAP, SNAP25, Tek), as well as the Syn-Cre line (for neurons). Two weeks after i.v. 
injection, we extracted, selectively amplified and deep-sequenced rAAV genomes from 
brain samples (as in R1). The synthetic pool library produced a greater number of enriched 
capsid variants than the PCR pool brain library (for example, ~1,700 versus ~700 variants 
per tissue library at the AA level in GFAP-Cre mice) (Figure 3.2d and Supplementary 
Figure 3.S2d). In the synthetic pool, ~90% of the variants from the spike-in library were 
enriched (Supplementary Figure 3.S2d, middle panel, and Supplementary Dataset 3.D1). 
The degree of correlation between variant enrichment scores for PCR and synthetic 
pool libraries varies in each Cre transgenic line, indicating the presence of noise within 
experiments (Supplementary Figure 3.S2e).  
Experimental noise 
The degree of enrichment at which correlation breaks down appears to vary with Cre-
line. A downside of PCR pool is that there is no way to tell whether it or synthetic pool is 
the more ‘true’ enrichment score, or even that there may be cause for concern regarding 
certain enrichment values. The correlation among positively enriched variants between the 
two methods were found to improve with the magnitude of positive enrichment. For each 
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experiment there is a level of enrichment below which the scores become 
irreproducible, or noisy.  
Supplementary Figure 3.S3a demonstrates that neither PCR pool nor Synthetic pool 
is inherently more ‘true’ at lower enrichment scores. This is because Synthetic pool 
methodology with its codon replicates has a self-contained control to determine an 
enrichment level below which enrichment value has no further predictive power. In the 
main text we use the term ‘noise’ to refer to regions of enrichment in a particular 
experiment below which values lose their reproducibility and predictive power. Being able 
to experimentally determine enrichment signal above noise allows researchers to focus 
their attention and data analyses on enrichment levels that are internally reproducible and 
thereby avoid selecting false positive variants or drawing invalid conclusions.  
Thus, if one is interested in only the highest enriched variants for a particular tissue, 
PCR pool design coupled with enrichment normalization to virus library may not 
drastically differ from synthetic pool design over one additional round of selection for a 
subset of in vivo selections (such as Tek-Cre or SNAP-Cre). Without additional validation, 
however, it is difficult to predict whether a given in vivo system will perform akin to Tek-
Cre. This becomes critical in a multiplexed selection study where target-specific variants 
may not garner the highest enrichments in one particular in vivo selection.  
The synthetic pool’s codon-replicate feature addresses this predicament by 
pinpointing the level of enrichment needed within each selection to rise above noise 
(Figure 3.2e and Supplementary Figure 3.S3a,b). This is a substantial advantage over the 
PCR pool design, allowing us to confidently interpret enrichment scores in a given 
selection. 
Analysis of capsid libraries after round-2 selections 
Whereas the amino acid distribution of the DNA library closely matched the 
Oligopool design, virus production selected for a motif within the hepta AA diversified 
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insertion (between AA 588 and AA 589), with Asn at position 2, β-branched amino 
acids (I, T, V) at position 4 and positively charged amino acids (K, R) at position 5 
(Figure 3.2f and Supplementary Figure 3.S3c). Fitness for BBB crossing resulted in a 
different pattern. For instance, variants highly enriched after recovery from brain tissue 
(across all Cre lines) shared preferences for Pro in position 5, and Phe in position 6. 
By assessing enrichment score reproducibility within the synthetic pool 
design, we next determined the brain enriched variants' distribution across peripheral 
organs (Figure 3.2g, left). About 60 variants that are highly enriched in brain are 
comparatively depleted across other organs (Figure 3.2g, middle). Encouraged by the 
expected behavior of spike-in control variants (AAV9, PHP.B, PHP.eB), we chose eleven 
additional variants for further validation (Figure 3.2g, right), including several that would 
have been overlooked if the choice had been based on PCR pool or CREATE (Table 3.T2). 
AAV 
Variants 
Synthetic pool 
enrichment rank 
PCR pool 
enrichment rank 
PCR pool           
read count rank 
PHP.V1 1 4 3 
PHP.V2 2 1 1 
PHP.B4 4 10 56 
PHP.B7 6 13 36 
PHP.B8 3 7 23 
PHP.C1 13 34 74 
PHP.C2 12 20 293 
PHP.C3 16 Not recovered Not recovered 
 
Table 3.T2: Ranking of AAV-PHP capsids across methods. 
 
Ranks of selected variants among all capsids recovered from R2 Tek-Cre selection by 
synthetic pool enrichment score (representing M-CREATE), PCR pool enrichment score 
(representing closer to M-CREATE), or PCR pool read counts (representing CREATE), 
the highest ranks of which starts from 1, and “Not recovered” represent absence of the 
variant from R2 sequencing data.    
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We chose these variants due to their enrichments and where they fall in sequence 
space. We noticed that the enriched variants cluster into distinct families based on sequence 
similarity. The most enriched variants form a distinct family across selections with a 
common motif: T in position 1, L in position 2, P in positive 5, F in position 6 and K or L 
in position 7 (Figure 3.3a and Supplementary Figure 3.S3d). This amino acid pattern 
closely resembles the TLAVPFK motif in the previously identified variant AAV-PHP.B157. 
Given the sequence similarity among members of this family, we next tested whether 
selected variants can cross the BBB and target the CNS with similar efficiency and tropism. 
The dominance of PHP.B-like motif 
The ability to twice recover the AAV-PHP.B sequence family from completely 
independently constructed and selected libraries confirms that the viral library’s sequence 
space coverage was broad enough to recover a family of variants sharing a common motif. 
Unlike CREATE which identified only one variant, AAV-PHP.B, M-CREATE yielded a 
diverse PHP.B-like family that hints toward important chemical features of this motif. The 
sequence diversity within this family suggests that isolating AAV-PHP.B was not simply 
good fortune in our prior study (considering a theoretical starting library size of ~1.3 
billion), and that this is a dominant family for this particular experiment. 
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Figure 3.3: Selected AAV capsids form sequence families and include variants for brain-
wide transduction of vasculature. 
 
(a), Clustering analysis of variants from synthetic pool brain libraries after enrichment in 
Tek-Cre (left), GFAP-Cre (middle) and combined SNAP-Cre and Syn-Cre (right) 
selections. The size of the nodes represents relative enrichment in the brain. Thickness of 
the edges (connecting lines) represents the degree of relatedness. Distinct families (yellow) 
with the corresponding AA frequency logos (AA size represents prevalence and color 
encodes AA properties) are shown. (b), The hepta AA insertion peptide sequences of 
AAV-PHP variants between AA positions 588–589 of AAV9 capsid are shown. AAs are 
colored by shared identity to AAV-PHP.B and eB (green) or among new variants (unique 
color per position). (c), AAV9 (left) and AAV-PHP.V1 (right) mediated expression using 
ssAAV:CAG-mNeongreen genome (green, n = 3, 3 weeks of expression in C57BL/6J adult 
mice with 3 × 1011 vg i.v. dose per mouse, imaged under the same settings) in sagittal 
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sections of brain (top) with higher-magnification image from cortex (bottom). Magenta, 
αGLUT1 antibody staining for vasculature. (d), Percentage of vasculature stained with 
αGLUT1 that overlaps with mNeongreen (XFP) expression in cortex. One-way analysis of 
variance (ANOVA) non-parametric Kruskal–Wallis test (P = 0.0036), and follow-up 
multiple comparisons using uncorrected Dunn’s test (P = 0.0070 for AAV9 versus 
PHP.V1) are reported. **P ≤ 0.01 is shown, P > 0.05 is not shown; data are 
mean ± s.e.m., n = 3 mice per AAV variant, cells quantified from 2–4 images per mouse 
per cell type. (e), Percentage of cells stained with each cell-type specific marker (αGLUT1, 
αS100 for astrocytes, αNeuN for neurons, and αOlig2 for oligodendrocyte lineage cells) 
that overlaps with mNeongreen (XFP) expression in cortex. Kruskal–Wallis test (P = 
0.0078), and uncorrected Dunn’s test (P = 0.0235 for neuron versus vascular cells, and 
0.0174 for neuron versus astrocyte) are reported. *P ≤ 0.05 is shown, and P > 0.05 is not 
shown; data are mean ± s.e.m., n = 3 mice, cells quantified from 2–4 images per mouse per 
cell type. (f), Vascular transduction by ssAAV-PHP.V1:CAG-DIO-EYFP in Tek-Cre adult 
mice (left) (n = 2, 4 weeks of expression, 1 × 1012 vg i.v. dose per mouse), and by ssAAV-
PHP.V1:Ple261-iCre in Ai14 reporter mice (right) (n = 2, 3 weeks of expression, 
3 × 1011 vg i.v. dose per mouse). Tissues are stained with αGLUT1 (magenta (left) and 
cyan (right)). (g), Efficiency of vascular transduction (as described in (d)) in Tek-Cre mice 
(n = 2, mean from 3 images per mouse per brain region). (h), Efficiency of vascular 
transduction in Ai14 mice (n = 2, a mean from 4 images per mouse per brain region). 
 
AAV9 variants with enhanced BBB entry and CNS transduction 
Given the dominance of the PHP.B family in the R2 selection, we characterized its 
most enriched member, harboring a TALKPFL motif and henceforth referred to as AAV-
PHP.V1 (Figure 3.3a,b). Despite its sequence similarity to AAV.PHP.B, the tropism of 
AAV-PHP.V1 is biased toward transducing brain vascular cells (Figure 3.3c and 
Supplementary Figure 3.S4a). When delivered intravenously, AAV-PHP.V1 carrying a 
fluorescent reporter under the control of the ubiquitous CAG promoter transduces ~60% 
of GLUT1+ cortical brain vasculature, compared with ~20% with AAV-PHP.eB and 
almost no transduction with AAV9 (Figure 3.3c,d). In addition to the vasculature, AAV-
PHP.V1 also transduced ~60% of cortical S100+ astrocytes (Figure 3.3e). However, AAV-
PHP.V1 is not as efficient for astrocyte transduction as the previously reported AAV-
PHP.eB (when packaged with an astrocyte specific GfABC1D promoter132, 
Supplementary Figure 3.S4b). 
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For applications requiring endothelial-cell-restricted transduction via i.v. 
delivery, AAV-PHP.V1 vectors can be used in three different systems: (1) in endothelial-
cell-type specific Tek-Cre246 mice with a Cre-dependent expression vector 
(Figure 3.3f (left),g and Supplementary Video 3.V1), (2) in fluorescent reporter mice 
where Cre is delivered with an endothelial-cell-type specific MiniPromoter (Ple261)129 
(Figure 3.3f (right),h and Supplementary Figure 3.S4c–e) and (3) in wild-type mice by 
packaging a self-complementary genome (scAAV) containing a ubiquitous promoter 
(Supplementary Figure 3.4f). The mechanism of endothelial-cell-specific transduction by 
AAV-PHP.V1 using scAAV genomes is unclear, but shifts in vector tropism when 
packaging scAAV genomes have been reported for another capsid160. 
Given the difference in tropism between AAV-PHP.V1 and AAV-PHP.B or AAV-
PHP.eB, we characterized several additional variants within the PHP.B-like family. One 
variant, AAV-PHP.V2, harboring the TTLKPFL 7-mer sequence and differing by only one 
amino acid from AAV-PHP.V1, has a similar tropism (Supplementary Figure 3.S5). 
AAV-PHP.V2 capsid 
AAV-PHP.V2 was found at high abundance in R1 selection across all brain libraries 
and was highly enriched in R2 (Figure 3.1d, 3.2g (right panel), 3.3a,b, Supplementary 
Figure 3.S1e). Given its sequence similarity, we predicted similar tropism to that of AAV-
PHP.V1. We validated this in vivo in C57BL/6J adult mice (ssAAV-PHP.V2:CAG-
mNeongreen genome, 3x1011 vg dose per adult mice, n = 3, Supplementary Figure 3.5a), 
in Tek-Cre mice (ssAAV-PHP.V2:CAG-DIO-EYFP genome, 1 × 1012 vg dose per adult 
mouse, n = 2, Supplementary Figure 3.S5b), and in GFAP-Cre mice (ssAAV-
PHP.V2:CAG-DIO-EYFP, 1 × 1012 vg dose per adult mouse, n = 2, Supplementary Figure 
3.S5c). 
Three other variants with sequences of roughly equal deviation from both 
AAV.PHP.V1 and AAV.PHP.B, AAV-PHP.B4 with TLQIPFK, AAV-PHP.B7 with 
SIERPFK and AAV-PHP.B8 with TMQKPFI (Figures 3.3a,b and 3.4a,b) have PHP.B-
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like tropism with biased transduction toward neurons and astrocytes (Figure 3.4b and 
Supplementary Figure 3.S6a–c). Similar variants among the spike-in library, AAV-
PHP.B5 with TLQLPFK and AAV-PHP.B6 with TLQQPFK, also shared this tropism 
(Figures 3.3b and 3.4a,b, Supplementary Figure 3.S6a). 
To evaluate the performance of the spike-in library, we chose two highly enriched 
variants similarly placed in sequence space: AAV-PHP.B6 – TLQLPFK and AAV-PHP.B7 
– TLQQPFK (Supplementary Figure 3.S2d (middle panel), 3.S3d) that were previously 
identified in the 3-mer-s PHP.B library133 but never validated in vivo. At a modest dose of 
1x1011 vg in C57BL/6J adult mice, these variants also display PHP.B-like tropism (Figure 
3.4a,b, Supplementary Figure 3.S6a). 
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Figure 3.4: Characterization of round-2 brain libraries and identification of capsids with 
broad CNS tropism. 
 
(a), Transduction by AAV-PHP.B4-B6 and C1 variants, as well as B, eB and AAV9 
controls in sagittal brain and liver sections (each column was imaged under the same 
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settings). White box, thalamus (this is not the precise region of the figures to the right). 
Vectors are packaged with ssAAV:CAG-2xNLS-EGFP genome (n = 3 per group, 
1 × 1011 vg i.v. dose per adult C57BL/6J mouse, 3 weeks of expression). Tissues are stained 
with cell-type specific markers (magenta): αNeuN for neurons, αS100 for astrocytes and 
αOlig2 for oligodendrocyte lineage cells. Liver tissues are stained with DAPI (blue). (b), 
The percentage of αNeuN+, αS100+ and αOlig2+ cells with detectable nuclear-localized 
EGFP in the indicated brain regions are shown (n = 3 per group, 1 × 1011 vg dose). A two-
way ANOVA with correction for multiple comparisons using Tukey’s test is reported with 
adjusted P values (****P ≤ 0.0001, ***P ≤ 0.001, **P ≤ 0.01, *P ≤ 0.05, is shown, 
and P > 0.05 is not shown on the plot; 95% confidence interval (CI), data are mean ± s.e.m. 
The dataset comprises a mean of two images per region per cell-type marker per mouse). 
 
We next investigated a series of variants selected to verify M-CREATE’s predictive 
power outside this family. A highly enriched variant with an unrelated sequence, AAV-
PHP.C1 harboring RYQGDSV (Figures 3.3a,b and 3.4a,b), transduced astrocytes at a 
similar efficiency and neurons at lower efficiency compared to other tested variants from 
the B family (Figure 3.4b). Two variants found in high abundance in the R2 synthetic pool 
virus library and underrepresented in brain (with both codon replicates in agreement), 
AAV-PHP.X1 with ARQMDLS and AAV-PHP.X2 with TNKVGNI (Supplementary 
Figure 3.S2b, right), poorly transduced the CNS (Supplementary Figure 3.S6b). Two 
variants that we found in higher abundance in brain libraries from the PCR pool R2, AAV-
PHP.X3 with QNVTKGV and AAV-PHP.X4 with LNAIKNI also failed to outperform 
AAV9 in the brain (Supplementary Figure 3.S6d). 
Collectively, our characterization of these AAV variants suggests several key points. 
First, within a diverse sequence family, there is room for both functional redundancy and 
the emergence of alternative tropisms. Second, highly enriched sequences outside the 
dominant family are also likely to possess enhanced function. Third, buoyed by codon 
replicate agreement in the synthetic pool, a variant’s enrichment across tissues may be 
predictive. Fourth, while the synthetic pool R2 library contains a subset of the sequences 
that are in the PCR pool R2 and may thereby lack some enhanced variants, those variants 
found exclusively within the PCR pool library are more likely to be false positives. 
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The ability to confidently predict in vivo transduction from a pool of 18,000 
nucleotide variants in R2 across multiple mice and Cre-lines is a substantial advance in the 
selection process and demonstrates the power of M-CREATE for the evolution of 
individual vectors. 
An AAV9 variant that specifically transduces neurons 
Using NGS, we re-investigated a 3-mer-s (s for substitution) PHP.B library generated 
by the prior CREATE methodology and that yielded AAV-PHP.eB133 (Figure 3.5a). 
Briefly, the re-investigated 3-mer-s PHP.B library diversified positions 587-597 of the 
AAV-PHP.B capsid (equivalent of 587-590 AA on AAV9) in portions of three consecutive 
AAs, (~40,000 total variants) (Figure 3.4a). Selections were performed in three Cre-
transgenic lines: Vglut2-IRES-Cre for glutamatergic neurons, Vgat-IRES-Cre for 
GABAergic neurons, and GFAP-Cre for astrocytes. 
We deep sequenced the libraries recovered from brain (using Cre-dependent PCR) 
and a R2 library from the livers of wild-type mice (processed via PCR for all capsid 
sequences regardless of Cre-mediated inversion) and identified 150–200 capsids enriched 
in brain tissue (Figure 3.5b and Supplementary Figure 3.S7a,b). 
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Figure 3.5: Recovery of AAV-PHP.B variants including one with high specificity for 
neurons. 
 
(a), Design of the 3-mer-s PHP.B library with combinations of three AA diversification 
between AA 587–597 of AAV-PHP.B (corresponding to AA 587–590 of AAV9). Shared 
amion acid identity with the parent AAV-PHP.B (green) is shown along with unique motifs 
for AAV-PHP.N (pink) and AAV-PHP.eB (blue). (b), Distributions of R2 brain and liver 
libraries (at the amino acid level) by enrichment score (normalized to R2 virus library, with 
variants sorted in decreasing order of enrichment score). The enrichment of AAV-PHP.eB 
and AAV-PHP.N across all libraries is mapped on the plot. (c), Heat map represents the 
magnitude (log2(fold change)) of a given amino acid’s relative enrichment or depletion at 
each position across the diversified region, only if statistical significance is reached on fold 
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change (boxed if P ≤ 0.0001, two-sided, two-proportion z-test, P corrected for multiple 
comparisons using Bonferroni correction). Plot includes variants that were highly enriched 
in brain (>0.5 mean enrichment score, where mean is drawn across Vglut2, Vgat and 
GFAP, n = 1 library per mouse line (sample pooled from 2 mice per line)) and 
underrepresented in liver (<0.0) (32 amino acid sequences). (d), Clustering analysis of 
enriched variants from Vgat brain library is shown. Node size represents the degree of 
depletion in liver. Thickness of edges (connecting lines) represents degree of relatedness 
between nodes. Two distinct families are highlighted in yellow and their corresponding 
amino acid frequency logos are shown below (amino acid size represents prevalence, and 
color encodes amino acid properties). (e), The percentage of neurons, astrocytes and 
oligodendrocyte lineage cells with ssAAV-PHP.N:CAG-2xNLS-EGFP in the indicated 
brain regions is shown (n = 3, 1 × 1011 vg i.v. dose per adult C57BL/6J mouse, 3 weeks of 
expression, data is mean ± s.e.m., 6–8 images for cortex, thalamus and striatum, and 2 
images for ventral midbrain, per mouse per cell-type marker using ×20 objective covering 
the entire regions). A two-way ANOVA with correction for multiple comparisons using 
Tukey’s test gave adjusted P values reported as ****P ≤ 0.0001, n.s. for P > 0.05, 95% 
CI. (f), Transduction by ssAAV-PHP.N:CAG-NLS-EGFP (n = 2, 2 × 1011 vg i.v. dose per 
adult C57BL/6J mouse, 3 weeks of expression) is shown with NeuN staining (magenta) 
across three brain areas (cortex, SNc (substantia nigra pars compacta) and thalamus). 
 
Variants that were enriched in brain and underrepresented in liver show a significant 
bias towards certain amino acids such as G, D and E at position 1; G and S at position 2 
(which includes the AAV-PHP.eB motif, DG); and S, N and P at position 9, 10 and 11 
(Figure 3.5c and Supplementary Figure 3.S7c; P ≤ 0.0001, two-sided, two-proportion z-
test, P values were corrected for multiple comparisons using Bonferroni correction). We 
clustered variants that were enriched in the brain according to their sequence similarities 
and ranked them by their underrepresentation in liver (represented by node size in clusters). 
A distinct family referred to as N emerged with the common motif SNP at positions 9–11 
in the PHP.B backbone (Figure 3.5d and Supplementary Figure 3.S7d). 
The core variant of the N-family cluster, with the AQTLAVPFSNP motif, was highly 
abundant in R1 and R2 selections, had higher enrichment score in Vglut2 and Vgat brain 
tissues compared to GFAP, and was underrepresented in liver tissue (Figure 3.5b and 
Supplementary Figure 3.S7a–d). Unlike AAV-PHP.eB, this variant (AAV-PHP.N) 
specifically transduced NeuN+ neurons even when packaged with a ubiquitous CAG 
promoter, although the transduction efficiency varied across brain regions (from ~10–70% 
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in NeuN+ neurons, including both VGLUT1+ excitatory and GAD1+ inhibitory 
neurons; Figure 3.5e,f and Supplementary Figure 3.S7e,f). 
Thus, by re-examining the 3-mer-s library we identified several useful variants, 
including one with notable cell-type-specific tropism. While Vglut2-Cre and Vgat-Cre 
mice were used for in vivo selection, we didn’t find variants that stood out for neuronal 
subtype-specific transduction of excitatory and inhibitory populations from our initial 
investigations on the NGS dataset. It is possible that a biological solution to this (stringent) 
selection was not present in this library. 
Investigation of capsid families beyond the C57BL/6J mouse strain 
The enhanced CNS tropism of AAV-PHP.eB and AAV-PHP.B relative to AAV9 is 
absent in a subset of mouse strains. Their CNS transduction is highly efficient in C57BL/6J, 
FVB/NCrl, DBA/2 and SJL/J, with intermediate enhancement in 129S1/SvimJ, and no 
apparent enhancement over AAV9 in BALB/cJ and several additional strains134,164–168. This 
pattern holds for the two variants from the PHP.B family that we characterized further, 
AAV-PHP.V1 and AAV-PHP.N (Figure 3.6a and Table 3.T3). These variants did not 
transduce the CNS in BALB/cJ, yet transduced the FVB/NJ strain (Figure 3.6b). AAV-
PHP.V1 transduced human brain microvascular endothelial cell (HBMEC) culture, 
resulting in increased mean fluorescent intensity compared with that following AAV9 and 
AAV-PHP.eB transduction (Supplementary Figure 3.S8a) however, suggesting 
mechanistic complexity. 
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AAV Variants Reference / Selection 
method 
Tropism Production Rounds of evolution 
from parent capsid 
PHP.B, B2, B3 Deverman et al, 2016 / 
CREATE 
Broad CNS 
transduction 
Good 1 round from AAV9 
PHP.A Deverman et al, 2016 / 
CREATE 
Astrocyte transduction Poor; prone to 
precipitate upon 
storage at 4oC. 
1 round from AAV9 
PHP.eB Chan et al, 2017 / CREATE Enhanced Broad CNS 
transduction 
Good 2 rounds from AAV9 
or  
1 round from PHP.B 
PHP.S Chan et al, 2017 / CREATE Sensory neuron 
transduction 
Good 1 round from AAV9 
PHP.V1, V2 Current study / M-CREATE BBB Vascular cells and 
astrocytes transduction 
Good 1 round from AAV9 
PHP.B4, B7, 
B8,  
Current study / M-CREATE Broad CNS 
transduction 
Good 1 round from AAV9 
PHP.B5, B6 Current study / M-CREATE 
and CREATE 
Broad CNS 
transduction 
Good 2 rounds from AAV9 
or 
1 round from PHP.B 
PHP.C1, C2, C3 Current study / M-CREATE Broad CNS 
transduction across 
mouse strains 
Good; PHP.C1 prone 
to precipitate upon 
storage at 4oC. 
1 round from AAV9 
PHP.N Current study / M-CREATE 
and CREATE 
Neuron transduction Average 2 rounds from AAV9 
or 
1 round from PHP.B 
 
*PHP variants – named in memory of late Professor Paul H. Patterson, Caltech. 
 
Table 3.T3: AAV-PHP vectors identified by CREATE and M-CREATE. 
 
The table provides a summary of the variants that have been identified so far using 
CREATE and M-CREATE, along with their tropism and the evolutionary steps from the 
parent capsid that was involved in their discovery. 
 
 
 
120 
 
Figure 3.6: Tropism of variants from distinct families across mouse strains. 
 
(a), Clustering analysis showing the brain-enriched sequence families of variants identified 
in prior studies (PHP.B-B3, PHP.eB) or in the current study (PHP.B4-B8, PHP.V1-2, 
PHP.C1-3). Thickness of edges (connecting lines) represents degree of relatedness between 
nodes. The amino acid sequences inserted between 588–589 (of AAV9 capsid) for all the 
variants discussed are shown below. (b), Transduction of AAV9, AAV-PHP.V1 and AAV-
PHP.N across the mouse strains C57BL/6J, BALB/cJ and FVB/NJ are shown in sagittal 
brain sections (right), along with a higher-magnification image of the thalamus brain region 
(left). (c), Transduction by AAV-PHP.B, AAV-PHP.C1-C3 in C57BL/6J and BALB/cJ 
mice are shown in sagittal brain sections (right), along with a higher-magnification image 
of the thalamus brain region (left). (b,c), White box, thalamus (this is not the precise area 
that is zoomed-in on the figure to the left). All sagittal sections and thalamus regions were 
acquired under same image settings. The insets in AAV-PHP.V1 are zoom-ins with 
enhanced brightness. The indicated capsids were used to package ssAAV:CAG-
mNeongreen (n = 2–3 per group, 1 × 1011 vg i.v. dose per 6- to 8-week-old adult mouse, 3 
weeks of expression. The data reported in (b) and (c) are from one experiment where all 
viruses were freshly prepared and titered in the same assay for dosage consistency. AAV-
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PHP.C2 and AAV-PHP.C3 were further validated in an independent experiment for 
BALB/cJ, n = 2 per group). 
 
Notably, M-CREATE revealed many non-PHP.B-like sequence families that 
enriched through selection for transduction of cells in the CNS. We tested the previously 
mentioned AAV-PHP.C1 (RYQGDSV), as well as AAV-PHP.C2 (WSTNAGY), and 
AAV-PHP.C3 (ERVGFAQ) (Figure 3.6a). These showed enhanced BBB crossing 
irrespective of mouse strain, with roughly equal CNS transduction in BALB/cJ and 
C57BL/6J (Figure 3.6c and Supplementary Figure 3.S8b). Collectively, these studies 
suggest that M-CREATE is capable of finding capsid variants with diverse mechanisms of 
BBB entry that do not exhibit strain specificity. 
3.4 DISCUSSION 
This work outlines the development and validation of the M-CREATE platform for 
multiplexed viral capsid selection. M-CREATE incorporates multiple internal controls to 
monitor sequence progression, minimize bias and accelerate the discovery of capsid 
variants with useful tropisms. Utilizing M-CREATE, we have identified both individual 
capsids and distinct families of capsids that are biased toward different cell-types of the 
adult brain when delivered intravenously. The outcome from 7-mer-i selection 
demonstrates the possibility of finding AAV capsids with improved efficiency and 
specificity towards one or more cell types. Patterns of CNS infectivity across mouse strains 
suggest that M-CREATE may also identify capsids with distinct mechanisms of BBB 
crossing. With additional rounds of evolution as shown in the 3-mer-s selection, the 
specificity or efficiency of 7-mer-i library variants may be improved, as was observed with 
AAV-PHP.N or AAV-PHP.eB133. 
We believe that the variants tested in vivo and their families will find broad 
application in neuroscience, including studies involving the BBB247, neural circuits248, 
neuropathologies249, and therapeutics99. AAV-PHP.V1 or AAV-PHP.N are well-suited for 
studies requiring gene delivery for optogenetic or chemogenetic manipulations86, or in rare 
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monogenic disorders (targeting brain endothelial cells, for example GLUT1-deficiency 
syndrome, NLS1-microcephaly249, or targeting neurons, for example 
mucopolysaccharidosis type IIIC244). 
The outcomes from our experiments employing M-CREATE opens several 
promising lines of inquiry, such as the assessment of identified capsid families across 
species, the investigation of the mechanistic properties that underlie the ability to cross 
specific barriers (such as the BBB) or target specific cell populations and further evolution 
of the identified variants for improved efficiency and specificity. In addition, the datasets 
generated by M-CREATE could be used as training sets for in silico selection by machine-
learning models. M-CREATE is presently limited by the low throughput of vector 
characterization in vivo; however, RNA-sequencing technologies250 offer hope in this 
regard. In summary, M-CREATE will serve as a next-generation capsid-selection platform 
that can open directions in vector engineering and potentially broaden the AAV toolbox 
for various applications in science and in therapeutics. 
3.5 METHODS 
Plasmids 
Library generation 
The rAAV-ΔCap-in-cis-Lox2 plasmid (Supplementary Figure 3.S1a, plasmid 
available upon request at Caltech CLOVER Center) is a modification of the rAAV-ΔCap-
in-cis-Lox plasmid157. For 7-mer-i library fragment generation, we used the pCRII-9Cap-
XE plasmid157 as a template. The AAV2/9 REP-AAP-ΔCap plasmid (Supplementary 
Figure 3.S1a, plasmid available upon request at Caltech CLOVER Center) was modified 
from the AAV2/9 REP-AAP plasmid157. 
The rAAV-Cap-in-cis-Lox2 plasmid consists of three major elements that are 
flanked by AAV2 ITRs. 
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(i) UBC ubiquitous promoter driving the expression of fluorescent protein, 
mNeongreen, followed by a synthetic polyadenylation sequence. The mCherry expression 
cassette of the previous version of the plasmid was replaced by mNeonGreen cassette.  
(ii) A portion of AAV2 rep gene that has the splicing sequences and AAV5 p41 promoter 
(1680-1974 residues of GenBank AF085716.1) followed by AAV9 cap gene. The prior 
version of this plasmid, rAAV-ΔCap-in-cis-Lox, has a short 12 bp sequence between 
restriction sites XbaI and AgeI at AA 450 and 592 of the AAV9 Cap gene. This was 
replaced by a 723 bp sequence of mRuby2 gene in-frame (acts as filler DNA) in the newer 
version of the plasmid.  
(iii) SV40 polyadenylation sequence that is flanked by lox71 and lox66 sites. The minor 
changes were introduced to the prior version of the plasmid to facilitate ease of cloning and 
to visualize mammalian cell transfection. The Lox sites in these rAAV plasmids show 
modest levels of Cre-independent flipping. This was minimized during PCR-based capsid 
recovery by lowering the number of amplification cycles to a point where we cannot 
recover any rAAV capsids from the control DNA extracted from wild-type mice (i.e., 
lacking Cre expression) that were injected with the library. 
The pCRII-9Cap-XE plasmid contains the AAV9 capsid gene sequence from AAs 
450-592 and is flanked by XbaI and AgeI restriction sites. 
The AAV2/9 REP-AAP-Cap plasmid has the five previously existing stop codons 
of AAV2/9 REP-AAP in addition to the deletion of AAs 450-592 of the AAV9 capsid 
sequence. These modifications did not affect vector production. The deletion of the 
overlapping fragment between the REP-AAP and rAAV-Cap-in-cis-Lox2 plasmids 
minimizes recombination between plasmids that could potentially generate AAV9 wild-
type capsids during co-transfection in vector production. 
Capsid characterization 
AAV capsids 
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The AAV capsid variants with heptamer insertions or 11-mer substitutions were 
made between AA positions 587–597 of AAV-PHP.B capsid using the pUCmini-iCAP-
PHP.B backbone157 (Addgene ID: 103002). 
ssAAV genomes 
To characterize the AAV capsid variants, we used the single-stranded (ss) rAAV 
genomes. We used genomes such as pAAV:CAG-mNeonGreen133 
(Addgene ID: 99134104055), pAAV:CAG-NLS-EGFP157 (equivalent version with one 
NLS is on Addgene ID: 104061), pAAV:CAG-DIO-EYFP134 (Addgene ID: 104052), 
pAAV: GfABC1D-2xNLS-mTurquoise2134 (Addgene ID: 104053) and pAAV:-Ple261-
iCre129 (Addgene ID: 49113).  
pAAV:CAG-mNeonGreen133 genome consists of a ubiquitous CMV-β-Actin-intron-
β-Globin (CAG) hybrid promoter driving the expression of a fluorescent protein, 
mNeonGreen (equivalent plasmid, pAAV: CAG-eYFP251; Addgene ID: 104055). 
pAAV:CAG-NLS-EGFP157 consists of NLS sequences at the N- and C-termini of EGFP 
and is driven by the CAG promoter. An equivalent version with one NLS is on Addgene 
(ID 104061). pAAV:CAG-DIO-EYFP251 (Addgene ID: 104052) consists of a EYFP gene 
built in the reverse direction of the CAG promoter, and it is flanked by a pair of Cre-Lox 
sites (Lox P and Lox 2272) on either ends. In cells expressing Cre, the Cre-lox pair inverts 
EYFP enabling transcription and translation, followed by excision in the lox site to prevent 
re-inversion. pAAV: GfABC1D-2xNLS-mTurquoise2251, referred to elsewhere as 
pAAV:GFAP-2xNLS-mTurquoise2 ( Addgene ID: 104053), consists of NLS sequences at 
the N- and C-termini of mTurquoise2 and is driven by the astrocyte-specific promoter 
GfABC1D132. pAAV:Ple261-iCre129 (Addgene ID 49113) contains an endothelial-cell-
specific promoter driving the expression of iCre.  
We packaged pAAV:CAG-XFP (mNeongreen) for characterizing AAV variants. 
However, when performing quantification of cell-types neurons, astrocytes, and 
oligodendrocytes, we use CAG-NLS-EGFP to restrict the expression to nucleus for easier 
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quantification using microscope images. GFAP-NLS-mTurq2 is used to quantify 
astrocytes. CAG-DIO-EYFP is used for Cre driver lines, due to the presence of lox sites in 
this plasmid. 
scAAV genomes 
To characterize the AAV capsid variant, AAV-PHP.V1, using self-complementary 
(sc) rAAV genomes, we used scAAV genomes from different sources. scAAV:CB6-EGFP 
was a gift from G. Gao (University of Massachusetts Medical School) and scAAV:CAG-
EGFP252 from Addgene (Addgene ID: 83279). 
The self-complementary genome from Dr. Guangping Gao, scAAV:CB6-EGFP 
genome has a hybrid ubiquitous CB6 promoter (975 bp) comprising a CMV enhancer 
(cytomegalovirus immediate early enhancer), a chicken-β-actin promoter and hybrid 
intron, that drives the expression of EGFP. The genome has a rabbit globin poly A (127 
bp) following the EGFP gene. The scAAV:CAG-EGFP252 (Addgene ID:83279), vector 
uses a ubiquitous CMV-β-Actin-intron-β-Globin (CAG) hybrid promoter to drive the 
expression of EGFP. 
AAV capsid library generation 
Round-1 AAV capsid DNA library 
Mutagenesis strategy 
The randomized (21-base) heptamer insertion was designed using the NNK 
saturation mutagenesis strategy, involving degenerate primers containing mixed bases 
(Integrated DNA Technologies). N can be an A, C, G or T base, and K can be G or T. Using 
this strategy, we obtained combinations of all 20 amino acids at each position of the 
heptamer peptide using 33 codons, resulting in a theoretical library size of 1.28 billion at 
the level of amino acid combinations. The mutagenesis strategy for the 3-mer-s PHP.B 
library is described in our prior work133. 
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Library cloning 
The 480-bp AAV capsid fragment (450–592 amino acids) with 
the randomized heptamer insertion between amino acids 588 and 589 was generated by 
conventional PCR methods using the pCRII-9Cap-XE157 template by Q5 Hot Start High-
Fidelity 2X Master Mix (NEB; M0494S) with forward primer, XF, and reverse primer, 
7xMNN-588i (Table 3.T4). 
To avoid PCR-induced biases resulting from point mutations, recombination, and 
template switching, PCR amplification of the library was limited to 15 – 20 cycles and the 
reactions were scaled up to get the required yield. The resulting PCR products were run on 
a 1% agarose gel and extracted with a Zymoclean Gel DNA Recovery kit (Zymo Research; 
D4007). It is critical to avoid AAV contamination during this step by taking precautionary 
measures like using a clean gel-running box and freshly prepared 1× TAE buffer. 
The rAAV-ΔCap-in-cis-Lox2 plasmid (6,960 bp) was linearized with the restriction 
enzymes AgeI and XbaI, and the amplified library fragment was assembled into the 
linearized vector at 1:2 molar ratio using the NEBuilder HiFi DNA Assembly Master Mix 
(NEB; E2621S) by following the NEB recommended protocol. 
Primer name Sequence (5’-3’) Forward or 
reverse 
direction  
XF ACTCATCGACCAATACTTGTACTATCTCTCTAGAAC Forward 
7xMNN-588i GTATTCCTTGGTTTTGAACCCAACCGGTCTGCGCCTGTGCMNNMNNMNNMNNMNNM
NNMNNTTGGGCACTCTGGTGGTTTGTG 
Reverse 
588-R2lib-F  CACTCATCGACCAATACTTGTACTATCTCTCT Forward 
588-R2lib-R GTATTCCTTGGTTTTGAACCCAACCG Reverse 
11-mer-588i GTATTCCTTGGTTTTGAACCCAACCGGTCTGCGCXXXXXXMNNMNNMNNMNNMNNM
NNMNNXXXXXXACTCTGGTGGTTTGTG 
Reverse 
71F  CTTCCAGTTCAGCTACGAGTTTGAGAAC  Forward 
CDF/R  CAAGTAAAACCTCTACAAATGTGGTAAAATCG  Forward/Revers
e, see Methods 
588i-lib-PCR1-6bpUID-
F  
CACGACGCTCTTCCGATCTAANNNNNNAGTCCTATGGACAAGTGGCCACA  Forward 
588i-lib-PCR1-R GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTTCCTTGGTTTTGAACCCAACCG  Reverse 
1527  ACACTCTTTCCCTACACGACGCTCTTCCGATCTGACAAGTGGCCACAAACCACCAG  Forward 
1532 GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTCCTTGGTTTTGAACCCAACCG  Reverse 
mNeonGreen-F  CGACACATGAGTTACACATCTTTGGCTC  Forward 
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Table 3.T4: Primers used in M-CREATE selection. 
 
The table provides a list of primers used in M-CREATE across the different steps of the 
selection process as described in the Methods. 
 
Library purification 
 
The assembled library was then subjected to Plasmid Safe (PS) DNase I (Epicentre; 
E3105K) treatment, or alternatively, Exonuclease V (RecBCD) (NEB; M0345S) following 
the recommended protocols, to purify the assembled product by degrading the un-
assembled DNA fragments from the mixture. The resulting mixture was purified with a 
PCR purification kit (DNA Clean and Concentrator kit, Zymo Research; D4013). 
Library yield 
With an assembly efficiency of 15–20% post-PS treatment, we obtained a yield of 
about 15–20 ng per 100 ng of input DNA per 20 µL of assembly reaction. 
Quality control 
The following four steps were carried out to ensure successful capsid library generation. 
1. To validate successful assembly of the library, 1 ng of the final assembled library was 
transformed into E. coli SURE 2 Supercompetent Cells (Integrated Sciences; 200152). We 
checked for colonies on an LB/Agar plate containing carbenicillin antibiotic after overnight 
incubation at 37°C.  
mNeonGreen-R  GGAGGTCACCCTTGGTGGACTTC  Reverse 
Mito-F  CCCAGCTACTACCATCATTCAAGT  Forward 
Mito-R  GATGGTTTGGGAGATTGGTTGATGT  Reverse 
CapF-56 ATTGGCACCAGATACCTG ACTCGTAA Forward 
Cre-R-57 GTCCAAACTCATCAATGTATCTTATCATGTCTG Reverse 
NGS-QC-F AATGATACGGCGACCACCGAG Forward 
NGS-QC-R CAAGCAGAAGACGGCATACGA Reverse 
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2. The DNA library was sequenced around the insertion site (Laragen; Sanger 
Sequencing). A non-biased library may match the diversity of the NNK/MNN motif (where 
N = 25% each of A, T, G, C; K = 50% each of G, T; M = 50% each of A, C) with some 
fluctuations across the diversified region.  
3. To verify that the ITRs were intact, SmaI digestion was carried out as per the NEB 
recommended protocol (NEB; R0141S).  
4. To validate successful transfection and assess the vector-production yield per 150 mm 
dish, 10 ng of 7-mer-i library was used to transfect 293T producer cells (293T; ATCC CRL 
3216). Uniform expression of mNeonGreen protein across HEK cells was observed, and 
an average yield of 0.1 – 1x1011 vg was obtained per 150 mm dish. Using the average yield 
per dish, we scaled up the vector production for in vivo selection (see Supplementary 
Figure 3.S2a). 
Round-2 AAV capsid DNA library 
PCR pool design 
To maintain proportionate pooling, we mathematically determined the fraction of 
each sample or library that needs to be pooled based on an individual library’s diversity. 
This process involved estimation of the diversity precluding noise and consideration 
of amplification of this diversity across samples by determining the area under the curve 
for the interval of high-confidence variants that falls in the higher RC range. We estimated 
the area under the curve (AUC) using the composite Simpson’s rule by plotting all the 
recovered variants in a library (X-coordinate) to their read counts (RCs or copy number 
from deep sequencing data, Y-coordinate) (see Supplementary Figure 3.S1e). To 
determine the definite intervals for AUC, we sorted the data based on the decreasing order 
of the RCs. Noticeably, the distribution has two phases, with a steadier slope of variants in 
the higher RC range, followed by a steep drop in the slope of the curve (~50-1000 fold 
lower RCs). By observation, this steeper side of the curve is predominant in sequencing 
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errors/ PCR mutations, hence we precluded this error dominant slope otherwise called 
noise from our AUC estimation. When comparing composite Simpson’s rule with another 
function, such as composite trapezoidal rule, the difference was miniscule.  
This area is then used to determine the fraction of an individual library that needs to 
be pooled into PCR pool library using the formula: [Area under the curve/ total number of 
libraries pooled]. 
The pooled sample was used as a template for further amplification with 12 cycles 
of 98 °C for 10 s, 60 °C for 20 s and 72 °C for 30 s by Q5 polymerase, using the primers 
588-R2lib-F and 588-R2lib-R (Table 3.T4). Similar to R1 library generation, the PCR 
product was assembled into the rAAV-ΔCap-in-cis-Lox2 plasmid and the virus was 
produced.  
The R1 libraries used to build R2 were the Cre-Lox flipped rAAV DNA from half of 
the mouse brains (~0.3 g) and portion of spinal cords (0.1-0.2g) from all Cre lines. The 
amount of tissue processed here was sufficient for complete capsid library recovery. The 
differentially pooled and amplified libraries (by PCR pool or synthetic pool) were 
assembled using Gibson assembly with a follow-up PS or Exonuclease V treatment (as 
described in R1 library generation). We validated successful library generation by 
transformation, Sanger sequencing, and an ITR SmaI digest.  
For vector production, about 10 ng of the purified and assembled library was used to 
transfect each 150 mm dish of 293T cells, and we obtained a yield of about 6×1011 vg per 
150 mm dish (i.e., the R2 yield was six times that of R1, unsurprisingly given these 
sequences have already produced well enough to survive R1 selection). 
Synthetic pool design 
As described in the PCR pool strategy, we chose high-confidence variants whose 
RCs were above the error-dominant noise slope from the plot of library distribution 
(Supplementary Figure 3.S1e). This came to about 9,000 sequences from all brain and 
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spinal-cord samples of all Cre lines. We used similar primer design as mentioned in the 
description of the R1 library generation. Primers XF and 11-mer-588i (Table 3.T4) were 
used. In 11-mer-588i primer, 
‘XXXXXXMNNMNNMNNMNNMNNMNNMNNXXXXXX' was replaced with unique 
nucleotide sequence of a heptamer tissue recovered variant (7xMNN) along with 
modification of two adjacent codons flanking on either end of the heptamer insertion site 
(6xX), which are residues 587–588 ‘AQ' and residues 589–590 ‘AQ' on AAV9 capsid. 
Since the spike-in library has 11-mer or 33-base oligonucleotide mutated variants, we used 
the same primer design where 
‘XXXXXXMNNMNNMNNMNNMNNMNNMNNXXXXXX' was replaced with a 
specific nucleotide sequence of a 33-base oligonucleotide variant. A duplicate of each 
sequence in this library was designed with different codons optimized for mammals. The 
primers were designed using a custom-built Python based script. The custom-designed 
oligopool was synthesized in an equimolar ratio by Twist Biosciences. The oligopool was 
used to minimally amplify the pCRII-XE Cap9 template over 13 cycles of 98 °C for 10 s, 
60 °C for 20 s and 72 °C for 30 s. To obtain a higher yield for large-scale library 
preparation, the product of the first PCR was used as a template for the second PCR using 
the primers XF and 588-R2lib-R (described above) and minimally amplified for 13 cycles. 
Following PCR, we assembled the R2 synthetic pool DNA library and produced the virus 
as described in R2 PCR pool design.  
AAV virus library production, purification and genome extraction 
To prevent capsid mosaic formation of the 7-mer-i library in 293 T producer cells, 
we transfected only 10 ng of assembled library per 150-mm dish along with other required 
reagents for AAV vector production.  
In addition to the 10 ng of library transfection per 150 mm dish of 293T producer 
cells, we transfected three plasmids: AAV2/9 REP-AAP-Cap, pUC18 and pHelper (genes 
encoding adenoviral proteins for AAV replication) at a ratio of 1:1:2. The plasmid pUC18 
acts as a filler DNA to compensate for the low amount of library DNA in order to maintain 
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the N:P ratio required for optimal transfection using polyethylenimine (PEI, 
Polysciences; 24765-1) transfection). The cells and culture media were harvested at 60 h 
post-transfection to collect the viral particles. rAAV harvest and purification were 
performed as per the protocol251. The small amount of library DNA per plate and early cell 
harvest time are critical for reducing the possibility of mosaic capsid assemblies during 
vector production (similar considerations seen in prior reports149,253,254). 
For 7-mer-i library, the production was scaled up to 60 dishes (~1.8x107 cells/dish) 
and with ~10% transfected with the library, resulted in ~1x108 total transformants. For an 
NNK 7-mer library with ~1x108 total transformants, the number of unique variants is 
9.99x107 (See Bosley & Ostermeier (2005)255, section 2.1.2 for mathematics). 
For the rAAV DNA extraction from purified rAAV viral library, ~10% of the 
purified viral library was used to extract the viral genome by proteinase K treatment. 
In order to degrade any contaminating DNA from the purified library, it was treated 
with DNase I enzyme (5 µl of 10 U/µl) (Sigma-Aldrich; 4716728001) in 100 µl of DNase 
I buffer and incubated for 1 h at 37°C. The enzyme was inactivated by adding 5 µl of 0.5 
M EDTA at 70°C for 10 min. Following DNase I treatment, the capsid protein shell was 
digested by adding 120 µl of proteinase solution containing 5 µl of 20 µg/µl of proteinase 
K and incubated at 50°C overnight. To inactivate the proteinase K, the mixture was boiled 
at 95°C. The extracted rAAV library DNA was then concentrated and purified using phenol 
chloroform and ethanol. An equal volume of Phenol:Chloroform:Isoamyl Alcohol 25:24:1, 
pH 8.0 (~250 µl; ThermoFisher Scientific; 15593031) was added and vortexed for 30 s. 
The mixture is incubated for 5 min at room temperature (RT) before centrifugation at 
15,000 rpm for 10 min at 4°C. The upper aqueous phase was separated and mixed with an 
equal volume of chloroform and vortexed for 30 s. Following 5 min incubation at RT, 
centrifuge at 15,000 rpm for 10 min at 4°C. The upper aqueous phase was separated and 
one-tenth volume of 3M sodium acetate (pH 5.2) along with 2 µl Co-Precipitant Pink 
(Bioline; BIO-37075) and 2.5 volumes of ice cold 100% ethanol was added before 
vortexing for 30 s. The mixture was incubated for at least 1 hr at -20°C before 
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centrifugation at 15,000 rpm for 15 min at 4°C. The pellet was air dried and resuspended 
in TE buffer. The DNA concentration was determined using the Qubit ssDNA assay. 
Animals 
All animal procedures performed in this study were approved by the California 
Institute of Technology Institutional Animal Care and Use Committee (IACUC), and we 
have complied with all relevant ethical regulations. The C57BL/6J (000664), Tek-Cre246 
(8863), SNAP25-Cre256 (23525), GFAP-Cre257 (012886), Syn1-Cre258 (3966), and Ai14259 
(007908) mouse lines used in this study were purchased from the Jackson Laboratory 
(JAX). The i.v. injection of rAAVs was into the retro-orbital sinus of 6- to 8-week-old male 
or female mice. For testing the transduction phenotypes of novel rAAVs, 6- to 8-week-old, 
male C57BL/6J or Tek-Cre or Ai14 mice were randomly assigned. The experimenter was 
not blinded for any of the experiments performed in this study. 
In vivo selection 
The 7-mer-i viral library selections were carried out in different lines of Cre 
transgenic adult mice: Tek-Cre, SNAP25-Cre and GFAP-Cre for the R1 selections, and 
those three plus Syn1-Cre for the R2 selections. Male and female mice, 6- to 8-weeks-old, 
were i.v. administered with a viral vector dose of 2 × 1011 vg per mouse for the R1 
selection, and a dose of 1 × 1012 vg per mouse for the R2 selection. The dose was 
determined on the basis of the virus yield, which was different across selection rounds 
(Supplementary Figure 3.S2a). Both genders were used to recover capsid variants with 
minimal gender bias. Two weeks’ post-injection, mice were euthanized and all organs 
including brain were collected, snap frozen on dry ice, and stored at −80 °C. 
rAAV genome extraction from tissue 
Optimization 
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For rAAV genome extraction from tissues, we used both the Trizol method (Life 
Technologies; 15596) and the QIAprep Spin Miniprep kit (Qiagen, Inc; 27104) according 
to the manufacturers’ recommended protocols, and found the Trizol method to be more 
efficient (see Supplementary Figure 3.S1f,g,i). The total rAAV genome recovery from 0.1 
g of mouse liver was quantified by quantitative PCR using the primers mNeonGreen-F and 
mNeonGreen-R, which binds to the mNeonGreen gene of the ssAAV-Cap-in-cis-Lox2 
genome (see Table 3.T4). As an internal control, we also quantified the amount of 
mitochondrial DNA (a surrogate for the recovery of circular, episomal genomes) using 
primers Mito-F and Mito-R (see Table 3.T4). Although the percentage of viral DNA per 1 
ng total extracted DNA was about 1.5 fold higher with the QIAprep kit than with the Trizol 
method, the overall recovery was lower with the QIAprep kit. 
The extracted viral genome was digested with a restriction enzyme, such as SmaI 
(found within the ITRs), as it appeared to help improve rAAV genome recovery by PCR 
with ~4 fold change (see Supplementary Fig. 1h, ΔCT ~ 2, 1 CT = 2-fold difference in 
DNA copies, fold change = (2ΔCT) = 4). This was analyzed by quantitative PCR with Cre− 
primers, CapF-56 and Cre-R-57 (see Table 3.T4). 
rAAV genome extraction with the Trizol method 
Half of a frozen brain hemisphere (0.3 g approx.) was homogenized with a 2 mL 
glass homogenizer (Sigma Aldrich; D8938) or a motorized plastic pestle (Fisher Scientific; 
12–141–361, 12–141–363) (for smaller tissues) or beads using BeadBug homogenizers 
(1.5–3.0 mm zirconium or steel beads per manufacturer recommendations) 
(Homogenizers, Benchmark Scientific, D1032-15, D1032-30, D1033-28) and processed 
using Trizol as described in our prior work157. The extracted DNA by Trizol method was 
then treated with 3–6 µL of 10 µg µL–1 RNase Cocktail Enzyme Mix (ThermoFisher 
Scientific; AM2286) to remove RNA. The mixture was also digested with SmaI restriction 
enzyme to improve rAAV genome recovery by PCR (Supplementary Figure 3.S1h). The 
treated mixture was then finally purified with a Zymo DNA Clean and Concentrator kit 
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(D4033). From deep-sequencing data analysis, we observed that the amount of tissue 
processed was sufficient for rAAV genome recovery. 
rAAV genome recovery by Cre-dependent PCR 
rAAV genomes with Lox sites flipped by Cre recombination were selectively 
recovered and amplified using PCR with primers that yield a PCR product only if the Lox 
sites are flipped (Supplementary Figure 3.S1b). We used the primers 71F and CDF/R and 
amplified the Cre-recombined genomes over 25 cycles of 98 °C for 10 s, 58 °C for 30 s and 
72 °C for 1 min, using Q5 DNA polymerase (Table 3.T4). 
Total rAAV genome recovery by PCR (Cre-independent) 
To recover all rAAV genomes from a tissue, we used the primers XF and 588-R2lib-
R to amplify the genomes over 25 cycles of 98 °C for 10 s, 60 °C for 30 s and 72 °C for 
30 min, using Q5 DNA polymerase (Table 3.T4). 
Sample preparation for NGS 
We processed the DNA library, the virus library and the tissue libraries following in 
vivo selection to add flow cell adaptors around the diversified heptamer insertion region 
(Supplementary Figure 3.S1b). 
Preparation of rAAV DNA and viral DNA library 
The Gibson-assembled rAAV DNA library and the DNA extracted from the viral 
library were amplified by Q5 DNA polymerase using the primers 588i-lib-PCR1-6bpUID-
F and 588i-lib-PCR1-R that are positioned around 50 bases from the randomized heptamer 
insertion on the capsid, and that contain the Read1 and Read2 flow cell sequences on the 
5′ end (Table 3.T4). The primer, 588i-lib-PCR1-6bpUID-F: 5’ 
CACGACGCTCTTCCGATCTAANNNNNNAGTCCTATGGACAAGTGGCCACA-3’ 
used to minimally amplify DNA and virus libraries for NGS has 6 nucleotides long UID 
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(unique identifier) “NNNNNN” that sits after 19 nucleotides of Read-1 sequence used 
in NGS “5’-CACGACGCTCTTCCGATCT” and linker “AA”. The sequence after UID 
“AGTCCTATGGACAAGTGGCCACA” is the region that anneals to the AAV9 capsid. 
UID is an optional feature for NGS data analysis to identify potential PCR amplification 
errors. However, this feature wasn’t utilized in the NGS data analysis in this study to 
maintain consistency with the primers used in rAAV genome recovery from tissues which 
lacks this UID feature (primers 71F and CDF/R, See Table 3.T4). The UID or any kind of 
overhangs seemed to affect the PCR based recovery from tissue. Presumably, the primer 
thermostability have a key role to play in very low amount of extracted rAAV genomes 
from tissues. 
Using 5–10 ng of template DNA in a 50 µL reaction, the DNA was minimally 
amplified for 4 cycles of 98 °C for 10 s, 60 °C for 30 s and 72 °C for 10 s. The mixture was 
then purified with a PCR purification kit. The eluted DNA was then used as a template in 
a second PCR to add the unique indices (single or dual) via the recommended primers 
(NEB; E7335S, E7500S, E7600S) in a 12-cycle reaction using the same temperature cycle 
as described above. The samples were then sent for deep sequencing following additional 
processing and validation. 
The PCR products post indices addition were run on a freshly prepared 2% low-
melting-point agarose gel (ThermoFisher Scientific; 16520050) for better separation and 
recovery of the approx. 120 bp DNA band on the gel. Before sending the sample for NGS, 
the nucleotide diversity at the randomized 7-mer position was verified by Sanger 
sequencing. If needed, an optional PCR was carried out to send sufficient sample for 
Sanger sequencing using 15 – 20 cycles of 98°C for 10 s, 60°C for 30 s, and 72°C for 10 s 
with the primers NGS-QC-F and NGS-QC-R (see Table 3.T4). Upon validation, the 
libraries were sent for deep sequencing using the Illumina HiSeq 2500 System (Millard 
and Muriel Jacobs Genetics and Genomics Laboratory, Caltech; Integrative Genomics 
Core, City of Hope). 
Preparation of rAAV tissue DNA library 
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The PCR-amplified rAAV DNA library from tissue (see sections: rAAV genome 
recovery by Cre-dependent PCR and total rAAV genome recovery by PCR (Cre-
independent)) was further amplified with a 1:100 dilution of this DNA as a template to the 
primers 1527 and 1532 that are positioned around 50 bases from the randomized heptamer 
insertion on the capsid, and that contain the Read1 and Read2 sequences on the 5’ end (see 
Table 3.T4). The DNA was amplified by Q5 DNA polymerase for 10 cycles of 98 °C for 
10 s, 59 °C for 30 s, and 72 °C for 10 s. The mixture was purified with a PCR purification 
kit. The eluted DNA was then used as a template in a second PCR to add the unique indices 
(single or dual) using the recommended primers (NEB; E7335S, E7500S, E7600S) in a 
ten-cycle reaction with the same temperature cycle as described above (for DNA and virus 
library preparation), and followed additional processing and validation before sequencing. 
The PCR products post indices addition were run on a freshly prepared 2% low-
melting-point agarose gel (ThermoFisher Scientific; 16520050) for better separation and 
recovery of the approx. 120 bp DNA band on the gel. Before sending the sample for NGS, 
the nucleotide diversity at the randomized 7-mer position was verified by Sanger 
sequencing. If needed, an optional PCR was carried out to send sufficient sample for 
Sanger sequencing using 15 – 20 cycles of 98°C for 10 s, 60°C for 30 s, and 72°C for 10 s 
with the primers NGS-QC-F and NGS-QC-R (see Table 3.T4). Upon validation, the 
libraries were sent for deep sequencing using the Illumina HiSeq 2500 System (Millard 
and Muriel Jacobs Genetics and Genomics Laboratory, Caltech; Integrative Genomics 
Core, City of Hope). 
In vivo characterization of AAV vectors 
Cloning AAV capsid variants 
The AAV capsid variants were cloned into a pUCmini-iCAP-PHP.B backbone 
(Addgene ID: 103002) using overlapping forward and reverse primers with 11-base 
oligonucleotide substitution (in case of 7-mer-i variants, the flanking amino acids from 
AAV9 capsid AA 587–588 ‘AQ' and AA 589–590 ‘AQ' were subjected to codon 
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modification) that spans from the MscI site (at position 581 AA) to the AgeI site (at 
position 600 AA) on the pUCmini plasmid. The primers were designed for all capsid 
variants using a custom Python script and cloned using standard molecular techniques. The 
designed primers cover the entire fragment that is inserted into the linearized pUCmini-
iCAP-PHP.B backbone. Hence these primers are simply self-annealed using PCR to 
synthesize double-stranded DNA fragment without the use of a template DNA. They are 
amplified by Q5 Hot Start High-Fidelity 2X Master Mix for 20 cycles of 98 °C for 10 s, 
60 °C for 30 s and 72 °C for 10 s. This fragment was then assembled into the MscI/AgeI 
digested pUCmini-iCAP-PHP.B backbone by the Gibson assembly method. There is a 
second MscI site on the backbone; however, this was blocked by methylation. The 
assembled plasmids were then transformed into NEB Stable competent E. coli (New 
England Biolabs; C3040H), and colonies were selected on carbenicillin/ampicillin-LB agar 
plates. A list of primers used to clone AAV-PHP variants is provided (Table 3.T5). 
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Table 3.T5: Sequence motifs of AAV-PHP variants  
 
The table provides the sequence motif information for all the new AAV-PHP variants 
identified in this study, and the primer information to clone them into pUCmini-iCAP-PHP.B 
Variant Name Amino acid motif of 
variants with “AQ” 
overhangs from 
AAV9: AA587-88 and 
AA589-90. (11-mer) 
Nucleotide sequence 
of 11-mer 
Forward primer (5’-3’) Reverse primer (5’-3’) 
AAV-PHP.V1 
(Addgene ID: 
127847) 
AQTALKPFLAQ GCCCAAACCGCCCT
CAAACCCTTCCTCG
CACAG 
GGAGTCCTATGGACAAG
TGGCCACAAACCACCAG
AGTGCCCAAACCGCCCT
CAAACCC 
TTCCTTGGTTTTGAACCCAA
CCGGTCTGCGCCTGTGCGA
GGAAGGGTTTGAGGGCGGT
TTGGGC 
AAV-PHP.V2 
(Addgene ID: 
127848) 
AQTTLKPFLAQ GCCCAAACCACCCT
CAAACCCTTCCTCG
CACAG 
GGAGTCCTATGGACAAG
TGGCCACAAACCACCAG
AGTGCCCAAACCACCCT
CAAACCC 
TTCCTTGGTTTTGAACCCAA
CCGGTCTGCGCCTGTGCGA
GGAAGGGTTTGAGGGTGGT
TTGGGC 
AAV-PHP.B4 
(Addgene ID: 
127849) 
AQTLQIPFKAQ GCCCAAACGTTGCA
GATTCCTTTTAAGGC
ACAG 
GGAGTCCTATGGACAAG
TGGCCACAAACCACCAG
AGTGCCCAAACGTTGCA
GATTCCT 
TTCCTTGGTTTTGAACCCAA
CCGGTCTGCGCCTGTGCCTT
AAAAGGAATCTGCAACGTTT
GGGC 
AAV-PHP.B5 AQTLQLPFKAQ GCCCAAACCCTCCA
ACTCCCCTTCAAAG
CCCAA 
GGAGTCCTATGGACAAG
TGGCCACAAACCACCAG
AGTGCCCAAACCCTCCA
ACTCCCC 
TTCCTTGGTTTTGAACCCAA
CCGGTCTGCGCTTGGGCTTT
GAAGGGGAGTTGGAGGGTT
TGGGC 
AAV-PHP.B6 AQTLQQPFKAQ GCCCAAACTTTGCA
GCAGCCGTTTAAGG
CACAG 
GGAGTCCTATGGACAAG
TGGCCACAAACCACCAG
AGTGCCCAAACTTTGCA
GCAGCCG 
TTCCTTGGTTTTGAACCCAA
CCGGTCTGCGCCTGTGCCTT
AAACGGCTGCTGCAAAGTTT
GGGC 
AAV-PHP.B7 AQSIERPFKAQ GCCCAAAGCATCGA
AAGACCCTTCAAAG
CACAG 
GGAGTCCTATGGACAAG
TGGCCACAAACCACCAG
AGTGCCCAAAGCATCGA
AAGACCC 
TTCCTTGGTTTTGAACCCAA
CCGGTCTGCGCCTGTGCTTT
GAAGGGTCTTTCGATGCTTT
GGGC 
AAV-PHP.B8 AQTMQKPFIAQ GCCCAAACCATGCA
AAAACCCTTCATCG
CACAG 
GGAGTCCTATGGACAAG
TGGCCACAAACCACCAG
AGTGCCCAAACCATGCA
AAAACCC 
TTCCTTGGTTTTGAACCCAA
CCGGTCTGCGCCTGTGCGA
TGAAGGGTTTTTGCATGGTT
TGGGC 
AAV-PHP.C1 AQRYQGDSVAQ GCCCAAAGGTATCA
GGGTGATTCTGTTG
CACAG 
GGAGTCCTATGGACAAG
TGGCCACAAACCACCAG
AGTGCCCAAAGGTATCA
GGGTGAT 
TTCCTTGGTTTTGAACCCAA
CCGGTCTGCGCCTGTGCAA
CAGAATCACCCTGATACCTT
TGGGC 
AAV-PHP.C2 AQWSTNAGYAQ GCCCAATGGTCGAC
AAACGCTGGTTACG
CACAG 
GGAGTCCTATGGACAAG
TGGCCACAAACCACCAG
AGTGCCCAATGGTCGAC
AAACGCT 
TTCCTTGGTTTTGAACCCAA
CCGGTCTGCGCCTGTGCGT
AACCAGCGTTTGTCGACCAT
TGGGC 
AAV-PHP.C3 AQERVGFAQAQ GCCCAAGAGCGTGT
AGGTTTCGCACAGG
CACAG 
GGAGTCCTATGGACAAG
TGGCCACAAACCACCAG
AGTGCCCAAGAGCGTGT
AGGTTTC 
TTCCTTGGTTTTGAACCCAA
CCGGTCTGCGCCTGTGCCT
GTGCGAAACCTACACGCTCT
TGGGC 
AAV-PHP.N 
(Addgene ID: 
127851) 
AQTLAVPFSNP GCGCAGACCCTAGC
TGTCCCTTTTTCGAA
CCCT 
GGAGTCCTATGGACAAG
TGGCCACAAACCACCAG
AGTGCGCAGACCCTAGC
TGTCCCT 
TTCCTTGGTTTTGAACCCAA
CCGGTCTGCGCAGGGTTCG
AAAAAGGGACAGCTAGGGTC
TGCGC 
AAV-PHP.X1 AQARQMDLSAQ GCCCAAGCCAGACA
AATGGACCTCAGCG
CACAG 
GGAGTCCTATGGACAAG
TGGCCACAAACCACCAG
AGTGCCCAAGCCAGACA
AATGGAC 
TTCCTTGGTTTTGAACCCAA
CCGGTCTGCGCCTGTGCGC
TGAGGTCCATTTGTCTGGCT
TGGGC 
AAV-PHP.X2 AQTNKVGNIAQ GCCCAAACCAACAA
AGTCGGCAACATCG
CACAG 
GGAGTCCTATGGACAAG
TGGCCACAAACCACCAG
AGTGCCCAAACCAACAA
AGTCGGC 
TTCCTTGGTTTTGAACCCAA
CCGGTCTGCGCCTGTGCGA
TGTTGCCGACTTTGTTGGTT
TGGGC 
AAV-PHP.X3 AQQNVTKGVAQ 
 
GCCCAACAGAACGT
AACGAAGGGTGTGG
CACAG 
GGAGTCCTATGGACAAG
TGGCCACAAACCACCAG
AGTGCCCAACAGAACGT
AACGAAG 
TTCCTTGGTTTTGAACCCAA
CCGGTCTGCGCCTGTGCCA
CACCCTTCGTTACGTTCTGT
TGGGC 
AAV-PHP.X4 AQLNAIKNIAQ 
 
GCCCAACTCAACGC
TATCAAGAACATCG
CACAG 
GGAGTCCTATGGACAAG
TGGCCACAAACCACCAG
AGTGCCCAACTCAACGC
TATCAAG 
TTCCTTGGTTTTGAACCCAA
CCGGTCTGCGCCTGTGCGA
TGTTCTTGATAGCGTTGAGT
TGGGC 
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backbone (Addgene ID: 103002) as described in Methods. The variants from 7-mer-i and 
3-mer-s libraries were cloned as 11-mer substitution. 
 
AAV vector production 
 
Using an optimized protocol134 (Chapter 2 in thesis), we produced AAV vectors from 
5–10 150-mm plates, which yielded sufficient amounts for administration to adult mice. 
AAV vector administration, dosage and expression time 
AAV vectors were administered intravenously to adult male mice (6–8 weeks of age) 
via retro-orbital injection at doses of 1 × 1011–10 × 1011 vg with 3–4 weeks of in vivo 
expression times unless mentioned otherwise in the figures or legends. 
The AAV doses are determined by the experimental needs. CAG-NLS-GFP related 
experiments for quantification were done at medium dose of 1x1011 vg given this was the 
dose previously determined for AAV-PHP.eB characterization. Otherwise, the non-NLS 
genome related experiments were done at 3x1011 vg, with the exception of Cre-driver lines 
(GFAP-Cre or Tek-Cre), or a lower strength promoter containing genome (GFAP-NLS-
mTurq) where the dose was 1x1012 vg. The high dose was chosen to understand the full 
potential of the new vectors in these systems. 
All experiments with vectors carrying CAG, a strong ubiquitous promoter, were 
incubated for 3 weeks. The 4 week incubations are those that involved expression from Cre 
driver lines or cell-type specific promoter where it is generally recommended for a longer 
wait time. The 2 week incubations are those where the vectors carried self-complementary 
genomes with strong ubiquitous promoters. 
Tissue processing 
After 3 weeks of expression (unless noted otherwise), the mice were anesthetized 
with Euthasol (pentobarbital sodium and phenytoin sodium solution, Virbac AH) and 
transcardially perfused with 30–50 mL of 0.1 M phosphate buffered saline (PBS) (pH 7.4), 
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followed by 30–50 ml of 4% paraformaldehyde (PFA) in 0.1 M PBS. After this 
procedure, all organs were harvested and post-fixed in 4% PFA at 4 °C overnight. The 
tissues were then washed and stored at 4 °C in 0.1 M PBS and 0.05% sodium azide. All 
solutions used for this procedure were freshly prepared. For the brain and liver, 100-µm 
thick sections were cut on a Leica VT1200 vibratome. 
For vascular labeling, the mice were anesthetized and transcardially perfused with 
20 mL of ice-cold PBS, followed by 10 mL of ice-cold PBS containing Texas Red-labeled 
Lycopersicon Esculentum (Tomato) Lectin (1:100, Vector laboratories, TL-1176) or 
DyLight 594 labeled Tomato Lectin (1:100, Vector laboratories, DL-1177), and then 
placed in 30 mL of ice-cold 4% PFA for fixation. 
Immunohistochemistry 
Immunohistochemistry was performed on 100-µm-thick tissue sections to label 
different cell-type markers such as NeuN (1:400, Abcam, ab177487) for neurons, S100 
(1:400, Abcam, ab868) for astrocytes, Olig2 (1:400; Abcam, ab109186) for 
oligodendrocyte lineage cells and GLUT-1 (1:400; Millipore Sigma, 07-1401) for brain 
endothelial cells using optimized protocols. 
Tissue sections, typically 100-µm thick, were first incubated in blocking buffer (10% 
normal donkey serum, 0.1% Triton X-100, and 0.01% sodium azide in 0.1 M PBS, pH 7.4) 
with primary antibodies at appropriate dilutions for 24 h at RT on a rocker. The primary 
antibodies used in this study were rabbit S100 (1:400, Abcam, ab868), rabbit Olig2 (1:400; 
Abcam, ab109186), rabbit NeuN (1:400, Abcam, ab177487), and rabbit GLUT-1 (1:400; 
Millipore Sigma, 07-1401). After primary antibody incubation, the tissues were washed 1 
– 3 times with wash buffer 1 (0.1% Triton X-100 in 0.1 M PBS buffer, pH 7.4) over a 
period of 5 – 6 h in total. The tissues were then incubated in blocking buffer with the 
secondary antibodies at appropriate dilutions for 12 – 24 h at RT and then washed in three 
times in 0.1 M PBS, pH 7.4 over a total duration of 5 – 6 h. The secondary antibody was 
Alexa Fluor 647 AffiniPure donkey anti-rabbit IgG (H+L) (Jackson ImmunoResearch Lab, 
 
 
141 
711-605-152). When performing DNA staining, 4′,6-Diamidine-2′-phenylindole 
dihydrochloride (DAPI, Sigma Aldrich, 10236276001) is used at a 1:1000 dilution in 0.1 
M PBS, pH 7.4 and incubated with tissues for 15 minutes followed by a single wash for 10 
minutes in 0.1 M PBS, pH 7.4. The DAPI and/or antibody-stained tissue sections were 
mounted with ProLong Diamond Antifade Mountant (ThermoFisher Scientific, P36970). 
Hybridization chain reaction (HCR)-based RNA labeling in tissues 
Fluorescence in situ hybridization chain reaction (FITC-HCR) was used to label 
excitatory neurons with VGLUT1 and inhibitory neurons with GAD1 to characterize the 
AAV capsid variant AAV-PHP.N in brain tissue using an adapted third-generation HCR260 
protocol. 
To characterize the AAV capsid variant AAV-PHP.N in brain tissue, HCR method 
was sought to label excitatory and inhibitory neurons. Fluorescence in situ hybridization 
chain reaction (FITC-HCR) was used to label excitatory neurons with VGLUT1 and 
inhibitory neurons with GAD1. Adapting the third-generation HCR260, we designed 13 
probe sets for each target by using custom-made software 
(https://github.com/GradinaruLab/HCRprobe).  
After 3 weeks of expression, the mice were transcardially perfused and fixed as 
described earlier (Section D. Tissue processing). To minimize RNase enzyme exposure in 
fixed tissues, following overnight fixation in 4% PFA, the tissues were washed and stored 
at 4°C in 0.1 M RNase-free PBS and 0.05% sodium azide. The harvested brains were 
henceforth handled with care to avoid exposure to RNase using reagents such as RNAlater 
stabilization solution/RNase-free PBS/ RNaseZap (ThermoFisher Scientific, AM7021, 
AM9624, AM9780). Once the harvested brains were sagittally sliced to 100-µm thick 
sections, we performed FITC-HCR to detect both genes. We permeabilized tissue slices 
with 0.1% Triton X-100 in 0.1 M RNase-free PBS for 1 h at RT and pre-hybridized them 
in hybridization solution (10% dextran sulfate and 10% ethylene carbonate in 2xSSC buffer 
(saline-sodium citrate)) for >30 min at 37oC. The designed probes were diluted in 
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hybridization solution to get a final concentration of 2 nM. The tissue sections were 
then subjected to hybridization with the probes overnight at 37oC. Following this, the 
sections were washed with pre-warmed wash buffer (10% ethylene carbonate in 2xSSC) at 
37oC for 30 min twice, followed by 2xSSC at RT for 30 min twice. Amplification with 
hairpin pairs (Molecular Technologies, CA) were performed in amplification buffer (10x 
dextran sulfate in 2xSSC); hairpins were snap-cooled at 95oC for 90 s, followed by RT for 
30 min, and diluted with amplification buffer (60 nM). Tissues were then incubated in this 
amplification buffer with hairpins overnight at RT with gentle agitation. Once the 
amplification was done, samples were briefly washed with 2xSSC and mounted in Prolong 
Diamond for imaging. 
Imaging and image processing 
All images in this study were acquired either with a Zeiss LSM 880 confocal 
microscope using the objectives Fluar ×5 0.25 M27, Plan-Apochromat ×10 0.45 M27 
(working distance, 2.0 mm), and Plan-Apochromat ×25 0.8 Imm Corr DIC M27 multi-
immersion; or with a Keyence BZ-X700 microscope.  
To prevent any imaging artifacts resulting from multiple fluorescence spectral 
overlap, the fluorescence excitation and emission spectra were kept distinct following the 
recommended linear unmixed acquisition of individual colors. A far-red fluorescent dye 
was chosen for any additional marker staining to keep the imaging parameters distinct from 
in vivo fluorescent expression thereby preventing any spectral overlap across detector 
channels. The tissues were routinely monitored for auto fluorescence or imaging artifacts 
before acquisition, and imaging parameters were adjusted if needed. The imaging 
parameters were cross-checked with tissues lacking in vivo transduction to avoid any 
imaging artifacts. The regions used for the images were closely matched across 
experimental groups to minimize bias during comparisons. 
The acquired images were processed in the respective microscope software Zen 
Black 2.3 SP1 (Zeiss), BZ-X Analyzer (Keyence), Keyence Hybrid Cell Count software 
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(BZ-H3C), ImageJ, Imaris (Bitplane) and with Photoshop CC 2018 (Adobe). The 
images were compiled in Illustrator CC 2018 (Adobe). 
Tissue clearing 
Brain hemispheres were cleared using iDISCO261 method and tissues over 500 µm 
thickness were optically cleared using ScaleS4(0)170. 
To demonstrate the ability of PHP.V1 to transduce the vasculature across thick 
tissues, such as a mouse-brain hemisphere, we assessed tissue from Tek-Cre mice 4 weeks’ 
post administration. The brain hemisphere was stained with the primary antibody, Anti-
GFP (1:200, Aves Labs, GFP-1020), and the secondary antibody, goat anti-Chicken IgY, 
Alexa Fluor 633 (1:200, ThermoFisher Scientific, A-21103), and cleared via the iDISCO 
protocol261. For imaging, a commercial light-sheet microscope (Lavision BioTec) with a 
custom objective lens (4×) was used262. The resulting image files were reorganized by a 
custom MATLAB script to allow stitching with TeraStitcher263. For 3-D visualization, 
Imaris (Bitplane) was used. 
For images of peripheral organs such as heart, muscle, spleen that were over 500 
microns in thickness, optical clearing was performed by incubating the tissues in 5 ml of 
ScaleS4(0)170 solution overnight at RT with gentle agitation, then mounted the tissues in 
fresh ScaleS4(0) solution and imaged under the confocal microscope.  
Tissue processing and imaging for quantification of rAAV transduction in vivo 
For quantification of rAAV transduction, 6- to 8-week-old male mice were i.v. 
injected with the virus, which was allowed to express for 3 weeks (unless specified 
otherwise). The mice were randomly assigned to groups and the experimenter was not 
blinded. The mice were perfused and the organs were fixed in PFA. The brains and livers 
were cut into 100-µm-thick sections and immunostained with different cell-type-specific 
antibodies, as described above. The images were acquired either with a ×25 objective on a 
Zeiss LSM 880 confocal microscope or with a Keyence BZ-X700 microscope; images that 
 
 
144 
were compared directly across groups were acquired and processed with the same 
microscope and settings. 
For quantification of PHP.B-family variant transduction in tissues, the images were 
acquired using 25x objective with 1x digital zoom on a Zeiss LSM 880 confocal 
microscope. With n=3 mice per variant, images were acquired across 4 brain regions – 
cortex, striatum, ventral midbrain and thalamus and tissues were stained with 3 cell type 
markers (NeuN, Olig2, and S100). For each mouse, 2 images per brain region per cell type 
marker were acquired, and the mean were plotted. 
For PHP.N transduction analysis, the images were acquired using 20x objective on 
Keyence BZ-X700 microscope. With n=3 mice, images across 4 brain regions - cortex, 
striatum, ventral midbrain and thalamus were acquired to cover the entire brain regions for 
3 cell type markers (NeuN, Olig2, and S100). This involved 6-8 images to cover cortex, 
thalamus and striatum, and 2 images to cover ventral midbrain per mouse per cell-type 
marker. For each mouse, across each region, the mean from the images were plotted. 
For PHP.V GLUT1+ transduction analysis, the images were acquired using 25x 
objective with 1x digital zoom on a Zeiss LSM 880 confocal microscope. Each distinct 
blood vessel in the image with GLUT1+ staining and XFP expression was determined as 
positive for transduction. Quantification of expression from the CAG-mNeonGreen vector 
was performed across the cortex (n = 3 per group). Each data point is drawn from the mean 
of 3-2 images per mouse. Different brain regions were quantified for Tek-Cre and Ai14 
mouse experiments with n = 2 per group. For cortex, cerebellum, striatum, and ventral 
midbrain, the mean was plotted from 3-4 images per mouse per region. 
In vitro characterization of AAV vectors 
Human brain microvascular endothelial cells (HBMEC) (ScienCell Research 
Laboratories, cat. no. 1000) were cultured as per the instructions provided by the vendor. 
HBMEC were cultured from a frozen stock vial in fibronectin-coated T-75 flask (7,000–
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9,000 cells per cm2 seeding density) using the endothelial cell medium (cat. no. 1001). 
The cells were subcultured in fibronectin-coated 48-well plates (0.95 cm2 growth area) at 
the recommended seeding density and incubated at 37 °C for ~24–48 h until the cells were 
completely adherent with ~70–80% confluence. The viral vectors packaging pAAV:CAG-
mNeongreen were added to the cell culture at a dose of either 1 × 108 or 1 × 1010 vg per 
well (3 wells per dose per vector). The medium was changed 24 h later, and the culture was 
assessed for fluorescence expression at 3 d post infection. Per vendor recommendation, the 
culture medium was changed every other day to maintain the cell culture. 
Data analysis 
Quantification of rAAV vector transduction 
Manual counting was performed with the Adobe Photoshop CC 2018 Count Tool for 
cell types in which expression and/or antibody staining covered the whole cell morphology. 
The Keyence Hybrid Cell Count software (BZ-H3C) was used where the software could 
reliably detect distinct cells in an entire dataset. To maintain consistency in counting across 
different markers and groups, one person was assigned to quantify across all groups in all 
brain areas. Manual counting was performed for GLUT-1-stained blood vessels and 
expression of the ssAAV:CAG-mNeonGreen and ssAAV:CAG-DIO-EYFP, where the 
efficiency was calculated as the percentage of XFP+ vessels relative to the GLUT-1 
staining. Manual counting was also performed to quantify nuclear or soma stained cells, 
including NeuN-, Olig2-, and S100-stained cells. The efficiency was calculated as the 
percentage of XFP+ cells relative to cell-marker+ cells.  
Keyence Hybrid Cell Count software (BZ-H3C) was used to quantify expression of 
nuclear localized AAV genomes in liver hepatocytes that co-localized with the DNA stain, 
DAPI; and also for the study involving ssAAV:GFAP-2xNLS-mTurquoise2 genomes with 
S100 cell marker. 
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The mean fluorescence intensity across microscopic images were quantified 
using ImageJ software. The images were processed for background subtraction and using 
the Threshold operation, the mean fluorescence intensity was measured. The experimenter 
was not blinded during data analysis. 
NGS data alignment and processing 
The raw fastq files from NGS runs were processed with custom-built scripts that 
align the data to AAV9 template DNA fragment containing the diversified region 7xNNK 
(for R1) or 11xNNN (for R2 since it was synthesized as 11xNNN).  
The pipeline to process these datasets involved filtering the dataset to remove the 
low-quality reads by using the deep sequencing quality score for each sequence. The 
variant sequences were then recovered from the sequencing reads by searching for the 
flanking template sequences, and extracting the nucleotides of the diversified region 
(perfect string match algorithm). The quality of the aligned data was further investigated 
to remove any erroneous sequences (such as ones with stop codons). The raw data was 
plotted (as shown in Supplementary Figure 3.S1e) to study the quality of recovery across 
every library. Based on the RC distribution, we adapted a thresholding method to remove 
plausible erroneous mutants that may have resulted from PCR or NGS based errors. The 
assumption is that if there is a PCR mutation or NGS error on the recovered parent 
sequence, the parent must have existed at least one round earlier than the erroneous 
sequence, and thus a difference in RCs should exist.  
For R1 tissue libraries, we observed a steep drop in the slope of the distribution curve 
following a long tail of low count sequences, and were found to be rich in sequences that 
are variations of the parents in the higher counts range. We manually setup a threshold for 
RCs to remove such erroneous mutants. The thresholded data were then processed 
differently based on the experimental needs as described elsewhere using custom Python 
based scripts. 
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For R2 tissue libraries from PCR pool and synthetic pool, given the smaller 
library size compared to R1, we thresholded the data in two steps. We only considered the 
tissue recovered sequences that were present in the respective input DNA and virus library 
(after removing lower count variants from input libraries following the same principle as 
R1 tissue libraries). This step partially removed the long tail of low count reads. As a 
second step, we applied the thresholding that was described for R1 tissue libraries.  
While it is plausible that true variants may be lost during thresholding, this method 
minimized false positives as the low count mutants in tissue and virus libraries often 
seemed to have very high enrichment score (as RCs are normalized to input library). In 
other words, thresholding allowed selective investigation on enriched variants that had a 
higher-confidence in their NGS RCs.  
As an alternative to our manual thresholding method, an optional error correction 
method called “Collapsing” was built to further validate the outcome from filtered datasets. 
This method starts at the lowest count variants (variants of count 1) and searches for 
potential parent variants that are off by one nucleotide but have at least 2-fold higher counts 
(fold change = (2ΔCT) where CT is PCR cycle threshold). This error correction method then 
transfers the counts of these potential erroneous sequences to their originating sequences 
and repeats recursively until all sequences have been considered. On applying this error 
correction to our thresholded data, an additional ~0.002-0.03% of sequences were captured 
(compared to >19% captured by thresholding), confirming that our thresholding strategy 
was largely successful. 
NGS data analysis 
The aligned data were then further processed via a custom data-processing pipeline, 
with scripts written in Python. 
The enrichment scores of variants (total, N) across different libraries were calculated 
from the read counts (RCs) according to the following formula: 
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Enrichment score = log10((variant 1 RC in tissue library1 / sum of variants N RC in 
library1) / (variant 1 RC in virus library / sum of variants N RC in virus library)) 
To consistently represent library recovery between R1 and R2 selected variants, we 
estimated the enrichment score of the variants in R1 selection.  
Since the DNA and virus libraries were not completely sampled unlike the tissue 
libraries, we assigned an estimated RC for variants that were not present in the input library 
but were present in the output library. For instance, R1 virus library is the input library to 
the R1 tissue libraries. The estimated RC is defined as a number that is lower than the 
lowest RC in the library with the assumption that these variants were found at a relatively 
lower abundance than the variants recovered from the deep sequencing. In virus libraries, 
since RC of 1.0 was the lowest, we assigned all missing variants an estimated RC of 0.9. 
We use this method to calculate the enrichment score of the R1 tissue libraries which is 
normalized to R1 virus library (Figure 3.1d). This was done to represent libraries across 
two selection rounds consistently. Although, the individual enrichment score among R1 
variants didn’t add a significant value to the variants selected for R2 selection as described 
in the criteria to separate signal vs noise in R1 using the RCs. 
The standard score of variants in a specific library was calculated using this formula: 
Standard score = (read count_i – mean) / s.d. 
Read count_i is raw copy number of a variant i. Mean is the mean of read counts of 
all variants across a specific library. The s.d. is the s.d. of read counts of all variants across 
a specific library. 
The plots generated in this article were using the following software: Plotly, 
GraphPad PRISM 7.05, Matplotlib, Seaborn and Microsoft Excel 2016. The AAV9 capsid 
structure (PDB 3UX1)264 was modeled in PyMOL. 
Heat map generation 
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The relative amino acid distributions of the diversified regions are plotted as heat 
maps. The plots were generated using the Python Plotly plotting library. The heat map 
values were generated from custom scripts written in Python, using functions in the custom 
“pepars” Python package.  
Each heatmap uses both an expected (input) distribution of amino acid sequences 
and an output distribution. The output distribution must be a list of sequences and their 
count, and the input distribution can be either a list of sequences and their count, or an 
expected amino acid frequency from a template, such as NNK. For both input and output, 
the total count of amino acids in each position is tallied in accordance to each sequence's 
count and then divided by the total sum of counts, giving a frequency of each amino acid 
at each position. Then, the log2 fold change is calculated between the output and the input. 
For amino acids with a count of 0 in either the input or output, no calculation is performed. 
In order to distinguish between statistically significant amino acid biases, a statistical test 
was performed using the statsmodels Python library. For the case where there are two 
amino acid counts, a two-sided, two-proportion z-test was performed; for comparing the 
output amino acid count to an expected input frequency from a template, a one-proportion 
z-test was performed. All p-values were then corrected for multiple comparisons using 
Bonferroni correction. Only bias differences below a significance threshold of 1e-4 are 
then outlined on the heatmap; all other (insignificant) squares are left empty. 
Clustering analysis 
Using custom scripts written in MATLAB (version R2017b; MathWorks), we 
determined the reverse Hamming distances representing the number of shared amino acids 
between two peptides. Cytoscape (version 3.7.1265) software was then used to cluster the 
variants. The amino acid frequency plot representing the highlighted cluster was created 
using Weblogo (Version 2.8.2)266,267. 
The reverse Hamming distances (representing the number of shared AAs between 
two peptides) was determined for all unique capsid variants with greater than 10 count and 
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greater than 2.5-fold enrichment after R2 selection. This process iteratively compares 
each variant with all other variants within the group. Capsid variants were then clustered 
by their reverse Hamming distances using Cytoscape. The minimum reverse Hamming 
distance for visualization was chosen manually based on sequence similarity. 
For the amino acid frequency plots, the number on the bottom represents the position 
of the diversified motif starting from 1. The size of the amino acid in the stack reflects the 
proportion of unique clones in which the AA appears at that specific position in the motif. 
The color code is based on the AA properties. The positively charged residues K, R, and 
H are in blue. The negatively charged residues D and E are in red. The amide containing 
polar residues Q, and N are in magenta. The polar residues T, and S, are in green. The 
hydrophobic residues A, L, V, I, P, F, M, and W are in black. 
Statistics and reproducibility 
Statistical tests were performed using GraphPad PRISM or Python scripts. All 
correlation analyses reported were carried out using a linear least-squares regression 
method by an inbuilt Python function from SciPy library ‘scipy.stats.linregress', and the 
coefficient of determination (R2) is reported. Tests evaluating the significance of amino 
acid bias were done using statsmodels Python library. A one-proportion z-test for a library 
versus known template frequency (NNK), and two-proportion z-test for two-library 
comparisons were performed. P values are corrected for multiple comparisons using a 
Bonferroni correction. For datasets with two experimental group comparisons, a Mann–
Whitney test was used and two-tailed exact P values are reported. For more than two 
experimental group comparisons with one variable, a one-way ANOVA non-parametric 
Kruskal–Wallis test with multiple comparisons using uncorrected Dunn’s test was 
performed. Exact P values are reported from both tests (unless indicated otherwise). For 
experimental group comparisons with two variables, a two-way ANOVA with Tukey’s test 
for multiple comparisons reporting corrected P values were performed with 95% CI. 
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All quantitative data reported in graphs are from biological replicates (mouse or 
tissue culture replicates), where each data point from a biological replicate is the mean 
from technical replicates (raw data such as images of a specific brain region). Statistical 
analyses were performed on datasets with at least three biological replicates. Error bars in 
the figures denote s.e.m. All experiments were validated in more than one independent trial 
unless otherwise noted. 
Data availability 
The NGS datasets using the synthetic pool and PCR pool selection methods that are 
reported in this article are available under the SRA accession code: PRJNA610987. The 
following vector plasmids are deposited on Addgene for distribution 
(http://www.addgene.org) AAV-PHP.V1: 127847, AAV-PHP.V2: 127848, AAV-
PHP.B4: 127849, and AAV-PHP.N: 127851, and viruses may be available for commonly 
packaged genomes. Other plasmids or viruses not available at Addgene may be requested 
from Caltech, CLOVER Center (http://clover.caltech.edu/). GenBank: AAV-
PHP.V1: MT162422, AAV-PHP.V2: MT162423, AAV-PHP.N: MT162424, AAV- 
PHP.C1: MT162425, AAV-PHP.C2: MT162426, AAV-PHP.C3: MT162427, AAV-
PHP.B4: MT162428, AAV-PHP.B5: MT162429, AAV-PHP.B6: MT162430, AAV-
PHP.B7: MT162431 and AAV-PHP.B8: MT162432. 
Code availability 
The codes used for M-CREATE data analysis were written in python or MATLAB 
and are made available on GitHub: https://github.com/GradinaruLab/mCREATE. The 
custom MATLAB scripts to generate HCR probes is accessible through GitHub on a 
different repository: https://github.com/GradinaruLab/HCRprobe. 
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3.6 SUPPLEMENTARY INFORMATION 
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Supplementary Figure 3.S1: Extended Schematic For Multiplexed-CREATE And 
Analysis Of Round-1 Selection. 
 
(a), Diagram of the genetic switch used in M-CREATE. The Acceptor Vector shows the 
position of the forward and reverse primers between the Lox sites that are used for selective 
recovery of capsids from the Cre+ cells. The Rep-AAP∆Cap vector shows a deletion of 
480 bp in cap gene in addition to the stop codons that are designed to prevent synthesis of 
VP1, VP2, and VP3 proteins. AAP protein translation is unaffected by these 
modifications. (b), Schematic of the protocol to selectively recover rAAV genomes from 
the target population using the Cre-Lox flipping strategy and preparation of the sample for 
deep sequencing. (c), The library coverage for R1 DNA and virus libraries obtained from 
specific sequencing depths. (d), The percentage of variant overlap within the sampled 
DNA and virus, or across different Cre lines within tissues, or across tissues from R1 
selection. (e), The distributions of AAV capsid RCs for libraries recovered by NGS from 
brain tissue across different Cre transgenic mice post R1 selection. The dotted line is 
illustrative only and roughly separates the signal from noise (see Methods for estimation 
of signal versus noise) where signal in this context represents the input for the R2 
selection. (f), rAAV genome recovery from tissues using different treatments are shown 
with total rAAV genome recovery from 0.1 g of liver, (g), Percentage of rAAV genomes 
recovered per ng of total extracted DNA, and (h), The CT value (cycle threshold from 
qPCR) of rAAV genome extracted by trizol that were treated with SmaI restriction enzyme 
or untreated and (i), CT value of mitochondrial DNA (internal control for smaller genome 
recovery, fold change = 10.79 (2ΔCT)) recovered from 1 ng of total DNA from liver tissue. 
In (f-i), n = 4 mice; 2 from GFAP-Cre line and 2 from Tek-Cre line, each data point is 
drawn from the mean of three technical replicates, error bar is mean ± S.E.M., Mann-
Whitney test, two-tailed (exact P-value of 0.0286 (*P ≤ 0.05), in (f, g, i), and 0.1143 (n.s., 
P > 0.05, CI 95%) in (h)). The data reported (f, g, i) are from one independent trial, and (h), 
from three independent trials. 
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Supplementary Figure 3.S2: Analysis Of 7-mer-i rAAV Libraries From Round-2 
Selections. 
 
(a), The vector yields obtained per 10 ng of capsid DNA library across R1 and R2 vector 
productions. (b), Distributions of the DNA and virus libraries produced by the synthetic 
pool and PCR pool methods by the standard score of NGS RCs. The variants in virus 
libraries are sorted by the decreasing order of standard score (SS) and their scores from 
respective DNA libraries are mapped onto them. (c), Correlations between 
the SS of RCs for the DNA and virus libraries (n = 1 per library) produced by the synthetic 
pool and PCR pool methods is determined by linear least-squares regression, and the 
regression line (best fit) and R2 representing the coefficient of determination is shown. (d), 
Distributions of capsid libraries from brain tissue of two mice (purple and green) used in 
each Cre line selection, as produced by the synthetic pool (left) and PCR pool (right) 
designs. The distribution of spike-in library introduced in the synthetic pool library design 
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is shown in red (center). (e), Correlations of enrichment scores of variants from the 
brain libraries (n = 2 per Cre line, mean is plotted) produced by synthetic pool and PCR 
pool methods is determined by the same method described in (c). 
 
 
Supplementary Figure 3.S3: Analysis Of Round-2 7-mer-i Tissue Libraries 
From Synthetic Pool And PCR Pool Methods. 
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(a), Correlation analysis between the enrichment score (log10) of two alternate codon 
replicates of variants from the GFAP-Cre (left), SNAP-Cre (center), and Syn-Cre (right) 
brain libraries by linear least-squares regression (n = 2 per Cre line, mean is plotted). The 
dotted line separates the high-confidence signal from noise. High confidence signal 
(below) is assessed by a linear regression line (best fit) and R2 represents the coefficient of 
determination. (b), The difference in enrichment score between the two codon replicates 
of a variant, across different brain libraries, with over 8000 variants recovered in 
replicates. (c), Heatmaps represent the magnitude (log2 fold change) of AA bias in 
“output” library 1 normalized to “input” library 2 that reach statistical significance (boxed 
if P-value ≤ 0.0001, two-sided, two-proportion z-test, except in R1 DNA normalized to 
known NNK template where one-proportion z-test was performed, and P-values corrected 
for multiple comparisons using Bonferroni correction) is shown. R1 DNA library 
normalized to NNK template (top left, ~9 million sequences), R1 virus normalized to R1 
DNA libraries (bottom left, ~10 million sequences), R2 GFAP library with enrichment 
score above 1.0 in brain normalized to R2 virus (top right, 20 sequences,) and R2 SNAP 
library with enrichment score above 1.2 normalized to R2 virus (bottom right, 17 
sequences) are shown (n = 1 for DNA, virus, and n = 2 for brain libraries). (d), Clustering 
analysis of positively enriched variants from Tek, GFAP, and combined neuron brain 
libraries (SNAP and Syn) by PCR pool design, and by synthetic pool design with spike-
in library are shown with size of nodes representing their relative enrichment in brain, and 
the thickness of edges (connecting lines) representing the extent of shared AA identity 
between nodes. A distinct family is highlighted in yellow with the corresponding AA 
frequency logo below (AA size reflects prevalence and color coded based on AA 
properties). 
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Supplementary Figure 3.S4: AAV-PHP.V1 Efficiently Targets The Brain Vasculature. 
 
(a), Expression of AAV9 (above) and AAV-PHP.V1 (below) packaging ssAAV:CAG-
mNeonGreen across all organs is shown (n=3, 3x1011 vg dose per adult C57BL/6J mouse, 
3 weeks of expression). The background auto fluorescence is represented in magenta. (b), 
Expression in cortical astrocytes (S100+) after i.v. delivery of AAV-PHP.V1 (left) and 
AAV-PHP.eB (right) capsids carrying ssAAV:GfABC1D-2xNLS-
mTurquoise2 (1x1012 vg dose per adult mouse, 4 weeks of expression). Percentage of 
cortical S100+ cells that overlapped with mTurquoise2 expression is quantified (n = 2, each 
data point is mean from 3 images per mouse). (c), Expression of AAV9, AAV-
PHP.eB (d), AAV-PHP.V1 (e) packaging ssAAV:Ple261-iCre transgene in Ai14-
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tdTomato reporter adult mouse (n=2–3 per group, 3x1011 vg dose per adult mouse, 3 
weeks of expression). (f), Expression of AAV-PHP.V1 carrying self-complementary 
(sc) scAAV:CB6-EGFP (above) and scAAV:CAG-EGFP (below). Magenta represents the 
lectin DyLight 594 staining (n=2-3, 3x1011 vg dose per adult C57BL/6J mouse, 2 weeks of 
expression). Experiments in (c-e) are reported from one independent trial from a fresh 
batch of viruses, and tittered in the same assay for dosage consistency, (e) and (f) validated 
in two independent trials (n = 2 per group). 
 
 
 
Supplementary Figure 3.S5: AAV-PHP.V2 Variant Exhibits Biased Transduction 
Towards Brain Vascular Cells. 
 
(a), Transduction of mouse brain by the AAV-PHP.V2 variant and control AAV9, carrying 
the ssAAV:CAG-mNeonGreen (n = 3, 3x1011 vg i.v. dose per C57BL/6J adult mouse, 3 
weeks of expression) is shown. The sagittal brain images (left) are imaged under the same 
settings (also matched to the settings of sagittal brain images in Fig. 3c). Higher-
magnification images of AAV-PHP.V2 transduced brain sections stained with αGLUT or 
αS100 or αOlig2 (magenta) are shown. (b), Transduction of brain vasculature by AAV-
PHP.V2 carrying ssAAV:CAG-DIO-EYFP (green) in Tek-Cre adult mice (left, 1x1012 vg 
i.v. dose per mouse, 4 weeks of expression) is shown, and its efficiency (right) is 
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determined by the overlap of αGLUT1 staining (red) with EYFP expression across 
different brain areas (n = 2, mean of 3 images per brain region per mouse) (c), Transduction 
of astrocytes by AAV-PHP.V2 in GFAP-Cre adult mouse (1x1012 vg i.v. dose per mouse, 
4 weeks of expression) is shown. Percentage of cortical S100+ cells that overlapped with 
EYFP expression is quantified (n = 2, mean of 3 images per mouse). 
 
 
 
 
Supplementary Figure 3.S6: Further Validation Of Synthetic Pool And PCR Pool 
Variants Demonstrates Higher Confidence In Synthetic Pool NGS Data. 
 
(a), Transduction levels of liver hepatocytes quantified as the percentage of DAPI+ cells 
that are EGFP+ (n = 3, vectors packaged with ssAAV:CAG-2xNLS-EGFP, 
1x1011 vg i.v. dose per adult C57BL/6J mouse, 3 weeks of expression, mean±S.E.M, 4 
images per mouse per group. One-way ANOVA non-parametric Kruskal-Wallis test 
(approximate P-value of 0.0088), and follow-up multiple comparisons using uncorrected 
Dunn’s test (P-value of 0.0353 for PHP.eB versus PHP.B, 0.0005 for 
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PHP.eB versus PHP.C1, 0.0025 for PHP.eB versus AAV9, 0.0179 for 
PHP.B4 versus PHP.C1, 0.0253 for PHP.B5 versus PHP.C1, 0.0414 for 
PHP.B6 versus PHP.C1) is performed. (b), Transduction of brain tissue by AAV-PHP.B4, 
B7, AAV-PHP.X1 (ARQMDLS), and AAV-PHP.X2 (TNKVGNI) 
packaging ssAAV:CAG-mNeonGreen genome (n = 3, 1x1011 vg i.v. dose per adult 
C57BL/6J mouse, 3 weeks of expression), imaged under the same settings as that of AAV9 
and AAV-PHP.V1 sagittal brain images in Fig. 3c. (c), Transduction of the brain by AAV-
PHP.B8 using the ssAAV:CAG-mRuby2 genome (n = 3, 3x1011 vg i.v. dose per adult 
C57BL/6J mouse, 3 weeks of expression). (d), Transduction of AAV9 (left), AAV-
PHP.X3 (QNVTKGV) (middle) and AAV-PHP.X4 (LNAIKNI) (right) vectors 
packaging ssAAV:CAG-2xNLS-EGFP (n = 2, 1x1011 vg i.v. dose per  adult C57BL/6J 
mouse, 3 weeks of expression). (a-d) data is reported from one independent trial. 
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Supplementary Figure 3.S7: Evolution Of The AAV-PHP.B Capsid By Diversifying 
Amino Acid Positions 587-597. 
 
(a), Distributions of R1 and (b), R2 brain libraries (at AA level, SS of RCs sorted in 
decreasing order of scores) is shown. The SS for AAV-PHP.N and AAV-PHP.eB across 
libraries are mapped on the zoomed-in view of this plot (dotted line box). (c), Heatmap of 
AA distributions across the diversified region of the enriched variants from R2 liver library 
(top 100 sequences) normalized to the R2 virus (input library). (d), Clustering analysis 
of enriched variants from GFAP and Vglut2 brain libraries are shown with size of nodes 
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representing their relative depletion in liver, and the thickness of edges (connecting 
lines) representing their relative identity between nodes. (e), Expression of AAV-PHP.B 
(above) and AAV-PHP.N (below) packaged with ssAAV:CAG-mNeonGreen across all 
organs is shown (n = 3, 3x1011 vg i.v. dose per adult C57BL/6J mouse, 3 weeks of 
expression). The background auto fluorescence is in magenta. (f), Transduction of mouse 
brain by the AAV-PHP.N variant, carrying the CAG promoter that drives the expression 
of mNeonGreen (n = 3, 1x1011 vg i.v. dose per C57BL/6J adult mouse, 3 weeks of 
expression) is shown. Fluorescence in situ hybridization chain reaction (FITC-HCR) was 
used to label excitatory neurons with Vglut1 and inhibitory neurons with Gad1. Few cells 
where EGFP expression co-localized with specific cell markers are highlighted by asterisks 
symbol. 
 
 
 
Supplementary Figure 3.S8: Investigation Of AAV-PHP Variants Across Different 
Mouse Strains And In Vitro Human Brain Microvascular Endothelial Cells. 
 
(a), Transduction of AAV9, AAV-PHP.eB and AAV-PHP.V1 in human brain 
microvascular endothelial cell culture (HBMEC) is shown. The vectors were packaged 
with ssAAV:CAG-mNeongreen. The mean fluorescence intensity across the groups were 
quantified (n=3 tissue culture wells of 0.95 cm2 surface area per group, 3 images per well 
per group per dose was imaged after three days of expression, doses 1x108 vg and 
1x1010 vg per 0.95 cm2 surface area). A two-way ANOVA with correction for multiple 
comparisons using Tukey’s test gave adjusted P-value of 0.0051 for 
AAV9 versus PHP.V1, 0.0096 for PHP.eB versus PHP.V1, 0.8222 for 
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AAV9 versus PHP.eB for 1x108 vg, and 0.0052 for AAV9 versus PHP.V1, 0.0049 for 
PHP.eB versus PHP.V1, 0.9996 for AAV9 versus PHP.eB for 1x1010 vg (**P ≤ 0.01, is 
shown and P > 0.05 is not shown on the plot; mean ± S.E.M., 95% CI). (b), The 
transduction of cortex brain region by AAV-PHP.B, AAV-PHP.C2 and AAV-PHP.C3 
across two different mouse strains: C57BL/6J and BALB/cJ are shown. The vectors were 
packaged with ssAAV:CAG-mNeongreen (n = 2-3 per group, 1x1011 vg i.v. dose per adult 
mouse, 3 weeks of expression), and imaged under the same settings. The data reported 
in (a,b) are from one independent trial where all viruses were freshly prepared and tittered 
in the same assay for dosage consistency, with additional validation for AAV-PHP.C2 and 
AAV-PHP.C3 in an independent trial for BALB/cJ. 
 
 
Supplementary Video 3.V1: Brain-Wide transduction of endothelial cells upon systemic 
delivery of the AAV-PHP.V1 capsid.  
 
ssAAV-PHP.V1:CAG-DIO-EYFP vector was systemically delivered at a dose of 1 × 
1012 vg per adult Tek-Cre mouse (n = 2). After 4 weeks of expression, mice were 
transcardially perfused and fixed with 4% PFA. Fixed brain hemispheres (one per mouse) 
were subjected to staining with αGFP primary and Alexa Fluor 633 secondary along with 
tissue clearing as described in the iDISCO protocol (the other fixed hemispheres from the 
same experiment were sliced sagitally (100-µm thickness), stained with αGLUT1, imaged 
and quantified to validate expression; data shown in Figure 3.4f,g). One of the cleared 
brain hemisphere was imaged using a commercial light-sheet microscope (Lavision 
BioTec) with a custom objective lens (×4). The resulting image files were reorganized by 
a custom MATLAB script to allow stitching with TeraStitcher. For three-dimensional 
visualization, Imaris (Bitplane) was used. The data are reported from one independent trial. 
 
 
Supplementary Dataset 3.D1: 7-mer-i spike-in library recovery in brain tissue across Cre 
transgenic lines.  
 
Sheet 1 contains the list of peptides included in the 7-mer-i spike-in library, along with 
their predicted enrichment in brain tissue as per prior study and their validation using the 
new method, M-CREATE. Sheet 2 includes the enrichment scores of the spike-in library 
in brain tissue across different Cre transgenic lines. 
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C h a p t e r  4  
FUTURE DIRECTIONS 
 
4.1 EXPANSION OF AAV VECTOR TOOLKIT 
The AAV-PHP vectors identified so far using CREATE and M-CREATE were 
predominantly focused on CNS cell types given the lack of precise, non-invasive gene 
delivery tools for neuroscience applications, and a lot remains to be done to develop a 
complete AAV-CNS toolkit. For instance, there are no good AAV vectors for targeting 
other widely studied CNS cell types such as microglia or oligodendrocyte by intravenous 
delivery39,268,269. In addition, there is room for further improvement of the AAV-PHP 
vectors’ efficiency and specificity, especially for AAV-PHP.C-like variants that may 
have the potential for translation across species.  
With the M-CREATE method in place, we can now push forward to apply similar 
parallel selections across other cell types of interest such as the peripheral nervous 
system. Although CREATE selected AAV-PHP.S vector from GFAP-Cre (astrocyte) 
selection, and is used for applications requiring gene delivery to sensory and enteric 
nervous system134,270, there is room for improving the selection using M-CREATE with 
the hope to find vectors with higher efficiency and specificity. And one could expand this 
further to do similar selections to obtain cell-type or organ specific variants, provided 
there are Cre transgenic lines that are highly specific to the cell populations of interest. 
Often times, this may not be feasible, and may require alternate strategies to supplement 
for the loss of selection pressures across different biological systems, or even require 
additional rounds of evolution, or rational or semi rational designs to achieve the desired 
vector properties. 
 
 
165 
4.2 INVESTIGATION OF MECHANISM OF ENGINEERED VECTORS 
While the directed evolution approach is very promising to yield the vectors with 
desired properties, understanding mechanism of how these vectors gain entry to cell types 
of interest can eventually allow us to understand how these vectors may perform across 
species. For instance, AAV-PHP.B vectors that performed really well in select strains in 
rodents uses a cell surface protein receptor, ly6a, the homolog of which is not seen in 
humans164,165,167,271. This is a very useful information to the community who would invest 
in the possibility of translation of such vectors in gene therapy applications.  
The engineered AAV-PHP.C variants identified by M-CREATE have distinct 
amino acid signatures. This opens up the possibility that they may act on different cell 
surface protein receptors, or in other words, may have different mechanisms of entry into 
cells, and this may or may not necessarily coincide across species. Hence for translation 
purposes, studies similar to the ones conducted to identify ly6a would be very useful to 
make an informed decision on the choice of the AAV-PHP.C vectors for translation. In 
addition to the protein target identification, we could also make progress towards 
understanding the kinetics of vector biodistribution in vivo using new imaging modalities 
such as PET (positron emission tomography)272 than the traditional methods involving 
quantification of viral genomes or expression of a protein over time. 
4.3 DEVELOPMENT OF TECHNOLOGIES TO EMPOWER M-CREATE 
While M-CREATE speeds up the selection process and the possible outcomes from 
a given experiment, this method is hit by the bottleneck of characterizing individual 
variants in vivo. Given the high yield of enriched variants or families of variants that may 
all be interesting in different aspects, it adds a huge burden on cost, labor, and time to 
screen them individually. Hence there is a need to increase the throughput of the 
screening process.  
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To this end, one could use the output from M-CREATE selection and feed the 
selected library of variants into one of a fast-screen technique such as the single-cell RNA 
sequencing250 or by RNA probe based hybridization methods260, either of which may 
have the power to rank variants based on their tropism, transduction efficiency and 
specificity in vivo.  
The high-confidence outcome from M-CREATE can also serve as a good learning 
dataset for machine learning or in silico pipelines that can capture information that were 
not previously identified in our data analysis. There are different algorithms that have 
been used to perform in silico evolution or protein structure predictions which could 
potentially be useful to apply to our datasets69,273–275. Such approaches can improve our 
understanding on the design of our selections or the hidden outcomes and alleviate some 
of the labor intensive bench-work involved in the traditional large scale selection studies. 
4.4 POTENTIAL APPLICATIONS OF AAV VECTOR TOOLKIT 
The AAV-PHP vectors identified by M-CREATE could have broad applications in 
neuroscience, and can be put to immediate use in studies involving rodents. For instance, 
previously, AAV-PHP.B vectors were used in basic neuroscience studies in 
mice163,189,191, in neurological disease models158, and in preclinical gene therapy 
applications161,276,277. And one can hope to see similar applications from vectors like 
AAV-PHP.N or AAV-PHP.Cs. The AAV-PHP.V variants will open up new application 
in the field that studies BBB malformations, that are widely associated with various 
neurodegenerative diseases including Alzheimer’s247,249, or aging studies278, or other 
neuropathologies215,279,280. For applications beyond rodents, further investigations are 
required for AAV-PHP.Cs across species to determine their use as gene delivery vector.   
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